0000946644 2026-01-01 2026-06-30 0000946644 2026-08-07 0000946644 2026-06-30 0000946644 2025-12-31 0000946644 AIM:SeriesAJuniorParticipatingPreferredStockMember 2026-06-30 0000946644 AIM:SeriesAJuniorParticipatingPreferredStockMember 2025-12-31 0000946644 AIM:SeriesBConvertiblePreferredStockMember 2026-06-30 0000946644 AIM:SeriesBConvertiblePreferredStockMember 2025-12-31 0000946644 AIM:SeriesGConvertiblePreferredStockMember 2026-06-30 0000946644 AIM:SeriesGConvertiblePreferredStockMember 2025-12-31 0000946644 2026-04-01 2026-06-30 0000946644 2025-04-01 2025-06-30 0000946644 2025-01-01 2025-06-30 0000946644 us-gaap:SeriesGPreferredStockMember us-gaap:PreferredStockMember 2025-12-31 0000946644 us-gaap:CommonStockMember 2025-12-31 0000946644 us-gaap:AdditionalPaidInCapitalMember 2025-12-31 0000946644 us-gaap:RetainedEarningsMember 2025-12-31 0000946644 us-gaap:SeriesGPreferredStockMember us-gaap:PreferredStockMember 2026-03-31 0000946644 us-gaap:CommonStockMember 2026-03-31 0000946644 us-gaap:AdditionalPaidInCapitalMember 2026-03-31 0000946644 us-gaap:RetainedEarningsMember 2026-03-31 0000946644 2026-03-31 0000946644 us-gaap:SeriesGPreferredStockMember us-gaap:PreferredStockMember 2024-12-31 0000946644 us-gaap:CommonStockMember 2024-12-31 0000946644 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0000946644 us-gaap:RetainedEarningsMember 2024-12-31 0000946644 2024-12-31 0000946644 us-gaap:SeriesGPreferredStockMember us-gaap:PreferredStockMember 2025-03-31 0000946644 us-gaap:CommonStockMember 2025-03-31 0000946644 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0000946644 us-gaap:RetainedEarningsMember 2025-03-31 0000946644 2025-03-31 0000946644 us-gaap:SeriesGPreferredStockMember us-gaap:PreferredStockMember 2026-01-01 2026-03-31 0000946644 us-gaap:CommonStockMember 2026-01-01 2026-03-31 0000946644 us-gaap:AdditionalPaidInCapitalMember 2026-01-01 2026-03-31 0000946644 us-gaap:RetainedEarningsMember 2026-01-01 2026-03-31 0000946644 2026-01-01 2026-03-31 0000946644 us-gaap:SeriesGPreferredStockMember us-gaap:PreferredStockMember 2026-04-01 2026-06-30 0000946644 us-gaap:CommonStockMember 2026-04-01 2026-06-30 0000946644 us-gaap:AdditionalPaidInCapitalMember 2026-04-01 2026-06-30 0000946644 us-gaap:RetainedEarningsMember 2026-04-01 2026-06-30 0000946644 us-gaap:SeriesGPreferredStockMember us-gaap:PreferredStockMember 2025-01-01 2025-03-31 0000946644 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0000946644 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0000946644 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0000946644 2025-01-01 2025-03-31 0000946644 us-gaap:SeriesGPreferredStockMember us-gaap:PreferredStockMember 2025-04-01 2025-06-30 0000946644 us-gaap:CommonStockMember 2025-04-01 2025-06-30 0000946644 us-gaap:AdditionalPaidInCapitalMember 2025-04-01 2025-06-30 0000946644 us-gaap:RetainedEarningsMember 2025-04-01 2025-06-30 0000946644 us-gaap:SeriesGPreferredStockMember us-gaap:PreferredStockMember 2026-06-30 0000946644 us-gaap:CommonStockMember 2026-06-30 0000946644 us-gaap:AdditionalPaidInCapitalMember 2026-06-30 0000946644 us-gaap:RetainedEarningsMember 2026-06-30 0000946644 us-gaap:SeriesGPreferredStockMember us-gaap:PreferredStockMember 2025-06-30 0000946644 us-gaap:CommonStockMember 2025-06-30 0000946644 us-gaap:AdditionalPaidInCapitalMember 2025-06-30 0000946644 us-gaap:RetainedEarningsMember 2025-06-30 0000946644 2025-06-30 0000946644 srt:MinimumMember 2024-12-11 0000946644 2025-04-04 0000946644 2025-04-30 2025-04-30 0000946644 2025-05-29 2025-05-29 0000946644 2025-07-01 2025-09-30 0000946644 2026-01-20 2026-01-20 0000946644 2026-01-20 0000946644 srt:MinimumMember 2026-01-20 0000946644 us-gaap:WarrantMember AIM:WarrantExerciseInducementOfferLetterAgreementMember 2026-05-07 2026-05-07 0000946644 AIM:InvestorsMember us-gaap:CommonStockMember 2026-05-21 2026-05-21 0000946644 AIM:InvestorsMember us-gaap:CommonStockMember us-gaap:PrivatePlacementMember 2026-05-21 0000946644 AIM:InvestorsMember AIM:ClassIWarrantsMember us-gaap:WarrantMember us-gaap:PrivatePlacementMember 2026-05-21 0000946644 AIM:InvestorsMember AIM:ClassIWarrantsMember us-gaap:WarrantMember us-gaap:PrivatePlacementMember 2026-05-21 2026-05-21 0000946644 AIM:InvestorsMember us-gaap:CommonStockMember 2026-06-10 2026-06-10 0000946644 AIM:InvestorsMember us-gaap:CommonStockMember us-gaap:PrivatePlacementMember 2026-06-10 2026-06-10 0000946644 AIM:InvestorsMember AIM:PreFundedWarrantsMember us-gaap:WarrantMember us-gaap:PrivatePlacementMember 2026-06-10 0000946644 AIM:InvestorsMember AIM:ClassJWarrantsMember us-gaap:WarrantMember us-gaap:PrivatePlacementMember 2026-06-10 0000946644 AIM:InvestorsMember AIM:ClassJWarrantsMember us-gaap:WarrantMember us-gaap:PrivatePlacementMember 2026-06-10 2026-06-10 0000946644 srt:MinimumMember 2026-06-30 0000946644 srt:MaximumMember 2026-06-30 0000946644 us-gaap:PatentsMember 2026-06-30 0000946644 us-gaap:PatentsMember 2025-12-31 0000946644 us-gaap:TrademarksMember 2026-06-30 0000946644 us-gaap:TrademarksMember 2025-12-31 0000946644 us-gaap:TrademarksMember 2026-03-31 0000946644 AIM:StreetervilleCapitalLlcMember AIM:NotePurchaseAgreementMember 2024-02-16 2024-02-16 0000946644 AIM:StreetervilleCapitalLlcMember AIM:NotePurchaseAgreementMember 2024-02-16 0000946644 AIM:StreetervilleCapitalLlcMember AIM:NotePurchaseAgreementMember 2026-01-01 0000946644 AIM:StreetervilleCapitalLlcMember AIM:NotePurchaseAgreementMember 2026-01-01 2026-03-31 0000946644 AIM:StreetervilleCapitalLlcMember AIM:NotePurchaseAgreementMember 2025-01-01 2025-12-31 0000946644 AIM:StreetervilleCapitalLlcMember AIM:NotePurchaseAgreementMember 2026-05-18 2026-05-18 0000946644 AIM:StreetervilleCapitalLlcMember AIM:NotePurchaseAgreementMember 2026-01-01 2026-06-30 0000946644 AIM:StreetervilleCapitalLlcMember AIM:NoteTwoPurchaseAgreementMember 2025-06-30 0000946644 AIM:StreetervilleCapitalLlcMember AIM:NoteTwoPurchaseAgreementMember 2025-06-30 2025-06-30 0000946644 AIM:StreetervilleCapitalLlcMember AIM:NoteThreePurchaseAgreementMember 2025-11-18 0000946644 AIM:StreetervilleCapitalLlcMember AIM:NoteThreePurchaseAgreementMember 2025-11-18 2025-11-18 0000946644 AIM:NotePurchaseAgreementMember 2026-06-30 0000946644 AIM:NoteTwoPurchaseAgreementMember 2026-06-30 0000946644 AIM:NoteThreePurchaseAgreementMember 2026-06-30 0000946644 AIM:NotePurchaseAgreementMember 2025-12-31 0000946644 AIM:NoteTwoPurchaseAgreementMember 2025-12-31 0000946644 AIM:NoteThreePurchaseAgreementMember 2025-12-31 0000946644 AIM:StreetervilleCapitalLlcMember AIM:NotePurchaseAgreementMember 2026-04-01 2026-06-30 0000946644 AIM:StreetervilleCapitalLlcMember AIM:NoteTwoPurchaseAgreementMember 2026-04-01 2026-06-30 0000946644 AIM:StreetervilleCapitalLlcMember AIM:NoteThreePurchaseAgreementMember 2026-04-01 2026-06-30 0000946644 AIM:StreetervilleCapitalLlcMember 2026-04-01 2026-06-30 0000946644 AIM:StreetervilleCapitalLlcMember AIM:NoteTwoPurchaseAgreementMember 2026-01-01 2026-06-30 0000946644 AIM:StreetervilleCapitalLlcMember AIM:NoteThreePurchaseAgreementMember 2026-01-01 2026-06-30 0000946644 AIM:StreetervilleCapitalLlcMember 2026-01-01 2026-06-30 0000946644 AIM:StreetervilleCapitalLlcMember AIM:NotePurchaseAgreementMember 2025-04-01 2025-06-30 0000946644 AIM:StreetervilleCapitalLlcMember AIM:NoteTwoPurchaseAgreementMember 2025-04-01 2025-06-30 0000946644 AIM:StreetervilleCapitalLlcMember AIM:NoteThreePurchaseAgreementMember 2025-04-01 2025-06-30 0000946644 AIM:StreetervilleCapitalLlcMember 2025-04-01 2025-06-30 0000946644 AIM:StreetervilleCapitalLlcMember AIM:NotePurchaseAgreementMember 2025-01-01 2025-06-30 0000946644 AIM:StreetervilleCapitalLlcMember AIM:NoteTwoPurchaseAgreementMember 2025-01-01 2025-06-30 0000946644 AIM:StreetervilleCapitalLlcMember AIM:NoteThreePurchaseAgreementMember 2025-01-01 2025-06-30 0000946644 AIM:StreetervilleCapitalLlcMember 2025-01-01 2025-06-30 0000946644 srt:MinimumMember 2026-01-01 2026-06-30 0000946644 srt:MaximumMember 2026-01-01 2026-06-30 0000946644 AIM:ResearchAndDevelopmentMember 2026-01-01 2026-06-30 0000946644 AIM:ResearchAndDevelopmentMember 2025-01-01 2025-06-30 0000946644 AIM:GeneralAndAdministrativeMember 2026-01-01 2026-06-30 0000946644 AIM:GeneralAndAdministrativeMember 2025-01-01 2025-06-30 0000946644 AIM:ClinicalStudiesMember 2026-04-01 2026-06-30 0000946644 AIM:ClinicalStudiesMember 2025-04-01 2025-06-30 0000946644 AIM:ClinicalStudiesMember 2026-01-01 2026-06-30 0000946644 AIM:ClinicalStudiesMember 2025-01-01 2025-06-30 0000946644 AIM:ManufacturingAndEngineeringMember 2026-04-01 2026-06-30 0000946644 AIM:ManufacturingAndEngineeringMember 2025-04-01 2025-06-30 0000946644 AIM:ManufacturingAndEngineeringMember 2026-01-01 2026-06-30 0000946644 AIM:ManufacturingAndEngineeringMember 2025-01-01 2025-06-30 0000946644 AIM:QualityControlMember 2026-04-01 2026-06-30 0000946644 AIM:QualityControlMember 2025-04-01 2025-06-30 0000946644 AIM:QualityControlMember 2026-01-01 2026-06-30 0000946644 AIM:QualityControlMember 2025-01-01 2025-06-30 0000946644 AIM:RegulatoryMember 2026-04-01 2026-06-30 0000946644 AIM:RegulatoryMember 2025-04-01 2025-06-30 0000946644 AIM:RegulatoryMember 2026-01-01 2026-06-30 0000946644 AIM:RegulatoryMember 2025-01-01 2025-06-30 0000946644 AIM:PancreaticCancerMember AIM:AmarexClinicalResearchLLCMember 2026-04-01 2026-06-30 0000946644 AIM:PancreaticCancerMember AIM:AmarexClinicalResearchLLCMember 2025-04-01 2025-06-30 0000946644 AIM:PancreaticCancerMember AIM:AmarexClinicalResearchLLCMember 2026-01-01 2026-06-30 0000946644 AIM:PancreaticCancerMember AIM:AmarexClinicalResearchLLCMember 2025-01-01 2025-06-30 0000946644 AIM:PostCOVIDConditionsMember AIM:AmarexClinicalResearchLLCMember 2026-04-01 2026-06-30 0000946644 AIM:PostCOVIDConditionsMember AIM:AmarexClinicalResearchLLCMember 2025-04-01 2025-06-30 0000946644 AIM:PostCOVIDConditionsMember AIM:AmarexClinicalResearchLLCMember 2026-01-01 2026-06-30 0000946644 AIM:PostCOVIDConditionsMember AIM:AmarexClinicalResearchLLCMember 2025-01-01 2025-06-30 0000946644 AIM:AmarexClinicalResearchLLCMember 2026-04-01 2026-06-30 0000946644 AIM:AmarexClinicalResearchLLCMember 2025-04-01 2025-06-30 0000946644 AIM:AmarexClinicalResearchLLCMember 2026-01-01 2026-06-30 0000946644 AIM:AmarexClinicalResearchLLCMember 2025-01-01 2025-06-30 0000946644 AIM:SterlingPharmaSolutionsMember 2026-04-01 2026-06-30 0000946644 AIM:SterlingPharmaSolutionsMember 2025-04-01 2025-06-30 0000946644 AIM:SterlingPharmaSolutionsMember 2026-01-01 2026-06-30 0000946644 AIM:SterlingPharmaSolutionsMember 2025-01-01 2025-06-30 0000946644 AIM:AzenovaSalesInternationalMember 2026-04-01 2026-06-30 0000946644 AIM:AzenovaSalesInternationalMember 2025-04-01 2025-06-30 0000946644 AIM:AzenovaSalesInternationalMember 2026-01-01 2026-06-30 0000946644 AIM:AzenovaSalesInternationalMember 2025-01-01 2025-06-30 0000946644 AIM:AlcamiMember 2026-04-01 2026-06-30 0000946644 AIM:AlcamiMember 2025-04-01 2025-06-30 0000946644 AIM:AlcamiMember 2026-01-01 2026-06-30 0000946644 AIM:AlcamiMember 2025-01-01 2025-06-30 0000946644 AIM:AmarexClinicalResearchLLCMember 2022-04-01 2022-04-30 0000946644 AIM:AmarexClinicalResearchLLCMember 2022-09-01 2022-09-30 0000946644 AIM:AmarexClinicalResearchLLCMember 2023-01-01 2023-12-31 0000946644 us-gaap:SubsequentEventMember AIM:SterlingProposalAgreementMember 2026-08-01 2026-08-15 0000946644 AIM:AzenovaSalesInternationalMember 2023-10-31 0000946644 AIM:AzenovaSalesInternationalMember 2024-08-31 0000946644 AIM:AlcamiMember 2023-09-01 2023-09-30 0000946644 AIM:FourZeroOnekPlanMember 2026-01-01 2026-06-30 0000946644 AIM:TwoThousandEighteenEquityIncentivePlanMember 2025-06-12 2025-06-12 0000946644 AIM:TwoThousandEighteenEquityIncentivePlanMember 2025-06-12 0000946644 AIM:AmendedAndRestatedTwoThousandEighteenEquityIncentivePlanMember 2025-07-01 2025-07-01 0000946644 AIM:TwoThousandEighteenEquityIncentivePlanMember 2026-06-30 0000946644 AIM:TwoThousandEighteenEquityIncentivePlanMember us-gaap:SubsequentEventMember 2026-07-01 0000946644 AIM:TwoThousandEighteenEquityIncentivePlanMember 2026-01-01 2026-06-30 0000946644 2025-01-01 2025-12-31 0000946644 us-gaap:ShareBasedPaymentArrangementEmployeeMember 2026-01-01 2026-06-30 0000946644 us-gaap:ShareBasedPaymentArrangementNonemployeeMember 2026-01-01 2026-06-30 0000946644 us-gaap:ShareBasedPaymentArrangementEmployeeMember 2026-03-31 0000946644 us-gaap:ShareBasedPaymentArrangementEmployeeMember 2026-04-01 2026-06-30 0000946644 us-gaap:ShareBasedPaymentArrangementEmployeeMember 2026-06-30 0000946644 us-gaap:ShareBasedPaymentArrangementNonemployeeMember 2026-03-31 0000946644 us-gaap:ShareBasedPaymentArrangementNonemployeeMember 2026-04-01 2026-06-30 0000946644 us-gaap:ShareBasedPaymentArrangementNonemployeeMember 2026-06-30 0000946644 us-gaap:ShareBasedPaymentArrangementEmployeeMember 2025-12-31 0000946644 us-gaap:ShareBasedPaymentArrangementNonemployeeMember 2025-12-31 0000946644 us-gaap:CommonStockMember AIM:SecuritiesPurchaseAgreementMember 2024-06-03 2024-06-03 0000946644 AIM:ClassAWarrantMember AIM:SecuritiesPurchaseAgreementMember 2024-06-03 0000946644 AIM:ClassBWarrantMember AIM:SecuritiesPurchaseAgreementMember 2024-06-03 0000946644 us-gaap:CommonStockMember 2024-09-30 2024-09-30 0000946644 AIM:ClassCAndClassDWarrantsMember 2024-09-30 0000946644 us-gaap:WarrantMember 2025-07-30 0000946644 AIM:ClassEWarrantsMember 2025-07-30 0000946644 AIM:ClassFWarrantsMember 2025-07-30 0000946644 AIM:PreFundedWarrantsMember 2025-07-30 0000946644 AIM:PreFundedWarrantsMember 2025-07-30 2025-07-30 0000946644 us-gaap:CommonStockMember 2025-12-30 2025-12-30 0000946644 us-gaap:CommonStockMember 2026-01-13 2026-01-13 0000946644 AIM:ClassEAndFCommonStockPurchaseWarrantsMember 2026-01-13 0000946644 AIM:TwoThousandTwentySixRightsOfferingMember 2026-03-06 2026-03-06 0000946644 AIM:SeriesGConvertiblePreferredStockMember AIM:TwoThousandTwentySixRightsOfferingMember 2026-03-06 0000946644 AIM:GWarrantsMember AIM:TwoThousandTwentySixRightsOfferingMember 2026-03-06 0000946644 AIM:ExistingMayTwoThousandTwentyFourWarrantsMember AIM:ClassAAndClassBCommonStockMember AIM:WarrantExerciseInducementOfferLetterAgreementMember 2026-05-07 0000946644 AIM:ExistingSeptemberTwoThousandTwentyFourWarrantsMember AIM:ClassCAndClassDCommonStockMember AIM:WarrantExerciseInducementOfferLetterAgreementMember 2026-05-07 0000946644 AIM:ExistingJulyTwoThousandTwentyFiveWarrantsMember AIM:ClassEAndClassFCommonStockMember AIM:WarrantExerciseInducementOfferLetterAgreementMember 2026-05-07 0000946644 AIM:InvestorsMember AIM:WarrantExerciseInducementOfferLetterAgreementMember 2026-05-07 0000946644 AIM:InvestorsMember AIM:ClassHWarrantsMember AIM:WarrantExerciseInducementOfferLetterAgreementMember 2026-05-07 0000946644 AIM:InvestorsMember AIM:ClassHWarrantsMember AIM:WarrantExerciseInducementOfferLetterAgreementMember 2026-05-07 2026-05-07 0000946644 us-gaap:WarrantMember AIM:WarrantExerciseInducementOfferLetterAgreementMember 2026-05-08 2026-05-08 0000946644 AIM:PlacementAgentWarrantsMember AIM:WarrantExerciseInducementOfferLetterAgreementMember AIM:LadenburgThalmannAndCoIncMember 2026-05-08 2026-05-08 0000946644 AIM:PlacementAgentWarrantsMember AIM:WarrantExerciseInducementOfferLetterAgreementMember AIM:LadenburgThalmannAndCoIncMember 2026-05-08 0000946644 AIM:SeriesAJuniorParticipatingPreferredStockMember 2023-05-10 0000946644 AIM:SeriesAJuniorParticipatingPreferredStockMember 2023-05-09 0000946644 AIM:SeriesGConvertiblePreferredStockMember 2026-03-04 0000946644 AIM:SeriesGConvertiblePreferredStockMember AIM:TwoThousandTwentySixRightsOfferingMember 2026-03-04 0000946644 AIM:GWarrantsMember us-gaap:CommonStockMember AIM:TwoThousandTwentySixRightsOfferingMember 2026-03-06 0000946644 AIM:GWarrantsMember AIM:TwoThousandTwentySixRightsOfferingMember 2026-03-06 2026-03-06 0000946644 AIM:SeriesGConvertiblePreferredStockMember us-gaap:SubsequentEventMember 2026-07-01 0000946644 AIM:SeriesGConvertiblePreferredStockMember us-gaap:SubsequentEventMember 2026-07-01 2026-08-07 0000946644 AIM:SeriesGConvertiblePreferredStockMember us-gaap:SubsequentEventMember 2026-08-07 0000946644 AIM:EmployeeStockPurchasePlanMember AIM:DirectorsOfficersAndEmployeesMember 2020-07-07 2020-07-07 0000946644 AIM:EquityDistributionAgreementMember AIM:MaximGroupLLCMember 2023-04-19 2023-04-19 0000946644 srt:MaximumMember AIM:EquityDistributionAgreementMember AIM:MaximGroupLLCMember 2023-04-19 2023-04-19 0000946644 srt:MinimumMember AIM:EquityDistributionAgreementMember AIM:MaximGroupLLCMember 2023-04-19 2023-04-19 0000946644 AIM:SalesAgreementMember AIM:MaximGroupLLCMember 2025-04-01 2025-04-01 0000946644 AIM:SalesAgreementMember AIM:MaximGroupLLCMember 2025-01-01 2025-12-31 0000946644 AIM:EquityDistributionAgreementMember AIM:MaximGroupLLCMember 2026-04-10 2026-04-10 0000946644 AIM:EquityDistributionAgreementMember AIM:MaximGroupLLCMember 2026-04-10 0000946644 AIM:EquityDistributionAgreementMember AIM:MaximGroupLLCMember 2026-04-01 2026-06-30 0000946644 AIM:EquityDistributionAgreementMember AIM:MaximGroupLLCMember 2026-01-01 2026-06-30 0000946644 AIM:SalesAgreementMember AIM:MaximGroupLLCMember 2026-01-01 2026-06-30 0000946644 us-gaap:SubsequentEventMember AIM:EquityDistributionAgreementMember AIM:MaximGroupLLCMember 2025-04-01 2026-07-31 0000946644 us-gaap:SubsequentEventMember AIM:SalesAgreementMember AIM:MaximGroupLLCMember 2025-04-01 2026-07-31 0000946644 us-gaap:CommonStockMember AIM:EquityPurchaseAgreementMember AIM:AtlasSciencesLlcMember 2024-03-28 2024-03-28 0000946644 AIM:EquityPurchaseAgreementMember AIM:AtlasSciencesLlcMember 2024-03-28 0000946644 AIM:EquityPurchaseAgreementMember AIM:AtlasSciencesLlcMember 2024-03-28 2024-03-28 0000946644 srt:MinimumMember AIM:EquityPurchaseAgreementMember AIM:AtlasSciencesLlcMember 2024-03-28 0000946644 srt:MaximumMember AIM:EquityPurchaseAgreementMember AIM:AtlasSciencesLlcMember 2024-03-28 0000946644 AIM:EquityPurchaseAgreementMember 2024-04-01 2024-04-30 0000946644 AIM:EquityPurchaseAgreementMember AIM:AtlasSciencesLlcMember 2024-04-01 2024-04-30 0000946644 AIM:CommitmentSharesMember AIM:EquityPurchaseAgreementMember AIM:AtlasSciencesLlcMember 2024-04-01 2024-04-30 0000946644 AIM:EquityPurchaseAgreementMember 2024-01-01 2024-12-31 0000946644 AIM:EquityPurchaseAgreementMember 2025-01-01 2025-12-31 0000946644 AIM:ClassBWarrantMember AIM:SecuritiesPurchaseAgreementMember 2024-06-03 2024-06-03 0000946644 AIM:PlacementAgentMember 2024-05-01 2024-05-31 0000946644 AIM:ClassAWarrantsMember 2026-04-01 2026-06-30 0000946644 AIM:ClassAWarrantsMember 2026-01-01 2026-06-30 0000946644 AIM:ClassBWarrantsMember 2026-04-01 2026-06-30 0000946644 AIM:ClassBWarrantsMember 2026-01-01 2026-06-30 0000946644 AIM:ClassAWarrantsMember 2026-06-30 0000946644 AIM:ClassBWarrantsMember 2026-06-30 0000946644 2024-09-01 2024-09-30 0000946644 AIM:ClassCWarrantsMember 2026-04-01 2026-06-30 0000946644 AIM:ClassCWarrantsMember 2026-01-01 2026-06-30 0000946644 AIM:ClassDWarrantsMember 2026-04-01 2026-06-30 0000946644 AIM:ClassDWarrantsMember 2026-01-01 2026-06-30 0000946644 AIM:ClassCWarrantsMember 2026-06-30 0000946644 AIM:ClassDWarrantsMember 2026-06-30 0000946644 2025-12-30 2025-12-30 0000946644 2026-01-13 2026-01-13 0000946644 AIM:ClassEWarrantsMember 2026-04-01 2026-06-30 0000946644 AIM:ClassFWarrantsMember 2026-04-01 2026-06-30 0000946644 AIM:ClassEWarrantsMember 2026-06-30 0000946644 AIM:ClassFWarrantsMember 2026-06-30 0000946644 AIM:ClassEWarrantsMember 2026-01-01 2026-06-30 0000946644 AIM:ClassFWarrantsMember 2026-01-01 2026-06-30 0000946644 AIM:ClassEAndClassFWarrantsMember AIM:PurchaseAgreementMember 2026-06-30 0000946644 us-gaap:SeriesGPreferredStockMember 2026-04-01 2026-06-30 0000946644 us-gaap:SeriesGPreferredStockMember 2026-01-01 2026-06-30 0000946644 us-gaap:CommonStockMember 2026-01-01 2026-06-30 0000946644 AIM:ClassGWarrantsMember 2026-01-01 2026-06-30 0000946644 AIM:SeriesGConvertiblePreferredStockMember us-gaap:SubsequentEventMember 2026-07-01 2026-08-15 0000946644 us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2026-07-01 2026-08-15 0000946644 AIM:ClassGWarrantsMember 2026-06-30 0000946644 us-gaap:SeriesGPreferredStockMember 2026-06-30 0000946644 AIM:ClassAWarrantMember AIM:InducementLetterAgreementsMember 2026-05-08 0000946644 AIM:ClassFWarrantMember AIM:InducementLetterAgreementsMember 2026-05-08 0000946644 AIM:ClassAWarrantMember AIM:InducementLetterAgreementsMember 2026-05-07 2026-05-08 0000946644 AIM:ClassHWarrantMember AIM:InducementLetterAgreementsMember 2026-05-08 0000946644 AIM:InducementLetterAgreementsMember AIM:LadenburgThalmannAndCoMember 2026-05-08 0000946644 AIM:InducementLetterAgreementsMember 2026-05-07 2026-05-08 0000946644 AIM:ClassHWarrantMember AIM:InducementLetterAgreementsMember 2026-05-07 2026-05-08 0000946644 AIM:PlacementAgentWarrantMember AIM:InducementLetterAgreementsMember 2026-05-07 2026-05-08 0000946644 AIM:ClassHPlacementAgentWarrantMember AIM:InducementLetterAgreementsMember 2026-05-07 2026-05-08 0000946644 AIM:HolderSideConsiderationAndPlacementAgentWarrantMember AIM:InducementLetterAgreementsMember 2026-05-07 2026-05-08 0000946644 AIM:HolderSideInducementConsiderationMember AIM:InducementLetterAgreementsMember 2026-05-07 2026-05-08 0000946644 2026-05-07 2026-05-08 0000946644 AIM:PlacementAgentWarrantsMember 2026-06-30 0000946644 AIM:ClassHWarrantsMember 2026-06-30 0000946644 AIM:MayClassTwoThousandTwentySixClassIOfferingMember 2026-05-21 2026-05-21 0000946644 AIM:ClassICommonStockPurchaseWarrantsMember 2026-05-21 0000946644 AIM:ClassIWarrantsMember 2026-05-21 0000946644 AIM:ClassIWarrantsMember 2026-05-21 2026-05-21 0000946644 AIM:MayClassTwoThousandTwentySixClassIOfferingMember AIM:LadenburgThalmannAndCoIncMember 2026-05-21 0000946644 AIM:MayClassTwoThousandTwentySixClassIOfferingMember AIM:LadenburgThalmannAndCoIncMember 2026-05-21 2026-05-21 0000946644 AIM:MayClassTwoThousandTwentySixClassIOfferingMember AIM:PlacementAgentMember AIM:LadenburgThalmannAndCoIncMember 2026-05-21 0000946644 AIM:MayClassTwoThousandTwentySixClassIOfferingMember AIM:ClassIWarrantdMember AIM:LadenburgThalmannAndCoIncMember 2026-05-21 2026-05-21 0000946644 AIM:PlacementAgentWarrantsMember AIM:LadenburgThalmannAndCoIncMember 2026-06-30 0000946644 AIM:ClassIWarrantsMember AIM:LadenburgThalmannAndCoIncMember 2026-06-30 0000946644 AIM:JuneClassTwoThousandTwentySixClassJOfferingMember 2026-06-10 2026-06-10 0000946644 AIM:JuneClassTwoThousandTwentySixClassJOfferingMember 2026-06-10 0000946644 AIM:JuneClassTwoThousandTwentySixClassJOfferingMember AIM:ClassJWarrantsMember 2026-06-10 0000946644 AIM:JuneClassTwoThousandTwentySixClassJOfferingMember AIM:LadenburgThalmannAndCoIncMember 2026-06-10 0000946644 AIM:JuneClassTwoThousandTwentySixClassJOfferingMember AIM:LadenburgThalmannAndCoIncMember 2026-06-10 2026-06-10 0000946644 AIM:JuneClassTwoThousandTwentySixClassJOfferingMember AIM:PlacementAgentMember AIM:LadenburgThalmannAndCoIncMember 2026-06-10 0000946644 AIM:PreFundedWarrantsMember 2026-04-01 2026-06-30 0000946644 AIM:June2026ClassJOfferingMember AIM:PreFundedWarrantsMember AIM:LadenburgThalmannAndCoIncMember 2026-06-30 0000946644 AIM:June2026ClassJOfferingMember AIM:PlacementAgentWarrantsMember AIM:LadenburgThalmannAndCoIncMember 2026-06-30 0000946644 AIM:June2026ClassJOfferingMember AIM:ClassJWarrantsMember AIM:LadenburgThalmannAndCoIncMember 2026-06-30 0000946644 AIM:JuneClassTwoThousandTwentySixClassJOfferingMember us-gaap:SubsequentEventMember 2026-08-04 0000946644 us-gaap:WarrantMember 2026-01-01 2026-06-30 0000946644 us-gaap:WarrantMember 2025-01-01 2025-12-31 0000946644 AIM:ClassAWarrantMember 2024-06-30 0000946644 us-gaap:MeasurementInputExercisePriceMember AIM:ClassAWarrantMember 2024-06-30 0000946644 us-gaap:MeasurementInputRiskFreeInterestRateMember AIM:ClassAWarrantMember 2024-06-30 0000946644 us-gaap:MeasurementInputExpectedTermMember AIM:ClassAWarrantMember 2024-06-30 0000946644 us-gaap:MeasurementInputPriceVolatilityMember AIM:ClassAWarrantMember 2024-06-30 0000946644 us-gaap:MeasurementInputExpectedDividendRateMember AIM:ClassAWarrantMember 2024-06-30 0000946644 us-gaap:MeasurementInputSharePriceMember AIM:ClassBWarrantMember 2024-06-30 0000946644 us-gaap:MeasurementInputExercisePriceMember AIM:ClassBWarrantMember 2024-06-30 0000946644 us-gaap:MeasurementInputRiskFreeInterestRateMember AIM:ClassBWarrantMember 2024-06-30 0000946644 us-gaap:MeasurementInputExpectedTermMember AIM:ClassBWarrantMember 2024-06-30 0000946644 us-gaap:MeasurementInputPriceVolatilityMember AIM:ClassBWarrantMember 2024-06-30 0000946644 us-gaap:MeasurementInputExpectedDividendRateMember AIM:ClassBWarrantMember 2024-06-30 0000946644 us-gaap:MeasurementInputSharePriceMember AIM:ClassCWarrantMember 2025-10-01 0000946644 us-gaap:MeasurementInputExercisePriceMember AIM:ClassCWarrantMember 2025-10-01 0000946644 us-gaap:MeasurementInputRiskFreeInterestRateMember AIM:ClassCWarrantMember 2025-10-01 0000946644 us-gaap:MeasurementInputExpectedTermMember AIM:ClassCWarrantMember 2025-10-01 0000946644 us-gaap:MeasurementInputPriceVolatilityMember AIM:ClassCWarrantMember 2025-10-01 0000946644 us-gaap:MeasurementInputExpectedDividendRateMember AIM:ClassCWarrantMember 2025-10-01 0000946644 us-gaap:MeasurementInputSharePriceMember AIM:ClassDWarrantMember 2025-10-01 0000946644 us-gaap:MeasurementInputExercisePriceMember AIM:ClassDWarrantMember 2025-10-01 0000946644 us-gaap:MeasurementInputRiskFreeInterestRateMember AIM:ClassDWarrantMember 2025-10-01 0000946644 us-gaap:MeasurementInputExpectedTermMember AIM:ClassDWarrantMember 2025-10-01 0000946644 us-gaap:MeasurementInputPriceVolatilityMember AIM:ClassDWarrantMember 2025-10-01 0000946644 us-gaap:MeasurementInputExpectedDividendRateMember AIM:ClassDWarrantMember 2025-10-01 0000946644 us-gaap:MeasurementInputSharePriceMember AIM:ClassEWarrantMember 2025-12-31 0000946644 us-gaap:MeasurementInputSharePriceMember AIM:ClassEWarrantMember 2026-01-20 0000946644 us-gaap:MeasurementInputExercisePriceMember AIM:ClassEWarrantMember 2025-12-31 0000946644 us-gaap:MeasurementInputExercisePriceMember AIM:ClassEWarrantMember 2026-01-20 0000946644 us-gaap:MeasurementInputRiskFreeInterestRateMember AIM:ClassEWarrantMember 2025-12-31 0000946644 us-gaap:MeasurementInputRiskFreeInterestRateMember AIM:ClassEWarrantMember 2026-01-20 0000946644 us-gaap:MeasurementInputExpectedTermMember AIM:ClassEWarrantMember 2025-12-31 0000946644 us-gaap:MeasurementInputExpectedTermMember AIM:ClassEWarrantMember 2026-01-20 0000946644 us-gaap:MeasurementInputPriceVolatilityMember AIM:ClassEWarrantMember 2025-12-31 0000946644 us-gaap:MeasurementInputPriceVolatilityMember AIM:ClassEWarrantMember 2026-01-20 0000946644 us-gaap:MeasurementInputExpectedDividendRateMember AIM:ClassEWarrantMember 2025-12-31 0000946644 us-gaap:MeasurementInputExpectedDividendRateMember AIM:ClassEWarrantMember 2026-01-20 0000946644 us-gaap:MeasurementInputSharePriceMember AIM:ClassFWarrantMember 2025-12-31 0000946644 us-gaap:MeasurementInputSharePriceMember AIM:ClassFWarrantMember 2026-01-20 0000946644 us-gaap:MeasurementInputExercisePriceMember AIM:ClassFWarrantMember 2025-12-31 0000946644 us-gaap:MeasurementInputExercisePriceMember AIM:ClassFWarrantMember 2026-01-20 0000946644 us-gaap:MeasurementInputRiskFreeInterestRateMember AIM:ClassFWarrantMember 2025-12-31 0000946644 us-gaap:MeasurementInputRiskFreeInterestRateMember AIM:ClassFWarrantMember 2026-01-20 0000946644 us-gaap:MeasurementInputExpectedTermMember AIM:ClassFWarrantMember 2025-12-31 0000946644 us-gaap:MeasurementInputExpectedTermMember AIM:ClassFWarrantMember 2026-01-20 0000946644 us-gaap:MeasurementInputPriceVolatilityMember AIM:ClassFWarrantMember 2025-12-31 0000946644 us-gaap:MeasurementInputPriceVolatilityMember AIM:ClassFWarrantMember 2026-01-20 0000946644 us-gaap:MeasurementInputExpectedDividendRateMember AIM:ClassFWarrantMember 2025-12-31 0000946644 us-gaap:MeasurementInputExpectedDividendRateMember AIM:ClassFWarrantMember 2026-01-20 0000946644 us-gaap:MeasurementInputSharePriceMember AIM:ClassGWarrantMember 2026-03-06 0000946644 us-gaap:MeasurementInputExercisePriceMember AIM:ClassGWarrantMember 2026-03-06 0000946644 us-gaap:MeasurementInputRiskFreeInterestRateMember AIM:ClassGWarrantMember 2026-03-06 0000946644 us-gaap:MeasurementInputExpectedTermMember AIM:ClassGWarrantMember 2026-03-06 0000946644 us-gaap:MeasurementInputPriceVolatilityMember AIM:ClassGWarrantMember 2026-03-06 0000946644 us-gaap:MeasurementInputExpectedDividendRateMember AIM:ClassGWarrantMember 2026-03-06 0000946644 us-gaap:MeasurementInputSharePriceMember AIM:ClassHWarrantMember 2026-05-07 0000946644 us-gaap:MeasurementInputExercisePriceMember AIM:ClassHWarrantMember 2026-05-07 0000946644 us-gaap:MeasurementInputRiskFreeInterestRateMember AIM:ClassHWarrantMember 2026-05-07 0000946644 us-gaap:MeasurementInputExpectedTermMember AIM:ClassHWarrantMember 2026-05-07 0000946644 us-gaap:MeasurementInputPriceVolatilityMember AIM:ClassHWarrantMember 2026-05-07 0000946644 us-gaap:MeasurementInputExpectedDividendRateMember AIM:ClassHWarrantMember 2026-05-07 0000946644 us-gaap:MeasurementInputSharePriceMember AIM:ClassIWarrantMember 2026-05-20 0000946644 us-gaap:MeasurementInputExercisePriceMember AIM:ClassIWarrantMember 2026-05-20 0000946644 us-gaap:MeasurementInputRiskFreeInterestRateMember AIM:ClassIWarrantMember 2026-05-20 0000946644 us-gaap:MeasurementInputExpectedTermMember AIM:ClassHWarrantMember 2026-05-20 0000946644 us-gaap:MeasurementInputPriceVolatilityMember AIM:ClassIWarrantMember 2026-05-20 0000946644 us-gaap:MeasurementInputExpectedDividendRateMember AIM:ClassIWarrantMember 2026-05-20 0000946644 us-gaap:MeasurementInputSharePriceMember AIM:ClassJWarrantsMember 2026-06-10 0000946644 us-gaap:MeasurementInputExercisePriceMember AIM:ClassJWarrantsMember 2026-06-10 0000946644 us-gaap:MeasurementInputRiskFreeInterestRateMember AIM:ClassJWarrantsMember 2026-06-10 0000946644 us-gaap:MeasurementInputExpectedTermMember AIM:ClassJWarrantsMember 2026-06-10 0000946644 us-gaap:MeasurementInputPriceVolatilityMember AIM:ClassJWarrantsMember 2026-06-10 0000946644 us-gaap:MeasurementInputExpectedDividendRateMember AIM:ClassJWarrantsMember 2026-06-10 0000946644 us-gaap:MeasurementInputExpectedDividendRateMember 2026-06-30 0000946644 srt:WeightedAverageMember 2026-01-01 2026-06-30 0000946644 us-gaap:FairValueMeasurementsRecurringMember 2026-06-30 0000946644 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2026-06-30 0000946644 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2026-06-30 0000946644 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2026-06-30 0000946644 us-gaap:FairValueMeasurementsRecurringMember 2025-12-31 0000946644 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2025-12-31 0000946644 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2025-12-31 0000946644 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2025-12-31 0000946644 AIM:SeriesGConvertiblePreferredStockMember us-gaap:SubsequentEventMember 2026-07-01 2026-07-01 0000946644 AIM:TwoThousandEighteenEquityIncentivePlanMember us-gaap:SubsequentEventMember 2026-07-09 0000946644 us-gaap:SubsequentEventMember 2026-07-15 2026-07-15 0000946644 us-gaap:SubsequentEventMember 2026-07-15 0000946644 AIM:UnsecuredPromissoryNoteMember us-gaap:SubsequentEventMember 2026-08-06 2026-08-06 0000946644 AIM:UnsecuredPromissoryNoteOneMember us-gaap:SubsequentEventMember 2026-08-06 2026-08-06 iso4217:USD shares iso4217:USD shares pure false --12-31 Q2 0000946644 10-Q true false 2026-06-30 2026 001-27072 AIM IMMUNOTECH INC. DE 52-0845822 2117 SW Highway 484 Ocala FL 34473 (352) 448-7797 Common Stock, par value $0.001 per share AIM NYSEAMER Yes Yes Non-accelerated Filer true false false 30442139 9900000 2985000 64000 62000 7000 468000 241000 10432000 3295000 54000 71000 260000 378000 1714000 1661000 271000 377000 12731000 5782000 480000 1630000 586000 795000 259000 250000 3621000 3549000 4946000 6224000 41000 170000 927000 8244000 4987000 15565000 0.001 0.001 4000000 250000 1000 1000 10000 10000 0 0 0 0 0.01 0.01 1000 1000 12000 12000 529 529 0 0 0.001 0.001 350000000 350000000 28990073 28990073 3069875 3069875 29000 3000 455312000 431000000 -447597000 -440786000 7744000 -9783000 12731000 5782000 26000 25000 48000 41000 26000 25000 48000 41000 5000 10000 9000 20000 589000 1174000 1071000 2254000 2945000 1487000 4707000 4032000 3539000 2671000 5787000 6306000 -3513000 -2646000 -5739000 -6265000 -1000 -9000 -2000 18000 21000 10000 29000 21000 295000 149000 631000 273000 468000 -3788000 -2794000 -6811000 -6499000 -0.43 -0.43 -3.68 -3.68 -0.96 -0.96 -8.88 -8.88 17118695 17118695 759289 759289 10819484 10819484 731650 731650 3069875 3000 431000000 -440786000 -9783000 2032815 2000 1999000 2001000 1842000 1662000 1662000 -1164000 1164000 1000 -1000 1593008 2000 2154000 2156000 8712000 8712000 364084 400000 400000 -3023000 -3023000 678000 8223782 8000 445926000 -443809000 2125000 1019570 1000 536000 537000 -149000 149000 7451920 8000 3569000 3577000 12145801 12000 5082000 5094000 199000 199000 -3788000 -3788000 529000 28990073 29000 455312000 -447597000 7744000 655263 1000 425505000 -426828000 -1322000 42854 660000 660000 4242 60000 60000 20541 450000 450000 -3705000 -3705000 722900 1000 426675000 -430533000 -3857000 722900 1000 426675000 -430533000 -3857000 41339 105000 105000 51 -2794000 -2794000 764188 1000 426780000 -433327000 -6546000 764188 1000 426780000 -433327000 -6546000 -6811000 -6499000 571000 377000 24000 615000 60000 18000 468000 -32000 121000 -770000 -120000 -78000 -1359000 881000 -7000 -7309000 -3892000 4000 2026000 6000 91000 147000 283000 -149000 1652000 2538000 765000 250000 5733000 821000 5293000 1630000 14373000 1015000 6915000 -1225000 2985000 1701000 9900000 476000 85000 400000 421000 <p id="xdx_809_eus-gaap--BusinessDescriptionAndBasisOfPresentationTextBlock_zSj9dxKzNtOk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 1: <span id="xdx_825_zSmejp8rll02">Business and Basis of Presentation</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AIM ImmunoTech Inc. and its subsidiaries are an immuno-pharma company headquartered in Ocala, Florida, with a strong foundation of laboratory, pre-clinical and clinical data with respect to the development of nucleic acids and natural interferon to enhance the natural antiviral defense system of the human body. AIM’s products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (“dsRNA”) molecule being developed for the treatment of late-stage pancreatic cancer, in addition to other globally important cancers, viral diseases and disorders of the immune system. Ampligen has not been approved by the FDA or marketed in the United States, but it is approved for commercial sale in the Argentine Republic for the treatment of severe Chronic Fatigue Syndrome (“CFS”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s research and development of Ampligen includes a variety of diseases and health matters:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conducting clinical trials to evaluate the efficacy and safety of Ampligen for the treatment of pancreatic cancer.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluating Ampligen across multiple cancers as a potential therapy that modifies the tumor microenvironment with the goal of increasing anti-tumor responses to checkpoint inhibitors.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exploring Ampligen’s antiviral activities and potential use as a prophylactic or treatment for existing viruses, new viruses and mutated viruses thereof.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluating Ampligen as a treatment for myalgic encephalomyelitis/chronic fatigue syndrome (“ME/CFS”) and fatigue and/or the Post-COVID condition of fatigue.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluating Ampligen as a vaccine adjuvant in the combination of Ampligen and AstraZeneca’s FluMist as an intranasal vaccine for influenza, including avian influenza.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ampligen is a wide-spectrum therapeutic that has shown positive safety and efficacy in clinical trials of several different solid tumor types. Based specifically on clinical success as to safety and efficacy in our pancreatic cancer Early Access Program and an ongoing Phase 2 trial, AIM has made the business decision to focus its efforts on the development of Ampligen for the treatment of late-stage pancreatic cancer, as we believe that this path will potentially lead to the most lucrative outcome. Pancreatic cancer is expected to kill an estimated 100,000 people in the American and European Union markets — and more than 450,000 people worldwide in 2026. When AIM looks at the global health problem of pancreatic cancer, we see a large market for an unmet medical need and with relatively little clinical competition. We believe we are well positioned to serve this market with our intellectual property program which includes broad-combination therapy patents in the United States, Japan and Europe, as well as market exclusivity provided by orphan drug designations in the United States and the European Union.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oncology is an area of biotech which can generate multibillion-dollar mergers and acquisitions – large-market Phase 3 oncology clinical trials with positive data are a desirable focus for acquisition. AIM strongly believes that such a Phase 3 study will be possible following the ongoing Phase 2 clinical study evaluating Ampligen in combination with AstraZeneca’s anti-PD-L1 immune checkpoint inhibitor Imfinzi (durvalumab) in the treatment of metastatic pancreatic cancer patients with stable disease post-FOLFIRINOX standard of care (the “DURIPANC” study). The DURIPANC study is an investigator-initiated, exploratory, open-label, single-center study expected to enroll up to 25 subjects in the Phase 2 portion. The primary objective of the study is to determine the clinical benefit rate of the combination therapy. The secondary/exploratory objectives include assessing overall survival and progression-free survival; exploring immune-monitoring using available tissue biopsies and peripheral immune profiling; and assessing quality of life. According to the Erasmus MC Cancer Institute, the promising progression-free survival and overall survival seen in Phase 1 of the study – which we believe supported advancement to the ongoing Phase 2 portion of the study – continue to be seen. As of June 30, 2026, all subjects have been enrolled in the study and have received the first dose of study medication. Erasmus MC expects that detailed data will be published later this year. According to Erasmus MC, there has also been no significant toxicity – an encouraging safety profile for a post-chemo setting – and Ampligen subjects are consistently reporting “high quality of life” during treatment.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In March 2026, the Company announced an agreement with the PPD clinical research business of Thermo Fisher Scientific to design AIM’s anticipated Phase 3 clinical trial in the use of Ampligen in the treatment of late-stage pancreatic cancer. Thermo Fisher Scientific Inc. is a global leader in scientific progress.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In management’s opinion, all adjustments necessary for a fair presentation of its consolidated financial statements have been included. Such adjustments consist of normal recurring items. Interim results are not necessarily indicative of results for a full year.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The interim consolidated financial statements and notes thereto are presented as permitted by the Securities and Exchange Commission (“SEC”), and do not contain certain information which will be included in the Company’s annual consolidated financial statements and notes thereto.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The consolidated financial statements contained herein should be read in conjunction with the Company’s audited consolidated financial statements for the years ended December 31, 2025, and 2024, contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, filed on March 27, 2026.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span>Use of Estimates</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure (“GAAP”) of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses for the reporting period. Actual results could differ from those estimates, and those differences may be material. Accounts requiring the use of significant estimates include determination of other-than-temporary impairment on securities, valuation of deferred taxes, patent and trademark valuations, equity-based compensation calculations, fair value of warrants, and contingency accruals.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span>Liquidity and Going Concern</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying unaudited condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern. The going concern basis of presentation assumes that the Company will continue in operation one year after the date these financial statements are issued and will be able to realize its assets and discharge its liabilities and commitments in the normal course of business.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to the requirements of the Financial Accounting Standards Board’s (the “FASB”) Accounting Standards Codification (“ASC”) Topic 205-40, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern, management must evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern for one year from the date these financial statements are issued. This evaluation does not take into consideration the potential mitigating effect of management’s plans that have not been fully implemented or are not within control of the Company as of the date the financial statements are issued. When substantial doubt about the Company’s ability to continue as a going concern exists, management evaluates whether the mitigating effect of its plans sufficiently alleviates the substantial doubt. The mitigating effect of management’s plans, however, is only considered if both (1) it is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued, and (2) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the financial statements are issued.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s principal source of liquidity is its cash and cash equivalents, marketable securities, and proceeds from financing activities to provide the necessary funding to meet our obligations as they become due. The Company has incurred losses from operations and operating cash outflows exceeded cash inflows from operating activities for the six months ended June 30, 2026. These conditions raise substantial doubt regarding the Company’s ability to continue as a going concern for a period of at least one year from the date of issuance of these consolidated financial statements. Management evaluated the conditions, and the significance of these conditions related to the Company’s ability to meet its obligations. If the Company is unable to implement sufficient mitigation efforts, the Company may be forced to limit its business activities or be unable to continue as a going concern, which would have a material adverse effect on its results of operations and financial condition.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December 11, 2024, the Company received an official notice of noncompliance with the NYSE American’s continued listing requirements. This included the need for the Company to have stockholders’ equity of $<span id="xdx_906_eus-gaap--StockholdersEquity_iI_pn6n6_c20241211__srt--RangeAxis__srt--MinimumMember_zDC0hkHKH1s5" title="Stockholders equity">6</span> million or more. The NYSE American’s review showed that the Company was not in compliance with that requirement. As required, the Company submitted a plan (the “Plan”) to the NYSE American illustrating how it planned to regain compliance by June 11, 2026. The NYSE American accepted the Plan on February 26, 2025, and the Company has submitted quarterly updates to the NYSE American since that time. If the Company was not able to raise sufficient capital as set forth in the Plan or by other means, it may have been unable to regain compliance with the NYSE American’s listing standards, and its securities could have been subject to delisting. In addition, in the event that the price of the common stock drops to $<span id="xdx_90C_eus-gaap--SharePrice_iI_pid_c20260630_zpbUQuuNh05" title="Share price">0.10</span> per share, trading in the common stock would automatically be suspended and the common stock would be subject to delisting. The price dropped below $<span id="xdx_909_eus-gaap--SharePrice_iI_pid_c20250404_zifBpkFORIhc" title="Share price">0.10</span> and on April 4, 2025, the Company received a delisting letter from the NYSE American and trading in its common stock on the NYSE American was suspended.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 30, 2025, the Company held a special meeting of stockholders and authorized the Company’s Board of Directors to effect a reverse split at its discretion on a basis of up to <span id="xdx_90C_eus-gaap--StockholdersEquityReverseStockSplit_c20250430__20250430_zflFmKds5WAg" title="Reverse stock split">one for 100</span> outstanding shares of Common Stock. On May 29, 2025, the Board authorized the reverse split and on June 10, 2025, the Company filed an amendment to its Articles of Incorporation effecting a reverse split of its outstanding shares of Common Stock on a <span id="xdx_90A_eus-gaap--StockholdersEquityReverseStockSplit_c20250529__20250529_zXctRniG1Mzg" title="Reverse stock split">one for 100</span> basis (the “Reverse Split”). Stockholders were given cash in lieu of any fractional shares on a post-split basis.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 11, 2025, the Company was notified by the NYSE American that the Company had regained compliance with Section 1003(f)(v) of the NYSE American’s Company Guide (low selling price) and that trading in the Company’s Common Stock was reinstated on the NYSE American on June 17, 2025.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the third quarter of 2025, an agreement was reached with a vendor surrounding legal fees. The agreement provided that $<span id="xdx_907_eus-gaap--LegalFees_pn6n6_c20250701__20250930_z88dr4hRRjje" title="Previously billed fees">3</span> million of previously billed fees would be forgiven in exchange for payments totaling $<span id="xdx_90B_eus-gaap--ExchangeFees_pn5n6_c20250701__20250930_zBefcaFfwsej" title="Exchange for payments">1.9</span> million. The reduction was included as “other income” and accounts payable was reduced.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_ecustom--CommonStockDividendPaymentRatioDescription_c20260120__20260120_z4JT7f1zcxu2" title="Common stock dividend payment ratio description">On January 20, 2026, the Company distributed a stock dividend of one share of our common stock for every 1,000 shares of common stock issued and outstanding as of January 9, 2026, as well as one share of common stock for every 1,000 outstanding options or 1,000 warrants that has a right to receive stock dividends.</span> The distribution was effected on January 20, 2026. This resulted in a reset of the terms of our Class E and Class F Warrants. Per the reset, the exercise price of these warrants dropped to $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260120_zBTYK7fHXLia" title="Warrants exercise price per share">1.439</span>, additional warrants were issued and a provision in these warrants that resulted in the classification of these warrants as a liability rather than equity was nullified. This resulted in a $<span id="xdx_90D_eus-gaap--StockholdersEquity_iI_pn5n6_c20260120__srt--RangeAxis__srt--MinimumMember_zsG8w0j9VrC3" title="Increase in stockholders equity">8.7</span> million increase in stockholders’ equity.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 7, 2026, the Company entered into a warrant exercise inducement offer letter agreement with certain holders of existing warrants, pursuant to which the holders agreed to exercise their warrants in cash at a reduced exercise price for aggregate gross proceeds of approximately $<span id="xdx_903_eus-gaap--ProceedsFromIssuanceOfWarrants_pn5n6_c20260507__20260507__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--TypeOfArrangementAxis__custom--WarrantExerciseInducementOfferLetterAgreementMember_zpmESikzLlOf" title="Gross proceeds">3.5</span> million in consideration of the Company’s agreement to issue new warrants upon such exercise.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 21, 2026, the Company issued and sold <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20260521__20260521__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--InvestorsMember_zIYXt3GfksRi" title="Shares issued">7,519,351</span> shares of common stock, par value $<span id="xdx_90B_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20260521__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__srt--TitleOfIndividualAxis__custom--InvestorsMember_zs0Ni3Vb2OT2" title="Common stock, par value">0.001</span> per share, and, in a concurrent private placement, Class I warrants to purchase up to <span id="xdx_904_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20260521__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassIWarrantsMember__srt--TitleOfIndividualAxis__custom--InvestorsMember_zIdOT0Vs8bul" title="Purchase of warrants">15,038,702</span> shares of common stock to certain investors for aggregate gross proceeds of approximately $<span id="xdx_90E_eus-gaap--ProceedsFromIssuanceOfWarrants_pn5n6_c20260521__20260521__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassIWarrantsMember__srt--TitleOfIndividualAxis__custom--InvestorsMember_zn1YsUsm0GEb" title="Gross proceeds">2.4</span> million.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 10, 2026, the Company issued and sold <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20260610__20260610__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--InvestorsMember_z4VnYkFZRVy7" title="Shares issued">2,554,119</span> shares of common stock and, in a concurrent private placement, <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20260610__20260610__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__srt--TitleOfIndividualAxis__custom--InvestorsMember_zSHvoyi00D47" title="Shares issued">771,503</span> shares of common stock, pre-funded warrants to purchase up to <span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20260610__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember__srt--TitleOfIndividualAxis__custom--InvestorsMember_zeoopG3Tmjyl" title="Purchase of warrants">1,782,616</span> shares of common stock, and Class J warrants to purchase up to <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20260610__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassJWarrantsMember__srt--TitleOfIndividualAxis__custom--InvestorsMember_z2dfjIiu2q2e" title="Purchase of warrants">10,216,476</span> shares of common stock to certain investors for aggregate gross proceeds of approximately $<span id="xdx_905_eus-gaap--ProceedsFromIssuanceOfWarrants_pn5n6_c20260610__20260610__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassJWarrantsMember__srt--TitleOfIndividualAxis__custom--InvestorsMember_zHWcsgH6eYy6" title="Gross proceeds">2.6</span> million. Following the closing of these transactions, the Company satisfied the NYSE $<span id="xdx_90A_eus-gaap--StockholdersEquityOther_pn5n6_c20260610__20260610__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassJWarrantsMember__srt--TitleOfIndividualAxis__custom--InvestorsMember_zKq0QqcsAty7" title="Stockholders' equity minimum requirement">6.0</span> stockholders equity requirement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The NYSE American formally notified the Company on June 12, 2026, confirming that the Company had successfully addressed and resolved all deficiencies related to Sections 1003(a)(i), (ii), and (iii) of the NYSE American Company Guide. As a result, the “below compliance” (“.BC”) indicator was removed from the Company’s trading symbol for its common stock, and the Company was removed from NYSE American’s list of noncompliant issuers on its website. The Company will remain subject to NYSE American’s continued listing monitoring procedures and remains committed to maintaining strong financial discipline and governance going forward.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> 6000000 0.10 0.10 one for 100 one for 100 3000000 1900000 On January 20, 2026, the Company distributed a stock dividend of one share of our common stock for every 1,000 shares of common stock issued and outstanding as of January 9, 2026, as well as one share of common stock for every 1,000 outstanding options or 1,000 warrants that has a right to receive stock dividends. 1.439 8700000 3500000 7519351 0.001 15038702 2400000 2554119 771503 1782616 10216476 2600000 6000000.0 <p id="xdx_80F_eus-gaap--NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_zKyUkDZ7uzx9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 2: <span id="xdx_82C_zAVi6yTe2tQe">Recent Accounting Pronouncements</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has implemented all new accounting pronouncements that are in effect. These pronouncements did not have any material impact on the financial statements unless otherwise disclosed, and the Company does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations. ASU 2024-03 “Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses” is applicable to AIM beginning for the quarter ending March 31, 2027 and will require additional disclosures for certain income statement line items. The Company is still evaluating the impact of this update. Accounting pronouncements issued by the FASB since filing the Annual Report on Form 10-K for the year ended December 31, 2025 did not or are not believed by management to have a material impact on the Company’s present or future financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_80C_eus-gaap--CashAndCashEquivalentsDisclosureTextBlock_zXHkFBhPwgHe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 3</b>: <b><span id="xdx_828_z04IqbitRuhi">Cash and Cash Equivalents</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash includes bank deposits maintained at several financial institutions. The Company considers highly liquid instruments with an original maturity of three months or less to be cash equivalents. As of June 30, 2026 and at other various times throughout the six months ended June 30, 2026, some accounts held at financial institutions were in excess of the federally insured limit of $<span id="xdx_90F_eus-gaap--CashFDICInsuredAmount_iI_pn3n3_c20260630_zVnj4ILYqaBc" title="Federally insured limit">250</span> thousand. The Company has not experienced any losses on these accounts and believes credit risk to be minimal.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 250000 <p id="xdx_803_eus-gaap--InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_zl59exLQ2tmf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 4: <span id="xdx_823_zklDDMXSFeb">Marketable Securities</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marketable securities consist of mutual funds. At June 30, 2026 and December 31, 2025, it was determined that none of the marketable securities had an other-than-temporary impairment. At June 30, 2026 and December 31, 2025, all securities were measured as Level 1 instruments of the fair value measurements standard (See Note 16: Fair Value). At June 30, 2026, and December 31, 2025 the Company held $<span id="xdx_909_eus-gaap--MarketableSecurities_iI_pn3n3_c20260630_zN8jqHNd81m4" title="Marketable securities held in mutual funds">64</span> thousand and $<span id="xdx_907_eus-gaap--MarketableSecurities_iI_pn3n3_c20251231_zfUPyVO0VPye" title="Marketable securities held in mutual funds">62</span> thousand, respectively, in mutual funds.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mutual Funds classified as available for sale consisted of $<span id="xdx_900_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20260630_z5eK3Smawvpj" title="Marketable securities held for sale">64</span> thousand at June 30, 2026. There was <span id="xdx_90C_eus-gaap--GainLossOnSaleOfInvestments_pn3n3_do_c20260101__20260630_zmBQUGyMm1Ke" title="Net gain (loss) on equity securities">no</span> realized gain or loss recognized for the six-month period ended June 30, 2026 on equity securities. There was <span id="xdx_908_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_iN_pn3n3_dixL_c20260101__20260630_znVwTLcojhNl" title="Unrealized gains recognized::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0690">no</span></span> unrealized loss recognized for the six-month period ended June 30, 2026 on equity securities still held.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mutual Funds classified as available for sale consisted of $<span id="xdx_90C_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20250630_zdwOOJuTPR04" title="Marketable securities held for sale">359</span> thousand at June 30, 2025. The net loss recognized for the six-month period ended June 30, 2025 on equity securities was ($<span id="xdx_90C_eus-gaap--GainLossOnSaleOfInvestments_pn3n3_do_c20250101__20250630_zOP0Mb7BLhJh" title="Net gain (loss) on equity securities">68</span>) thousand. The unrealized gains recognized for the six-month period ended June 30, 2025 on equity securities still held was $<span id="xdx_90E_eus-gaap--GainLossOnSaleOfOtherInvestments_pn3n3_c20250101__20250630_z24BzkaMwdE1" title="Unrealized gains recognized">85</span> thousand. The net gain recognized for the six-month period ended June 30, 2025 on equity securities was $<span id="xdx_905_eus-gaap--EquitySecuritiesFvNiRealizedGainLoss_pn3n3_c20250101__20250630_z9FAZpllCww2" title="Recognized gain (loss)">18</span> thousand.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 64000 62000 64000 0 359000 68000 85000 18000 <p id="xdx_807_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zVMunTjPEBMa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 5: <span id="xdx_824_zDAHvH1jURZ3">Property and Equipment, Net</span></b></span></p> <p id="xdx_891_eus-gaap--PropertyPlantAndEquipmentTextBlock_z3TdO5U8sC61" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BF_zAbfkd9d9xpe" style="display: none">Schedule of Property and Equipment</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="display: none; text-align: center"> </td><td style="display: none; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49A_20260630_zFDW3i6mRHtl" style="border-bottom: Black 1pt solid; display: none; text-align: center">June 30, 2026</td><td style="display: none; padding-bottom: 1pt"> </td><td style="display: none; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20251231_zDp1YyNGcZh9" style="border-bottom: Black 1pt solid; display: none; text-align: center">December 31, 2025</td><td style="display: none; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">(in thousands)</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">June 30, 2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_405_eus-gaap--FurnitureAndFixturesGross_iI_pn3n3_maPPAENzOpl_zmds68867QXh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Furniture, fixtures, and equipment</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,466</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,466</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_msPPAENzOpl_z9jZpU9FQCgk" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Less: accumulated depreciation</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(1,412</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(1,395</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_401_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pn3n3_mtPPAENzOpl_z51B7JTUk17c" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Property and equipment, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">54</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">71</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AD_zpIU96ed8qTb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment are recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the respective assets, ranging from three</span><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20260630__srt--RangeAxis__srt--MinimumMember_zMAUzJXAvG6h" title="Estimated useful life">3</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">to <span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dc_c20260630__srt--RangeAxis__srt--MaximumMember_zOomeS9jVsPd" title="Estimated useful life">ten years</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">. Depreciation expense for the six months ended June 30, 2026 and 2025 was $<span id="xdx_901_eus-gaap--Depreciation_pn3n3_c20260101__20260630_zOkb6XqR06Fc" title="Depreciation expense">17</span> thousand and $<span id="xdx_909_eus-gaap--Depreciation_pn3n3_c20250101__20250630_ztH9F7DDYyja" title="Depreciation expense">19</span> thousand, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_891_eus-gaap--PropertyPlantAndEquipmentTextBlock_z3TdO5U8sC61" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BF_zAbfkd9d9xpe" style="display: none">Schedule of Property and Equipment</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="display: none; text-align: center"> </td><td style="display: none; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49A_20260630_zFDW3i6mRHtl" style="border-bottom: Black 1pt solid; display: none; text-align: center">June 30, 2026</td><td style="display: none; padding-bottom: 1pt"> </td><td style="display: none; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20251231_zDp1YyNGcZh9" style="border-bottom: Black 1pt solid; display: none; text-align: center">December 31, 2025</td><td style="display: none; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">(in thousands)</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">June 30, 2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_405_eus-gaap--FurnitureAndFixturesGross_iI_pn3n3_maPPAENzOpl_zmds68867QXh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Furniture, fixtures, and equipment</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,466</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,466</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_msPPAENzOpl_z9jZpU9FQCgk" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Less: accumulated depreciation</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(1,412</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(1,395</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_401_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pn3n3_mtPPAENzOpl_z51B7JTUk17c" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Property and equipment, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">54</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">71</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 1466000 1466000 1412000 1395000 54000 71000 P3Y P10Y 17000 19000 <p id="xdx_809_eus-gaap--IntangibleAssetsDisclosureTextBlock_zzH5xI4FiBR5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 6: <span id="xdx_82B_zGJa4z5AJzyg">Patents and Trademark Rights, Net</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_898_eus-gaap--ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_zIlPMclexTC1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patent and trademark rights consist of the following (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BC_zG1O7A4JLXf2" style="display: none">Schedule of Patent and Trademark Rights</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="10" style="border-bottom: Black 1pt solid; text-align: center">June 30, 2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="10" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Gross Carrying Value</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Accumulated Amortization</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Net Carrying Value</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Gross Carrying Value</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Accumulated Amortization</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Net Carrying Value</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Patents</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20260630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zWlA0YFIPsM3" style="width: 6%; text-align: right" title="Gross carrying value">2,267</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20260630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zDjoGTgnxih2" style="width: 6%; text-align: right" title="Accumulated amortization">(610</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20260630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zkCAXVwhlw7e" style="width: 6%; text-align: right" title="Net carrying value">1,657</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20251231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zvUpCON46xG7" style="width: 6%; text-align: right" title="Gross carrying value">2,150</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20251231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zsCbFevqqblj" style="width: 6%; text-align: right" title="Accumulated amortization">(551</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20251231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zky6YYRwqmxl" style="width: 6%; text-align: right" title="Net carrying value">1,599</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Trademarks</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20260630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zSvcjK3mpjj5" style="border-bottom: Black 1pt solid; text-align: right" title="Gross carrying value">182</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20260630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zNweedESeqS5" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated amortization">(125</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20260630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zSZlzB1Xm3J7" style="border-bottom: Black 1pt solid; text-align: right" title="Net carrying value">57</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20251231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zRau9D9sppYj" style="border-bottom: Black 1pt solid; text-align: right" title="Gross carrying value">182</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20260331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zBbxBSoYs452" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated amortization">(120</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20251231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zDnF8vsSTwZf" style="border-bottom: Black 1pt solid; text-align: right" title="Net carrying value">62</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Net amortizable patents and trademarks rights</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20260630_zRb5rY8nHQh5" style="border-bottom: Black 2.5pt double; text-align: right" title="Gross carrying value">2,449</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20260630_zQN0s2TBxWLf" style="border-bottom: Black 2.5pt double; text-align: right" title="Accumulated amortization">(735</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20260630_zcb9rVEglcv2" style="border-bottom: Black 2.5pt double; text-align: right" title="Net carrying value">1,714</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20251231_zPOhiBNzTWe3" style="border-bottom: Black 2.5pt double; text-align: right" title="Gross carrying value">2,332</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20251231_zcJMfqGf2TBh" style="border-bottom: Black 2.5pt double; text-align: right" title="Accumulated amortization">(671</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20251231_zq0F2D8EFxG3" style="border-bottom: Black 2.5pt double; text-align: right" title="Net carrying value">1,661</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AE_zlt0UHE3e99" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_895_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zBFCE0jYisb1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patent and trademark rights acquisitions, abandonments and amortization (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B7_zEYf5hB56QUd" style="display: none">Schedule of Changes in Patents, Trademark Rights</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: justify">December 31, 2025</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsNet_iS_pn3n3_c20260101__20260630_zZWWspUYS88" style="width: 16%; text-align: right" title="Beginning balance">1,661</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Acquisitions</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--FinitelivedIntangibleAssetsAcquired1_pn3n3_c20260101__20260630_zwiv7jZzpJu9" style="text-align: right" title="Acquisitions">147</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Abandonments</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_ecustom--FinitelivedIntangibleAssetsAbandonments_iN_pn3n3_di_c20260101__20260630_zRuOIqcHmKZa" style="text-align: right" title="Abandonments and expirations">(24</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">Amortization <br/></td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--AmortizationOfIntangibleAssets_iN_pn3n3_di_c20260101__20260630_zI1lmYSYA84h" style="border-bottom: Black 1pt solid; text-align: right" title="Amortization">(70</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">June 30, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsNet_iE_pn3n3_c20260101__20260630_zDNPQH8vDxmb" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance">1,714</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A7_zMOzShmM6dh4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patents and trademarks are stated at cost (primarily legal fees) and are amortized using the straight-line method over an estimated useful life of <span id="xdx_90F_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20260630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zSsA2svODMZ1" title="Finite lived intangible assets, estimated useful life">17</span> years for patents and <span id="xdx_906_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20260630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zGDYTY9FuZO9" title="Finite lived intangible assets, estimated useful life">10</span> years for trademarks. The weighted remaining average amortization period is <span id="xdx_908_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_iI_dtY_c20260630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_z8F3PFXZaJL3" title="Intangible assets, weighted remaining average amortization period">12</span> years for patents and <span id="xdx_90D_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_iI_dtY_c20260630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_za01emeX6f21" title="Intangible assets, weighted remaining average amortization period">3</span> years for trademarks, respectively. The Company expenses annuity costs related to its trademarks and patents.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89F_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zxjLinkYyQGg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortization of patents and trademarks for each of the next five years and thereafter is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B6_zo2ARHdFuI0i" style="display: none">Schedule of Amortization of Patents and Trademarks</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="display: none; text-align: justify"> </td><td style="display: none"> </td> <td style="display: none; text-align: left"> </td><td id="xdx_495_20260630_zGF0AnRQUR06" style="display: none; text-align: right"> </td><td style="display: none; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="5" style="border-bottom: Black 1pt solid; font-weight: bold">Year Ending December 31,</td></tr> <tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_iI_pn3n3_maFLIANzzOp_zJBURpVbNf5e" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: justify">2026</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">88</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_pn3n3_maFLIANzzOp_z8tXe5nwQOH1" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">2027</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">156</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_pn3n3_maFLIANzzOp_zwZ4P05Nb0qh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">2028</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">150</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_pn3n3_maFLIANzzOp_zrWYG7mdKVU6" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">2029</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">144</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_pn3n3_maFLIANzzOp_z1CXt2BbhHv6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">2030</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">135</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_ecustom--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour_iI_pn3n3_maFLIANzzOp_zNWV3WL2jLxj" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">Thereafter</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,041</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_pn3n3_mtFLIANzzOp_zhTy5QlASfMe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: justify; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,714</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A4_zW9o3TOjM0m3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_898_eus-gaap--ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_zIlPMclexTC1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patent and trademark rights consist of the following (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BC_zG1O7A4JLXf2" style="display: none">Schedule of Patent and Trademark Rights</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="10" style="border-bottom: Black 1pt solid; text-align: center">June 30, 2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="10" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Gross Carrying Value</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Accumulated Amortization</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Net Carrying Value</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Gross Carrying Value</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Accumulated Amortization</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Net Carrying Value</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Patents</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20260630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zWlA0YFIPsM3" style="width: 6%; text-align: right" title="Gross carrying value">2,267</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20260630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zDjoGTgnxih2" style="width: 6%; text-align: right" title="Accumulated amortization">(610</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20260630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zkCAXVwhlw7e" style="width: 6%; text-align: right" title="Net carrying value">1,657</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20251231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zvUpCON46xG7" style="width: 6%; text-align: right" title="Gross carrying value">2,150</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20251231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zsCbFevqqblj" style="width: 6%; text-align: right" title="Accumulated amortization">(551</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20251231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zky6YYRwqmxl" style="width: 6%; text-align: right" title="Net carrying value">1,599</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Trademarks</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20260630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zSvcjK3mpjj5" style="border-bottom: Black 1pt solid; text-align: right" title="Gross carrying value">182</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20260630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zNweedESeqS5" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated amortization">(125</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20260630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zSZlzB1Xm3J7" style="border-bottom: Black 1pt solid; text-align: right" title="Net carrying value">57</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20251231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zRau9D9sppYj" style="border-bottom: Black 1pt solid; text-align: right" title="Gross carrying value">182</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20260331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zBbxBSoYs452" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated amortization">(120</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20251231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zDnF8vsSTwZf" style="border-bottom: Black 1pt solid; text-align: right" title="Net carrying value">62</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Net amortizable patents and trademarks rights</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20260630_zRb5rY8nHQh5" style="border-bottom: Black 2.5pt double; text-align: right" title="Gross carrying value">2,449</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20260630_zQN0s2TBxWLf" style="border-bottom: Black 2.5pt double; text-align: right" title="Accumulated amortization">(735</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20260630_zcb9rVEglcv2" style="border-bottom: Black 2.5pt double; text-align: right" title="Net carrying value">1,714</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20251231_zPOhiBNzTWe3" style="border-bottom: Black 2.5pt double; text-align: right" title="Gross carrying value">2,332</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20251231_zcJMfqGf2TBh" style="border-bottom: Black 2.5pt double; text-align: right" title="Accumulated amortization">(671</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20251231_zq0F2D8EFxG3" style="border-bottom: Black 2.5pt double; text-align: right" title="Net carrying value">1,661</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 2267000 -610000 1657000 2150000 -551000 1599000 182000 -125000 57000 182000 -120000 62000 2449000 -735000 1714000 2332000 -671000 1661000 <p id="xdx_895_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zBFCE0jYisb1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patent and trademark rights acquisitions, abandonments and amortization (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B7_zEYf5hB56QUd" style="display: none">Schedule of Changes in Patents, Trademark Rights</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: justify">December 31, 2025</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsNet_iS_pn3n3_c20260101__20260630_zZWWspUYS88" style="width: 16%; text-align: right" title="Beginning balance">1,661</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Acquisitions</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--FinitelivedIntangibleAssetsAcquired1_pn3n3_c20260101__20260630_zwiv7jZzpJu9" style="text-align: right" title="Acquisitions">147</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Abandonments</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_ecustom--FinitelivedIntangibleAssetsAbandonments_iN_pn3n3_di_c20260101__20260630_zRuOIqcHmKZa" style="text-align: right" title="Abandonments and expirations">(24</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">Amortization <br/></td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--AmortizationOfIntangibleAssets_iN_pn3n3_di_c20260101__20260630_zI1lmYSYA84h" style="border-bottom: Black 1pt solid; text-align: right" title="Amortization">(70</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">June 30, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsNet_iE_pn3n3_c20260101__20260630_zDNPQH8vDxmb" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance">1,714</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 1661000 147000 24000 70000 1714000 P17Y P10Y P12Y P3Y <p id="xdx_89F_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zxjLinkYyQGg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortization of patents and trademarks for each of the next five years and thereafter is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B6_zo2ARHdFuI0i" style="display: none">Schedule of Amortization of Patents and Trademarks</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="display: none; text-align: justify"> </td><td style="display: none"> </td> <td style="display: none; text-align: left"> </td><td id="xdx_495_20260630_zGF0AnRQUR06" style="display: none; text-align: right"> </td><td style="display: none; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="5" style="border-bottom: Black 1pt solid; font-weight: bold">Year Ending December 31,</td></tr> <tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_iI_pn3n3_maFLIANzzOp_zJBURpVbNf5e" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: justify">2026</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">88</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_pn3n3_maFLIANzzOp_z8tXe5nwQOH1" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">2027</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">156</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_pn3n3_maFLIANzzOp_zwZ4P05Nb0qh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">2028</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">150</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_pn3n3_maFLIANzzOp_zrWYG7mdKVU6" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">2029</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">144</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_pn3n3_maFLIANzzOp_z1CXt2BbhHv6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">2030</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">135</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_ecustom--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour_iI_pn3n3_maFLIANzzOp_zNWV3WL2jLxj" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">Thereafter</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,041</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_pn3n3_mtFLIANzzOp_zhTy5QlASfMe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: justify; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,714</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 88000 156000 150000 144000 135000 1041000 1714000 <p id="xdx_806_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_zKG7yPsuYqLj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 7: <span id="xdx_82F_zf5onZGnQjS2">Accrued Expenses</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89A_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_z7TMfVxw3Zha" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued expenses consist of the following: (in thousands)</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B6_zaAegDqR4Doe" style="display: none">Schedule of Accrued Expenses</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20260630_z6uqn1Y5MOC1" style="border-bottom: Black 1pt solid; text-align: center">June 30, 2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49F_20251231_zWGNR4HEZP63" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_409_eus-gaap--EmployeeRelatedLiabilitiesCurrent_iI_pn3n3_maALCzYmu_zOcgvbtF5MV6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Compensation</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0801">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">218</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--AccruedProfessionalFeesCurrent_iI_pn3n3_maALCzYmu_zT1XQyJ1EAz7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Professional fees</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">478</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">303</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_ecustom--AccruedClinicalTrialExpensesCurrent_iI_pn3n3_maALCzYmu_z96YD2iwLec2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Clinical trial expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">11</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">20</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--InterestPayableCurrent_iI_pn3n3_maALCzYmu_zyfl7Ju8N9N4" style="vertical-align: bottom; background-color: White"> <td>Interest</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">24</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">64</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pn3n3_maALCzYmu_zVoXxuBWIrHd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Other expenses</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">73</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">190</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--AccruedLiabilitiesCurrent_iTI_pn3n3_mtALCzYmu_zktsNLfccbi3" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">586</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">795</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A2_zmSINP9EjJZ4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_89A_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_z7TMfVxw3Zha" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued expenses consist of the following: (in thousands)</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B6_zaAegDqR4Doe" style="display: none">Schedule of Accrued Expenses</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20260630_z6uqn1Y5MOC1" style="border-bottom: Black 1pt solid; text-align: center">June 30, 2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49F_20251231_zWGNR4HEZP63" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_409_eus-gaap--EmployeeRelatedLiabilitiesCurrent_iI_pn3n3_maALCzYmu_zOcgvbtF5MV6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Compensation</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0801">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">218</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--AccruedProfessionalFeesCurrent_iI_pn3n3_maALCzYmu_zT1XQyJ1EAz7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Professional fees</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">478</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">303</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_ecustom--AccruedClinicalTrialExpensesCurrent_iI_pn3n3_maALCzYmu_z96YD2iwLec2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Clinical trial expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">11</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">20</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--InterestPayableCurrent_iI_pn3n3_maALCzYmu_zyfl7Ju8N9N4" style="vertical-align: bottom; background-color: White"> <td>Interest</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">24</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">64</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pn3n3_maALCzYmu_zVoXxuBWIrHd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Other expenses</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">73</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">190</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--AccruedLiabilitiesCurrent_iTI_pn3n3_mtALCzYmu_zktsNLfccbi3" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">586</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">795</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 218000 478000 303000 11000 20000 24000 64000 73000 190000 586000 795000 <p id="xdx_809_eus-gaap--DebtDisclosureTextBlock_z7pjmdk0V7Xb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 8: <span id="xdx_825_zbFucTicr4t6">Unsecured Promissory Note</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the years ended 2025 and 2024 the Company entered into three separate agreements with Streeterville Capital LLC (“Streeterville” or the “Lender”). The terms of the agreements are described below:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note 1 –</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 16, 2024, the Company (“Borrower”) entered into a Note Purchase Agreement with Streeterville Capital LLC (“Streeterville” or the “Lender”). Under the terms of the agreement, Streeterville paid the Company $<span id="xdx_908_eus-gaap--DebtConversionConvertedInstrumentAmount1_pn5n6_c20240216__20240216__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementMember__us-gaap--CreditFacilityAxis__custom--StreetervilleCapitalLlcMember_z39Qi6qVevSi" title="Exchange of unsecured promissory notes">2.5</span> million in exchange for an unsecured promissory Note with an Original Issue Discount of $<span id="xdx_90B_eus-gaap--DebtConversionOriginalDebtAmount1_pn3n3_c20240216__20240216__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementMember__us-gaap--CreditFacilityAxis__custom--StreetervilleCapitalLlcMember_zM3w33CejhB3" title="Unsecured debt original issue discount">781</span> thousand. Under the original terms of the agreement, the Company agreed to pay $<span id="xdx_902_eus-gaap--LongTermDebt_iI_pn5n6_c20240216__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementMember__us-gaap--CreditFacilityAxis__custom--StreetervilleCapitalLlcMember_zdBYJWp9KOfe" title="Long term debt">3.3</span> million consisting of the principal amount of the Note, together with the original issue discount and $<span id="xdx_90F_eus-gaap--DeferredFinanceCostsGross_iI_pn3n3_c20240216__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementMember__us-gaap--CreditFacilityAxis__custom--StreetervilleCapitalLlcMember_z9lVQvyEz826" title="Debt issuance costs">20</span> thousand of lender transaction fees, no later than February 16, 2026. The stated interest rate of the note is <span id="xdx_906_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20260101__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementMember__us-gaap--CreditFacilityAxis__custom--StreetervilleCapitalLlcMember_zqMl6Hp2el3a" title="Debt instrument stated interest rate">10</span>%.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--DebtInstrumentRedemptionDescription_c20240216__20240216__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementMember__us-gaap--CreditFacilityAxis__custom--StreetervilleCapitalLlcMember_zcU2onhDbILa" title="Redemption description">The agreement allows the Lender to redeem up to $250 thousand per calendar month beginning in August 2024, upon providing written notice to Borrower.</span> The Note further contains triggering events which can be remedied by the Lender requiring the Borrower to correct the triggering event, increasing the outstanding balance by applying the triggering effect, or making the Note immediately due and payable.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the quarter ended March 31, 2026, the Company entered into an agreement with the Lender to settle a portion of its outstanding loan obligation in the amount of $<span id="xdx_906_eus-gaap--DebtConversionOriginalDebtAmount1_pn3n3_c20260101__20260331__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementMember__us-gaap--CreditFacilityAxis__custom--StreetervilleCapitalLlcMember_zZKlr8vjnOY1" title="Loan obligation settled">400</span> thousand through the issuance of <span id="xdx_900_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20260101__20260331__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementMember__us-gaap--CreditFacilityAxis__custom--StreetervilleCapitalLlcMember_zbc88ArELPK8" title="Shares issued for debt settlement">364,084</span> shares of common stock rather than cash payment. During the year ended December 31, 2025, the Company entered into agreements with the Lender to settle a portion of its outstanding loan obligation in the amount of $<span id="xdx_90D_eus-gaap--DebtConversionOriginalDebtAmount1_pn3n3_c20250101__20251231__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementMember__us-gaap--CreditFacilityAxis__custom--StreetervilleCapitalLlcMember_zUKjo4qltTfl" title="Loan obligation settled">700</span> thousand through the issuance of <span id="xdx_90E_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20250101__20251231__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementMember__us-gaap--CreditFacilityAxis__custom--StreetervilleCapitalLlcMember_zIyvVwtVVF2f" title="Shares issued for debt settlement">170,353</span> shares of common stock, rather than cash payment. These exchanges were completed pursuant to the terms of the loan agreement, which allows for the settlement of debt through stock issuance under certain conditions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An amendment to the Promissory Note was executed with the lender on March 10, 2026. Pursuant to the amendment the maturity date of the Note was extended until June 30, 2026. Other than the maturity date extension, there were no other changes to the agreement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 18, 2026, the Company and the Lender entered into Amendment #2, which amended the Note and further extended the maturity date of the Note until June 30, 2027. Pursuant to the Amendment, the Company agreed to pay the Lender an extension fee in the amount of $<span id="xdx_905_ecustom--ExtensionFee_pn3n3_c20260518__20260518__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementMember__us-gaap--CreditFacilityAxis__custom--StreetervilleCapitalLlcMember_zOgMfilgzYd7" title="Extension fee">10</span> thousand. The Extension Fee was added to the outstanding balance of the Note. The Amendment also contains customary representations and warranties of the Company, as well as a representation and warranty of the Company that, as of the date of the Amendment, the outstanding balance of the Note, following the application of the Extension Fee, was approximately $<span id="xdx_909_ecustom--ExtensionFee_pn5n6_c20260101__20260630__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementMember__us-gaap--CreditFacilityAxis__custom--StreetervilleCapitalLlcMember_zWZ0yBAo4up1" title="Extension fee">1.7</span> million.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note 2 –</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 30, 2025, the Company (“Borrower”) entered into a Note and Note Purchase Agreement with Streeterville Capital LLC (“Streeterville” or the “Lender”). Under the terms of the agreements, Streeterville paid the Company $<span id="xdx_909_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20250630__us-gaap--TypeOfArrangementAxis__custom--NoteTwoPurchaseAgreementMember__us-gaap--CreditFacilityAxis__custom--StreetervilleCapitalLlcMember_ze4FsuyNQS39" title="Principal amount">250</span> thousand in exchange for an unsecured promissory Note with an Original Issue Discount of $<span id="xdx_907_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pn3n3_c20250630__us-gaap--TypeOfArrangementAxis__custom--NoteTwoPurchaseAgreementMember__us-gaap--CreditFacilityAxis__custom--StreetervilleCapitalLlcMember_zQ2rGwGvie9g" title="Original issue discount">50</span> thousand. The Note required the Company to pay $<span id="xdx_90C_eus-gaap--DebtInstrumentPeriodicPaymentPrincipal_pn3n3_c20250630__20250630__us-gaap--TypeOfArrangementAxis__custom--NoteTwoPurchaseAgreementMember__us-gaap--CreditFacilityAxis__custom--StreetervilleCapitalLlcMember_zX1i32j1dJw8" title="Debt instrument periodic payment, principal">310</span> thousand consisting of the principal amount of the Note, together with the original issue discount and $<span id="xdx_906_eus-gaap--DebtInstrumentPeriodicPaymentInterest_pn3n3_c20250630__20250630__us-gaap--TypeOfArrangementAxis__custom--NoteTwoPurchaseAgreementMember__us-gaap--CreditFacilityAxis__custom--StreetervilleCapitalLlcMember_zQ8n5HBASoq5" title="Lender transaction fees">10</span> thousand of lender transaction fees, no later than October 28, 2025. On August 12, 2025, the Company repaid the note in full.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note 3 –</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 18, 2025, the Company (“Borrower”) entered into a Note Purchase Agreement with Streeterville Capital LLC (“Streeterville” or the “Lender”). Under the terms of the agreement, Streeterville paid the Company $<span id="xdx_905_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20251118__us-gaap--TypeOfArrangementAxis__custom--NoteThreePurchaseAgreementMember__us-gaap--CreditFacilityAxis__custom--StreetervilleCapitalLlcMember_zs6N97zaDku8" title="Principal amount">2.5</span> million in exchange for an unsecured promissory Note with an Original Issue Discount of $<span id="xdx_90B_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pn3n3_c20251118__us-gaap--TypeOfArrangementAxis__custom--NoteThreePurchaseAgreementMember__us-gaap--CreditFacilityAxis__custom--StreetervilleCapitalLlcMember_zJZd5kNsI2wl" title="Original issue discount">781</span> thousand. The Company agreed to pay $<span id="xdx_903_eus-gaap--DebtInstrumentPeriodicPaymentPrincipal_pn5n6_c20251118__20251118__us-gaap--TypeOfArrangementAxis__custom--NoteThreePurchaseAgreementMember__us-gaap--CreditFacilityAxis__custom--StreetervilleCapitalLlcMember_zfBiW2c9slEd" title="Debt instrument periodic payment, principal">3.3</span> million consisting of the principal amount of the Note, together with the original issue discount and $<span id="xdx_900_eus-gaap--DebtInstrumentPeriodicPaymentInterest_pn3n3_c20251118__20251118__us-gaap--TypeOfArrangementAxis__custom--NoteThreePurchaseAgreementMember__us-gaap--CreditFacilityAxis__custom--StreetervilleCapitalLlcMember_zRfl8PrDy6J" title="Lender transaction fees">20</span> thousand of lender transaction fees, no later than November 18, 2027. The stated interest rate of the note is <span id="xdx_904_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20251118__us-gaap--TypeOfArrangementAxis__custom--NoteThreePurchaseAgreementMember__us-gaap--CreditFacilityAxis__custom--StreetervilleCapitalLlcMember_zAcjawhtin1d" title="Interest rate percentage">10</span>%.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--DebtInstrumentRedemptionDescription_c20251118__20251118__us-gaap--TypeOfArrangementAxis__custom--NoteThreePurchaseAgreementMember__us-gaap--CreditFacilityAxis__custom--StreetervilleCapitalLlcMember_z1QpVSX3hlE" title="Redemption description">The agreement allows the Lender to redeem up to $250 thousand per calendar month beginning in May 2026, upon providing written notice to Borrower.</span> The Note further contains triggering events which can be remedied by the Lender requiring the Borrower to correct the triggering event, increasing the outstanding balance by applying the triggering effect, or making the Note immediately due and payable.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Maturities and charges associated with these notes are summarized below:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_89F_eus-gaap--ScheduleOfDebtTableTextBlock_gL3SODTTB-RNA_zfGtxc5fxmx" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Debt schedule at June 30, 2026 (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BF_zy0QSgmGCQE" style="display: none">Schedule of Long Term Debt</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20260630__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementMember_z5Zww98iWmya" style="border-bottom: Black 1pt solid; text-align: center">Note 1</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20260630__us-gaap--TypeOfArrangementAxis__custom--NoteTwoPurchaseAgreementMember_z9GiXvjIEd6h" style="border-bottom: Black 1pt solid; text-align: center">Note 2</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49E_20260630__us-gaap--TypeOfArrangementAxis__custom--NoteThreePurchaseAgreementMember_zJQGpUJ4hVF8" style="border-bottom: Black 1pt solid; text-align: center">Note 3</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49B_20260630_zM8L2J2VRY58" style="border-bottom: Black 1pt solid; text-align: center">Total</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_40B_eus-gaap--DebtInstrumentCarryingAmount_iI_pn3n3_zcTQznDlkiS7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: justify">Long-term debt</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">1,440</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0871">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">2,634</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">4,074</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumNet_iI_pn3n3_z0NUfSNJYioa" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Unamortized Original issue discount</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0875">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0876">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(431</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(431</td><td style="text-align: left">)</td></tr> <tr id="xdx_403_eus-gaap--DeferredFinanceCostsNet_iNI_pn3n3_di_zCDCqpHnfI6g" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1pt">Unamortized Financing fees</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(8</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0881">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(14</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(22</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_402_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iI_pn3n3_zUWRIVrdTXm4" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Unamortized discount and debt issuance costs</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,432</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0886">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,189</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,621</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--LongTermDebtCurrent_iNI_pn3n3_di_ze7SIXe5DBa2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1pt">Less current portion of long-term debt, net</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(1,432</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0891">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(2,189</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(3,621</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40B_eus-gaap--LongTermDebtNoncurrent_iI_pn3n3_zIJBIk5SB383" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Long-term debt, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0895">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0896">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0897">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0898">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AA_zwC8R7cpow8i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89F_eus-gaap--ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_gL3SOMOLTDTTB-NKPI_z3h1pH5zJNul" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future maturities for long-term debt as of June 30, 2026, were as follows (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B9_zxaW5ZzBXozd" style="display: none">Schedule of Maturities of Long-Term Debt</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; text-align: justify">Fiscal years ending December 31:</td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49B_20260630__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementMember_zZcWwEEOPwwh" style="border-bottom: Black 1pt solid; text-align: center">Note 1</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20260630__us-gaap--TypeOfArrangementAxis__custom--NoteTwoPurchaseAgreementMember_z3QyG2EyYChh" style="border-bottom: Black 1pt solid; text-align: center">Note 2</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20260630__us-gaap--TypeOfArrangementAxis__custom--NoteThreePurchaseAgreementMember_zmB4r4fJFdW2" style="border-bottom: Black 1pt solid; text-align: center">Note 3</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49B_20260630_z3AHlEkMFbUb" style="border-bottom: Black 1pt solid; text-align: center">Total</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_40D_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_iI_pn3n3_maDIUDPzluS_ztkoKr0L4D5b" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: justify">2026</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">1,432</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0906">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">1,500</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">2,932</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_iI_pn3n3_maDIUDPzluS_zjnNJIKPaSQa" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">2027</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0910">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0911">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">689</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">689</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--LongTermDebt_iTI_pn3n3_mtDIUDPzluS_zG9Br7N2YJyb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,432</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0916">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,189</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,621</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--DebtInstrumentUnamortizedDiscountCurrent_iI_pn3n3_zclP6sbdhQVk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Current portion of debt discount</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0920">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0921">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">431</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">431</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--DeferredFinanceCostsNoncurrentNet_iI_pn3n3_zlPnzEvXymRb" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Current portion of origination costs</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">8</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0926">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">14</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">22</td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8A8_zLuUoDWAdqN5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span id="xdx_C0C_gL3SODTTB-RNA_z9mMINcAsj3e"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Debt schedule at December 31, 2025 (in thousands):</span></span></p> <div id="xdx_C0C_gL3SODTTB-RNA_zyychKoEOTri"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" id="xdx_304_134_zwlgQcmWzqzh" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto" summary="xdx: Disclosure - Schedule of Long Term Debt (Details)"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 2.5pt"> </td> <td colspan="2" id="xdx_498_20251231__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementMember_zmFy01VL97fg" style="border-bottom: Black 2.5pt double; text-align: center">Note 1</td><td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td colspan="2" id="xdx_49B_20251231__us-gaap--TypeOfArrangementAxis__custom--NoteTwoPurchaseAgreementMember_zFAectrVIQAb" style="border-bottom: Black 2.5pt double; text-align: center">Note 2</td><td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td colspan="2" id="xdx_495_20251231__us-gaap--TypeOfArrangementAxis__custom--NoteThreePurchaseAgreementMember_zySlK7ieaUFk" style="border-bottom: Black 2.5pt double; text-align: center">Note 3</td><td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td colspan="2" id="xdx_49A_20251231_zEu1XBVN9OO5" style="border-bottom: Black 2.5pt double; text-align: center">Total</td><td style="padding-bottom: 2.5pt"> </td></tr> <tr id="xdx_407_eus-gaap--DebtInstrumentCarryingAmount_iI_pn3n3_zSuEIT9gkB57" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: justify">Long-term debt</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">1,984</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0931">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">3,301</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">5,285</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumNet_iI_pn3n3_zRto5JwtKPOk" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Unamortized Original issue discount</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(49</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0936">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(740</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(789</td><td style="text-align: left">)</td></tr> <tr id="xdx_40F_eus-gaap--DeferredFinanceCostsNet_iNI_pn3n3_di_z8hYgLnhW3Bj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1pt">Unamortized Financing fees</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(1</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0941">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(19</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(20</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_402_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iI_pn3n3_zetYytWznrsb" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Unamortized discount and debt issuance costs</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,934</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0946">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,542</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,476</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--LongTermDebtCurrent_iNI_pn3n3_di_zh14LghYLn2a" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1pt">Less current portion of long-term debt, net</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,934</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0951">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,615</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(3,549</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_400_eus-gaap--LongTermDebtNoncurrent_iI_pn3n3_zhWn5TQ41rW5" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Long-term debt, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0955">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0956">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">927</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">927</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_C02_gL3SODTTB-RNA_ziQeqO9rX5bh"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span id="xdx_C0B_gL3SOMOLTDTTB-NKPI_zHvZ4rlw6mbb"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future maturities for long-term debt as of December 31, 2025 were as follows (in thousands):</span></span></p> <div id="xdx_C0F_gL3SOMOLTDTTB-NKPI_z7bv0gLpF1z8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" id="xdx_30E_134_zHzVlc6BtU73" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto" summary="xdx: Disclosure - Schedule of Maturities of Long-Term Debt (Details)"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; text-align: justify">Fiscal years ending December 31:</td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20251231__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementMember_zepX1EPJCjI7" style="border-bottom: Black 1pt solid; text-align: center">Note 1</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_497_20251231__us-gaap--TypeOfArrangementAxis__custom--NoteTwoPurchaseAgreementMember_zfMDMuCqEgIh" style="border-bottom: Black 1pt solid; text-align: center">Note 2</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_491_20251231__us-gaap--TypeOfArrangementAxis__custom--NoteThreePurchaseAgreementMember_zuymjGBQnoZ8" style="border-bottom: Black 1pt solid; text-align: center">Note 3</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20251231_zd5NETJgBUqg" style="border-bottom: Black 1pt solid; text-align: center">Total</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_40B_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_iI_pn3n3_maDIUDPzluS_z17UG6FUwkr9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: justify">2025</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">1,934</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0961">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">1,615</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">3,549</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_iI_pn3n3_maDIUDPzluS_zZSjs2I9LoU1" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">2026</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0965">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0966">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">927</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">927</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--LongTermDebt_iTI_pn3n3_mtDIUDPzluS_ztqwaDPAP3T3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,934</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0971">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,542</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,476</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--DebtInstrumentUnamortizedDiscountCurrent_iI_pn3n3_zltIkEJadVbh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Current portion of debt discount</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">49</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0976">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">374</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">423</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--DeferredFinanceCostsNoncurrentNet_iI_pn3n3_zUbjQIWvmYH7" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Current portion of origination costs</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0981">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">10</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">11</td><td style="text-align: left"> </td></tr> </table> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_C0E_gL3SOMOLTDTTB-NKPI_zzFrjKgpn0S6"> </span></span></p> <p id="xdx_89A_ecustom--ScheduleOfInterestAndOtherChargesTableTextBlock_zl5OmRtsApi2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest and other charges related to the Streeterville notes were as follows (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BA_zpXjPal6goLi" style="display: none">Schedule of Interest and Other Charges</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; text-align: justify">Three months ended June 30, 2026</td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_499_20260401__20260630__us-gaap--CreditFacilityAxis__custom--StreetervilleCapitalLlcMember__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementMember_z68Z1eOyd2C6" style="border-bottom: Black 1pt solid; text-align: center">Note 1</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20260401__20260630__us-gaap--CreditFacilityAxis__custom--StreetervilleCapitalLlcMember__us-gaap--TypeOfArrangementAxis__custom--NoteTwoPurchaseAgreementMember_zCG94400hxE5" style="border-bottom: Black 1pt solid; text-align: center">Note 2</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_498_20260401__20260630__us-gaap--CreditFacilityAxis__custom--StreetervilleCapitalLlcMember__us-gaap--TypeOfArrangementAxis__custom--NoteThreePurchaseAgreementMember_zhkM10GE8Gg3" style="border-bottom: Black 1pt solid; text-align: center">Note 3</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20260401__20260630__us-gaap--CreditFacilityAxis__custom--StreetervilleCapitalLlcMember_zyWtLAUXVHod" style="border-bottom: Black 1pt solid; text-align: center">Total</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_40B_eus-gaap--InterestExpenseDebtExcludingAmortization_pn3n3_zORawqUOQz8l" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: justify">Interest</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">40</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0988">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">76</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">116</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--AmortizationOfDebtDiscountPremium_pn3n3_zt64bOhRpQO3" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">Original issue discount amortization</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0992">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0993">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">179</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">179</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--InterestExpense_pn3n3_zwHBlyuGfgn6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Total interest charges</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">40</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0998">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">255</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">295</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--LoanProcessingFee_pn3n3_zAm7LdGs5oqh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Loan fee amortization</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">2</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1003">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">3</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">5</td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; text-align: justify">Six months ended June 30, 2026</td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20260101__20260630__us-gaap--CreditFacilityAxis__custom--StreetervilleCapitalLlcMember__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementMember_zecYQ8cc0osg" style="border-bottom: Black 1pt solid; text-align: center">Note 1</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_495_20260101__20260630__us-gaap--CreditFacilityAxis__custom--StreetervilleCapitalLlcMember__us-gaap--TypeOfArrangementAxis__custom--NoteTwoPurchaseAgreementMember_z4S3FOvE2zWf" style="border-bottom: Black 1pt solid; text-align: center">Note 2</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_498_20260101__20260630__us-gaap--CreditFacilityAxis__custom--StreetervilleCapitalLlcMember__us-gaap--TypeOfArrangementAxis__custom--NoteThreePurchaseAgreementMember_zO2H9UB3o9Pe" style="border-bottom: Black 1pt solid; text-align: center">Note 3</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_491_20260101__20260630__us-gaap--CreditFacilityAxis__custom--StreetervilleCapitalLlcMember_zLmgxUkEUlKd" style="border-bottom: Black 1pt solid; text-align: center">Total</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_40B_eus-gaap--InterestExpenseDebtExcludingAmortization_pn3n3_zEDwC0DJiZw8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: justify">Interest</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">84</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1008">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">160</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">244</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--AmortizationOfDebtDiscountPremium_pn3n3_z4D35W7hJQVf" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">Original issue discount amortization</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">49</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1013">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">306</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">355</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--InterestExpense_pn3n3_zopzLllNWnK" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Total interest charges</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">133</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1018">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">466</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">599</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--LoanProcessingFee_pn3n3_zgtLlBkE30u6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Loan fee amortization</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">3</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1023">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">5</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">8</td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; text-align: justify">Three months ended June 30, 2025</td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_499_20250401__20250630__us-gaap--CreditFacilityAxis__custom--StreetervilleCapitalLlcMember__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementMember_z44mWkIwECA1" style="border-bottom: Black 1pt solid; text-align: center">Note 1</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_493_20250401__20250630__us-gaap--CreditFacilityAxis__custom--StreetervilleCapitalLlcMember__us-gaap--TypeOfArrangementAxis__custom--NoteTwoPurchaseAgreementMember_zX7HdcBtGzLl" style="border-bottom: Black 1pt solid; text-align: center">Note 2</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_498_20250401__20250630__us-gaap--CreditFacilityAxis__custom--StreetervilleCapitalLlcMember__us-gaap--TypeOfArrangementAxis__custom--NoteThreePurchaseAgreementMember_zvCfmLVQabxk" style="border-bottom: Black 1pt solid; text-align: center">Note 3</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_493_20250401__20250630__us-gaap--CreditFacilityAxis__custom--StreetervilleCapitalLlcMember_zK5kLz7Q5Bl7" style="border-bottom: Black 1pt solid; text-align: center">Total</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_40B_eus-gaap--InterestExpenseDebtExcludingAmortization_pn3n3_zz8FxwF0i9Oe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: justify">Interest</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">87</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1028">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1029">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">87</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--AmortizationOfDebtDiscountPremium_pn3n3_zieXAmioP8nj" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">Original issue discount amortization</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">62</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1033">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1034">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">62</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--InterestExpense_pn3n3_zWZd6AG7S9yg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Total interest charges</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">149</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1038">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1039">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">149</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--LoanProcessingFee_pn3n3_zqUOhIbshLLd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Loan fee amortization</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">3</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1043">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1044">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">3</td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; text-align: justify">Six months ended June 30, 2025</td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49A_20250101__20250630__us-gaap--CreditFacilityAxis__custom--StreetervilleCapitalLlcMember__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementMember_zwsuTUVILfM1" style="border-bottom: Black 1pt solid; text-align: center">Note 1</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20250101__20250630__us-gaap--CreditFacilityAxis__custom--StreetervilleCapitalLlcMember__us-gaap--TypeOfArrangementAxis__custom--NoteTwoPurchaseAgreementMember_zOaPM0Bq3Zd3" style="border-bottom: Black 1pt solid; text-align: center">Note 2</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49E_20250101__20250630__us-gaap--CreditFacilityAxis__custom--StreetervilleCapitalLlcMember__us-gaap--TypeOfArrangementAxis__custom--NoteThreePurchaseAgreementMember_zf69JqtMsyk9" style="border-bottom: Black 1pt solid; text-align: center">Note 3</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_495_20250101__20250630__us-gaap--CreditFacilityAxis__custom--StreetervilleCapitalLlcMember_zDfk9zbG3ZX5" style="border-bottom: Black 1pt solid; text-align: center">Total</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_40B_eus-gaap--InterestExpenseDebtExcludingAmortization_pn3n3_zPI4XH2C8TSc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: justify">Interest</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">139</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1048">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1049">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">139</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--AmortizationOfDebtDiscountPremium_pn3n3_zdyQFoR1nYt" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">Original issue discount amortization</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">134</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1053">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1054">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">134</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--InterestExpense_pn3n3_zaaESc00NSSf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Total interest charges</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">273</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1058">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1059">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">273</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--LoanProcessingFee_pn3n3_zunvq4aSAJPf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Loan fee amortization</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">5</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1063">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1064">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">5</td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8A1_zT8EcX2oWCKc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> 2500000 781000 3300000 20000 0.10 The agreement allows the Lender to redeem up to $250 thousand per calendar month beginning in August 2024, upon providing written notice to Borrower. 400000 364084 700000 170353 10000 1700000 250000 50000 310000 10000 2500000 781000 3300000 20000 0.10 The agreement allows the Lender to redeem up to $250 thousand per calendar month beginning in May 2026, upon providing written notice to Borrower. <p id="xdx_89F_eus-gaap--ScheduleOfDebtTableTextBlock_gL3SODTTB-RNA_zfGtxc5fxmx" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Debt schedule at June 30, 2026 (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BF_zy0QSgmGCQE" style="display: none">Schedule of Long Term Debt</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20260630__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementMember_z5Zww98iWmya" style="border-bottom: Black 1pt solid; text-align: center">Note 1</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20260630__us-gaap--TypeOfArrangementAxis__custom--NoteTwoPurchaseAgreementMember_z9GiXvjIEd6h" style="border-bottom: Black 1pt solid; text-align: center">Note 2</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49E_20260630__us-gaap--TypeOfArrangementAxis__custom--NoteThreePurchaseAgreementMember_zJQGpUJ4hVF8" style="border-bottom: Black 1pt solid; text-align: center">Note 3</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49B_20260630_zM8L2J2VRY58" style="border-bottom: Black 1pt solid; text-align: center">Total</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_40B_eus-gaap--DebtInstrumentCarryingAmount_iI_pn3n3_zcTQznDlkiS7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: justify">Long-term debt</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">1,440</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0871">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">2,634</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">4,074</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumNet_iI_pn3n3_z0NUfSNJYioa" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Unamortized Original issue discount</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0875">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0876">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(431</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(431</td><td style="text-align: left">)</td></tr> <tr id="xdx_403_eus-gaap--DeferredFinanceCostsNet_iNI_pn3n3_di_zCDCqpHnfI6g" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1pt">Unamortized Financing fees</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(8</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0881">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(14</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(22</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_402_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iI_pn3n3_zUWRIVrdTXm4" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Unamortized discount and debt issuance costs</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,432</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0886">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,189</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,621</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--LongTermDebtCurrent_iNI_pn3n3_di_ze7SIXe5DBa2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1pt">Less current portion of long-term debt, net</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(1,432</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0891">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(2,189</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(3,621</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40B_eus-gaap--LongTermDebtNoncurrent_iI_pn3n3_zIJBIk5SB383" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Long-term debt, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0895">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0896">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0897">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0898">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Debt schedule at December 31, 2025 (in thousands):</span><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" id="xdx_304_134_zwlgQcmWzqzh" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto" summary="xdx: Disclosure - Schedule of Long Term Debt (Details)"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 2.5pt"> </td> <td colspan="2" id="xdx_498_20251231__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementMember_zmFy01VL97fg" style="border-bottom: Black 2.5pt double; text-align: center">Note 1</td><td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td colspan="2" id="xdx_49B_20251231__us-gaap--TypeOfArrangementAxis__custom--NoteTwoPurchaseAgreementMember_zFAectrVIQAb" style="border-bottom: Black 2.5pt double; text-align: center">Note 2</td><td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td colspan="2" id="xdx_495_20251231__us-gaap--TypeOfArrangementAxis__custom--NoteThreePurchaseAgreementMember_zySlK7ieaUFk" style="border-bottom: Black 2.5pt double; text-align: center">Note 3</td><td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td colspan="2" id="xdx_49A_20251231_zEu1XBVN9OO5" style="border-bottom: Black 2.5pt double; text-align: center">Total</td><td style="padding-bottom: 2.5pt"> </td></tr> <tr id="xdx_407_eus-gaap--DebtInstrumentCarryingAmount_iI_pn3n3_zSuEIT9gkB57" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: justify">Long-term debt</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">1,984</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0931">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">3,301</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">5,285</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumNet_iI_pn3n3_zRto5JwtKPOk" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Unamortized Original issue discount</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(49</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0936">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(740</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(789</td><td style="text-align: left">)</td></tr> <tr id="xdx_40F_eus-gaap--DeferredFinanceCostsNet_iNI_pn3n3_di_z8hYgLnhW3Bj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1pt">Unamortized Financing fees</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(1</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0941">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(19</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(20</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_402_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iI_pn3n3_zetYytWznrsb" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Unamortized discount and debt issuance costs</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,934</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0946">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,542</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,476</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--LongTermDebtCurrent_iNI_pn3n3_di_zh14LghYLn2a" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1pt">Less current portion of long-term debt, net</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,934</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0951">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,615</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(3,549</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_400_eus-gaap--LongTermDebtNoncurrent_iI_pn3n3_zhWn5TQ41rW5" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Long-term debt, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0955">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0956">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">927</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">927</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   1440000 2634000 4074000 -431000 -431000 8000 14000 22000 1432000 2189000 3621000 1432000 2189000 3621000 <p id="xdx_89F_eus-gaap--ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_gL3SOMOLTDTTB-NKPI_z3h1pH5zJNul" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future maturities for long-term debt as of June 30, 2026, were as follows (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B9_zxaW5ZzBXozd" style="display: none">Schedule of Maturities of Long-Term Debt</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; text-align: justify">Fiscal years ending December 31:</td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49B_20260630__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementMember_zZcWwEEOPwwh" style="border-bottom: Black 1pt solid; text-align: center">Note 1</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20260630__us-gaap--TypeOfArrangementAxis__custom--NoteTwoPurchaseAgreementMember_z3QyG2EyYChh" style="border-bottom: Black 1pt solid; text-align: center">Note 2</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20260630__us-gaap--TypeOfArrangementAxis__custom--NoteThreePurchaseAgreementMember_zmB4r4fJFdW2" style="border-bottom: Black 1pt solid; text-align: center">Note 3</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49B_20260630_z3AHlEkMFbUb" style="border-bottom: Black 1pt solid; text-align: center">Total</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_40D_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_iI_pn3n3_maDIUDPzluS_ztkoKr0L4D5b" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: justify">2026</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">1,432</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0906">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">1,500</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">2,932</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_iI_pn3n3_maDIUDPzluS_zjnNJIKPaSQa" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">2027</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0910">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0911">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">689</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">689</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--LongTermDebt_iTI_pn3n3_mtDIUDPzluS_zG9Br7N2YJyb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,432</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0916">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,189</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,621</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--DebtInstrumentUnamortizedDiscountCurrent_iI_pn3n3_zclP6sbdhQVk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Current portion of debt discount</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0920">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0921">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">431</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">431</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--DeferredFinanceCostsNoncurrentNet_iI_pn3n3_zlPnzEvXymRb" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Current portion of origination costs</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">8</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0926">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">14</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">22</td><td style="text-align: left"> </td></tr> </table> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future maturities for long-term debt as of December 31, 2025 were as follows (in thousands):</span><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" id="xdx_30E_134_zHzVlc6BtU73" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto" summary="xdx: Disclosure - Schedule of Maturities of Long-Term Debt (Details)"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; text-align: justify">Fiscal years ending December 31:</td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20251231__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementMember_zepX1EPJCjI7" style="border-bottom: Black 1pt solid; text-align: center">Note 1</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_497_20251231__us-gaap--TypeOfArrangementAxis__custom--NoteTwoPurchaseAgreementMember_zfMDMuCqEgIh" style="border-bottom: Black 1pt solid; text-align: center">Note 2</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_491_20251231__us-gaap--TypeOfArrangementAxis__custom--NoteThreePurchaseAgreementMember_zuymjGBQnoZ8" style="border-bottom: Black 1pt solid; text-align: center">Note 3</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20251231_zd5NETJgBUqg" style="border-bottom: Black 1pt solid; text-align: center">Total</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_40B_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_iI_pn3n3_maDIUDPzluS_z17UG6FUwkr9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: justify">2025</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">1,934</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0961">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">1,615</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">3,549</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_iI_pn3n3_maDIUDPzluS_zZSjs2I9LoU1" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">2026</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0965">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0966">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">927</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">927</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--LongTermDebt_iTI_pn3n3_mtDIUDPzluS_ztqwaDPAP3T3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,934</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0971">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,542</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,476</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--DebtInstrumentUnamortizedDiscountCurrent_iI_pn3n3_zltIkEJadVbh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Current portion of debt discount</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">49</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0976">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">374</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">423</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--DeferredFinanceCostsNoncurrentNet_iI_pn3n3_zUbjQIWvmYH7" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Current portion of origination costs</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0981">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">10</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">11</td><td style="text-align: left"> </td></tr> </table>   1432000 1500000 2932000 689000 689000 1432000 2189000 3621000 431000 431000 8000 14000 22000 1984000 3301000 5285000 -49000 -740000 -789000 1000 19000 20000 1934000 2542000 4476000 1934000 1615000 3549000 927000 927000 1934000 1615000 3549000 927000 927000 1934000 2542000 4476000 49000 374000 423000 1000 10000 11000 <p id="xdx_89A_ecustom--ScheduleOfInterestAndOtherChargesTableTextBlock_zl5OmRtsApi2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest and other charges related to the Streeterville notes were as follows (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BA_zpXjPal6goLi" style="display: none">Schedule of Interest and Other Charges</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; text-align: justify">Three months ended June 30, 2026</td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_499_20260401__20260630__us-gaap--CreditFacilityAxis__custom--StreetervilleCapitalLlcMember__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementMember_z68Z1eOyd2C6" style="border-bottom: Black 1pt solid; text-align: center">Note 1</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20260401__20260630__us-gaap--CreditFacilityAxis__custom--StreetervilleCapitalLlcMember__us-gaap--TypeOfArrangementAxis__custom--NoteTwoPurchaseAgreementMember_zCG94400hxE5" style="border-bottom: Black 1pt solid; text-align: center">Note 2</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_498_20260401__20260630__us-gaap--CreditFacilityAxis__custom--StreetervilleCapitalLlcMember__us-gaap--TypeOfArrangementAxis__custom--NoteThreePurchaseAgreementMember_zhkM10GE8Gg3" style="border-bottom: Black 1pt solid; text-align: center">Note 3</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20260401__20260630__us-gaap--CreditFacilityAxis__custom--StreetervilleCapitalLlcMember_zyWtLAUXVHod" style="border-bottom: Black 1pt solid; text-align: center">Total</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_40B_eus-gaap--InterestExpenseDebtExcludingAmortization_pn3n3_zORawqUOQz8l" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: justify">Interest</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">40</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0988">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">76</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">116</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--AmortizationOfDebtDiscountPremium_pn3n3_zt64bOhRpQO3" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">Original issue discount amortization</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0992">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0993">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">179</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">179</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--InterestExpense_pn3n3_zwHBlyuGfgn6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Total interest charges</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">40</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0998">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">255</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">295</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--LoanProcessingFee_pn3n3_zAm7LdGs5oqh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Loan fee amortization</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">2</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1003">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">3</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">5</td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; text-align: justify">Six months ended June 30, 2026</td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20260101__20260630__us-gaap--CreditFacilityAxis__custom--StreetervilleCapitalLlcMember__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementMember_zecYQ8cc0osg" style="border-bottom: Black 1pt solid; text-align: center">Note 1</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_495_20260101__20260630__us-gaap--CreditFacilityAxis__custom--StreetervilleCapitalLlcMember__us-gaap--TypeOfArrangementAxis__custom--NoteTwoPurchaseAgreementMember_z4S3FOvE2zWf" style="border-bottom: Black 1pt solid; text-align: center">Note 2</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_498_20260101__20260630__us-gaap--CreditFacilityAxis__custom--StreetervilleCapitalLlcMember__us-gaap--TypeOfArrangementAxis__custom--NoteThreePurchaseAgreementMember_zO2H9UB3o9Pe" style="border-bottom: Black 1pt solid; text-align: center">Note 3</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_491_20260101__20260630__us-gaap--CreditFacilityAxis__custom--StreetervilleCapitalLlcMember_zLmgxUkEUlKd" style="border-bottom: Black 1pt solid; text-align: center">Total</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_40B_eus-gaap--InterestExpenseDebtExcludingAmortization_pn3n3_zEDwC0DJiZw8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: justify">Interest</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">84</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1008">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">160</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">244</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--AmortizationOfDebtDiscountPremium_pn3n3_z4D35W7hJQVf" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">Original issue discount amortization</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">49</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1013">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">306</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">355</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--InterestExpense_pn3n3_zopzLllNWnK" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Total interest charges</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">133</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1018">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">466</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">599</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--LoanProcessingFee_pn3n3_zgtLlBkE30u6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Loan fee amortization</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">3</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1023">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">5</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">8</td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; text-align: justify">Three months ended June 30, 2025</td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_499_20250401__20250630__us-gaap--CreditFacilityAxis__custom--StreetervilleCapitalLlcMember__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementMember_z44mWkIwECA1" style="border-bottom: Black 1pt solid; text-align: center">Note 1</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_493_20250401__20250630__us-gaap--CreditFacilityAxis__custom--StreetervilleCapitalLlcMember__us-gaap--TypeOfArrangementAxis__custom--NoteTwoPurchaseAgreementMember_zX7HdcBtGzLl" style="border-bottom: Black 1pt solid; text-align: center">Note 2</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_498_20250401__20250630__us-gaap--CreditFacilityAxis__custom--StreetervilleCapitalLlcMember__us-gaap--TypeOfArrangementAxis__custom--NoteThreePurchaseAgreementMember_zvCfmLVQabxk" style="border-bottom: Black 1pt solid; text-align: center">Note 3</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_493_20250401__20250630__us-gaap--CreditFacilityAxis__custom--StreetervilleCapitalLlcMember_zK5kLz7Q5Bl7" style="border-bottom: Black 1pt solid; text-align: center">Total</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_40B_eus-gaap--InterestExpenseDebtExcludingAmortization_pn3n3_zz8FxwF0i9Oe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: justify">Interest</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">87</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1028">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1029">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">87</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--AmortizationOfDebtDiscountPremium_pn3n3_zieXAmioP8nj" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">Original issue discount amortization</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">62</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1033">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1034">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">62</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--InterestExpense_pn3n3_zWZd6AG7S9yg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Total interest charges</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">149</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1038">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1039">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">149</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--LoanProcessingFee_pn3n3_zqUOhIbshLLd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Loan fee amortization</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">3</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1043">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1044">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">3</td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; text-align: justify">Six months ended June 30, 2025</td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49A_20250101__20250630__us-gaap--CreditFacilityAxis__custom--StreetervilleCapitalLlcMember__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementMember_zwsuTUVILfM1" style="border-bottom: Black 1pt solid; text-align: center">Note 1</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20250101__20250630__us-gaap--CreditFacilityAxis__custom--StreetervilleCapitalLlcMember__us-gaap--TypeOfArrangementAxis__custom--NoteTwoPurchaseAgreementMember_zOaPM0Bq3Zd3" style="border-bottom: Black 1pt solid; text-align: center">Note 2</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49E_20250101__20250630__us-gaap--CreditFacilityAxis__custom--StreetervilleCapitalLlcMember__us-gaap--TypeOfArrangementAxis__custom--NoteThreePurchaseAgreementMember_zf69JqtMsyk9" style="border-bottom: Black 1pt solid; text-align: center">Note 3</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_495_20250101__20250630__us-gaap--CreditFacilityAxis__custom--StreetervilleCapitalLlcMember_zDfk9zbG3ZX5" style="border-bottom: Black 1pt solid; text-align: center">Total</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_40B_eus-gaap--InterestExpenseDebtExcludingAmortization_pn3n3_zPI4XH2C8TSc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: justify">Interest</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">139</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1048">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1049">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">139</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--AmortizationOfDebtDiscountPremium_pn3n3_zdyQFoR1nYt" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">Original issue discount amortization</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">134</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1053">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1054">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">134</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--InterestExpense_pn3n3_zaaESc00NSSf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Total interest charges</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">273</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1058">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1059">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">273</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--LoanProcessingFee_pn3n3_zunvq4aSAJPf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Loan fee amortization</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">5</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1063">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1064">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">5</td><td style="text-align: left"> </td></tr> </table> 40000 76000 116000 179000 179000 40000 255000 295000 2000 3000 5000 84000 160000 244000 49000 306000 355000 133000 466000 599000 3000 5000 8000 87000 87000 62000 62000 149000 149000 3000 3000 139000 139000 134000 134000 273000 273000 5000 5000 <p id="xdx_808_eus-gaap--LesseeOperatingLeasesTextBlock_zsIRgNegX582" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 9: <span id="xdx_82E_z747SLQFZy99">Leases</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company leases office and lab facilities and other equipment under non-cancellable operating leases with initial terms typically ranging from <span id="xdx_908_eus-gaap--LesseeOperatingLeaseRenewalTerm_iI_dtY_c20260630__srt--RangeAxis__srt--MinimumMember_zS7QfJaHzWgi" title="Operating lease term">1</span> to <span id="xdx_901_eus-gaap--LesseeOperatingLeaseRenewalTerm_iI_dtY_c20260630__srt--RangeAxis__srt--MaximumMember_zSgiSw4YkCtf" title="Operating lease term">5</span> years, expiring at various dates during 2026 through 2027, and requiring monthly payments ranging from less than $<span id="xdx_90D_eus-gaap--OperatingLeasePayments_pn3n3_c20260101__20260630__srt--RangeAxis__srt--MinimumMember_zqX1PG4vnFhc" title="Operating lease Payment">1</span> thousand to $<span id="xdx_90F_eus-gaap--OperatingLeasePayments_pn3n3_c20260101__20260630__srt--RangeAxis__srt--MaximumMember_zmitfc1bDJM9" title="Operating lease Payment">22</span> thousand. Certain leases include additional renewal options ranging from <span id="xdx_900_eus-gaap--LesseeOperatingLeaseRenewalTerm_iI_dtY_c20260630__srt--RangeAxis__srt--MinimumMember_zZDqqEmghNQ" title="Operating lease term">1</span> to <span id="xdx_900_eus-gaap--LesseeOperatingLeaseRenewalTerm_iI_dtY_c20260630__srt--RangeAxis__srt--MaximumMember_zE6eofvBdvB3" title="Operating lease term">5</span> years. AIM has classified all of its leases as operating leases.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At June 30, 2026 and December 31, 2025, the balance of the right of use assets was $<span id="xdx_903_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_c20260630_zTtw36orNYcc" title="Right of use asset">260</span> thousand and $<span id="xdx_90F_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_c20251231_zDhBUNsh4cH5" title="Right of use asset">378</span> thousand, respectively, and the corresponding operating lease liability balance was $<span id="xdx_901_eus-gaap--OperatingLeaseLiability_iI_pn3n3_c20260630_z65Hl45Yxjwj" title="Lease liability">300</span> thousand and $<span id="xdx_90E_eus-gaap--OperatingLeaseLiability_iI_pn3n3_c20251231_zVcDzORcxf48" title="Lease liability">420</span> thousand, respectively. Right of use assets are recorded net of accumulated amortization of $<span id="xdx_90F_ecustom--OperationLeaseRightOfUseAssetAccumulatedAmortization_iI_pn3n3_c20260630_zYN8FggnLDGk" title="Accumulated amortization">678</span> thousand and $<span id="xdx_907_ecustom--OperationLeaseRightOfUseAssetAccumulatedAmortization_iI_pn3n3_c20251231_zKZ60ZDq8D5d" title="Accumulated amortization">560</span> thousand as of June 30, 2026 and December 31, 2025, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_890_eus-gaap--LeaseCostTableTextBlock_zqofSByh2nO9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AIM recognized rent expense associated with these leases are follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B3_zKxvrY7OMZz3" style="display: none">Schedule of AIM Recognized Rent Expense Associated with Operating Lease</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 243pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="display: none; vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; display: none">(in thousands)</td><td style="display: none; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20260101__20260630_zU8MliYzkWWd" style="border-bottom: Black 1pt solid; display: none; text-align: center">2026</td><td style="display: none; padding-bottom: 1pt"> </td><td style="display: none; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_499_20250101__20250630_zN5JKQkzTTUh" style="border-bottom: Black 1pt solid; display: none; text-align: center">2025</td><td style="display: none; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Six months ended June 30,</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid">(in thousands)</td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_40A_eus-gaap--LeaseCostAbstract_iB_zCaP7OpjE21i" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Lease costs:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--OperatingLeaseCost_pn3n3_zauw8xsQrqIb" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 60%; text-align: left">Operating lease costs</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">137</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">151</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--ShortTermLeaseCost_pn3n3_zHiPDT7M5MNd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Short-term and variable lease costs</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">100</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">168</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--LeaseCost_pn3n3_zXDz8PXopfpb" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Total lease costs</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">237</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">319</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Classification of lease costs</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--LeaseCost_pn3n3_hcustom--StatementOfIncomeLocationBalancesAxis__custom--ResearchAndDevelopmentMember_zZNEbVbAXTBl" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Research &amp; development</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">174</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">215</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--LeaseCost_pn3n3_hcustom--StatementOfIncomeLocationBalancesAxis__custom--GeneralAndAdministrativeMember_zncfmNSNVxG2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1pt">General and administrative</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">63</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">104</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--LeaseCost_pn3n3_zzw4j9DtnBZg" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Total lease costs</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">237</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">319</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A7_z0Pk0wzjKOji" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s leases have remaining lease terms between <span id="xdx_90B_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dtM_c20260630__srt--RangeAxis__srt--MinimumMember_zw1XkrbnXZfd" title="Operating lease, remaining lease term">6</span> and <span id="xdx_90E_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dtM_c20260630__srt--RangeAxis__srt--MaximumMember_z7YTQ082YwP6" title="Operating lease, remaining lease term">17</span> months. As of June 30, 2026, the weighted-average remaining term was <span id="xdx_900_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtM_c20260630_zbQLVnTLKw68" title="Weighted average remaining lease term">14</span> months. At December 31, 2025, the weighted-average remaining term was <span id="xdx_905_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtM_c20251231_zuTk85lLSSR1" title="Weighted average remaining lease term">20</span> months. The Company’s weighted average incremental borrowing rate for its leases was <span id="xdx_903_eus-gaap--DebtWeightedAverageInterestRate_iI_pid_dp_uPure_c20260630_zTAo7gV3kdt9" title="Weighted average incremental borrowing rate"><span id="xdx_902_eus-gaap--DebtWeightedAverageInterestRate_iI_pid_dp_uPure_c20251231_zUAeiIFPSJUe" title="Weighted average incremental borrowing rate">10</span></span>% at June 30, 2026 and December 31, 2025.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_891_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zXlQ8mwmFGt8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future minimum payments as of June 30, 2026, are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B4_zvR4AoZyweee" style="display: none">Schedule of Operating Lease Future Payments</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto"> <tr style="display: none; vertical-align: bottom"> <td style="display: none; text-align: justify"> </td><td style="display: none"> </td> <td colspan="2" id="xdx_494_20260630_zmEftMSBr1ui" style="display: none; text-align: right"> </td><td style="display: none"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ending December 31, (in thousands)</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_pn3n3_zUPOOHYXsYba" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: justify">2026</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">136</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_zTsfoaNTguuk" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">2027</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">169</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_zIffHiZVoBZ8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1pt">Less imputed interest</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(5</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40D_eus-gaap--OperatingLeaseLiability_iTI_pn3n3_ztsTkeT6tAN3" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: justify; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">300</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A8_z3RN2gxMvHvc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> P1Y P5Y 1000 22000 P1Y P5Y 260000 378000 300000 420000 678000 560000 <p id="xdx_890_eus-gaap--LeaseCostTableTextBlock_zqofSByh2nO9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AIM recognized rent expense associated with these leases are follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B3_zKxvrY7OMZz3" style="display: none">Schedule of AIM Recognized Rent Expense Associated with Operating Lease</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 243pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="display: none; vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; display: none">(in thousands)</td><td style="display: none; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20260101__20260630_zU8MliYzkWWd" style="border-bottom: Black 1pt solid; display: none; text-align: center">2026</td><td style="display: none; padding-bottom: 1pt"> </td><td style="display: none; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_499_20250101__20250630_zN5JKQkzTTUh" style="border-bottom: Black 1pt solid; display: none; text-align: center">2025</td><td style="display: none; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Six months ended June 30,</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid">(in thousands)</td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_40A_eus-gaap--LeaseCostAbstract_iB_zCaP7OpjE21i" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Lease costs:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--OperatingLeaseCost_pn3n3_zauw8xsQrqIb" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 60%; text-align: left">Operating lease costs</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">137</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">151</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--ShortTermLeaseCost_pn3n3_zHiPDT7M5MNd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Short-term and variable lease costs</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">100</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">168</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--LeaseCost_pn3n3_zXDz8PXopfpb" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Total lease costs</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">237</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">319</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Classification of lease costs</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--LeaseCost_pn3n3_hcustom--StatementOfIncomeLocationBalancesAxis__custom--ResearchAndDevelopmentMember_zZNEbVbAXTBl" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Research &amp; development</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">174</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">215</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--LeaseCost_pn3n3_hcustom--StatementOfIncomeLocationBalancesAxis__custom--GeneralAndAdministrativeMember_zncfmNSNVxG2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1pt">General and administrative</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">63</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">104</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--LeaseCost_pn3n3_zzw4j9DtnBZg" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Total lease costs</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">237</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">319</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 137000 151000 100000 168000 237000 319000 174000 215000 63000 104000 237000 319000 P6M P17M P14M P20M 0.10 0.10 <p id="xdx_891_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zXlQ8mwmFGt8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future minimum payments as of June 30, 2026, are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B4_zvR4AoZyweee" style="display: none">Schedule of Operating Lease Future Payments</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto"> <tr style="display: none; vertical-align: bottom"> <td style="display: none; text-align: justify"> </td><td style="display: none"> </td> <td colspan="2" id="xdx_494_20260630_zmEftMSBr1ui" style="display: none; text-align: right"> </td><td style="display: none"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ending December 31, (in thousands)</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_pn3n3_zUPOOHYXsYba" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: justify">2026</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">136</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_zTsfoaNTguuk" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">2027</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">169</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_zIffHiZVoBZ8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1pt">Less imputed interest</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(5</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40D_eus-gaap--OperatingLeaseLiability_iTI_pn3n3_ztsTkeT6tAN3" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: justify; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">300</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 136000 169000 5000 300000 <p id="xdx_80D_ecustom--ResearchConsultingAndSupplyAgreementsTextBlock_zi4Gto8hBPP9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 10: <span id="xdx_82B_zmYnOQrbIfc">Research, Consulting and Supply Agreements</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has entered into research, consulting and supply agreements with third party service providers to perform research and development activities on therapeutics, including clinical trials. The identification of research and development costs involves reviewing open contracts and purchase orders, communicating with applicable company and third-party personnel to identify services that have been performed, and corroborating the level of service performed and the associated cost incurred for the service when the Company has not yet been invoiced or otherwise notified of actual expenses. The Company expenses these research and development costs when incurred.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_891_ecustom--ScheduleOfResearchandDevelopmentExpensesTableTextBlock_gL3SORDETTB-GZ_zTfogRZ6Yn3f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s research and development expenses were comprised of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B5_zBflUJ4n3VG5" style="display: none">Schedule of Research and Development Expenses</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; display: none; text-align: left">(in thousands)</td><td style="display: none; text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49F_20260401__20260630_zCyIlHwPCYl5" style="border-bottom: Black 1pt solid; display: none; text-align: center">June 30, 2026</td><td style="display: none; text-align: center; padding-bottom: 1pt"> </td><td style="display: none; text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_498_20250401__20250630_zxHlcjLoome5" style="border-bottom: Black 1pt solid; display: none; text-align: center">June 30, 2025</td><td style="display: none; text-align: center; padding-bottom: 1pt"> </td><td style="display: none; text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49E_20260101__20260630_zv50wlugg0rh" style="border-bottom: Black 1pt solid; display: none; text-align: center">June 30, 2026</td><td style="display: none; text-align: center; padding-bottom: 1pt"> </td><td style="display: none; text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_493_20250101__20250630_zP3lYqFYaGg4" style="border-bottom: Black 1pt solid; display: none; text-align: center">June 30, 2025</td><td style="display: none; text-align: center; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Three months ended</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Six months ended</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; text-align: left">(in thousands)</td><td style="text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">June 30, 2026</td><td style="text-align: center; padding-bottom: 1pt"> </td><td style="text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">June 30, 2025</td><td style="text-align: center; padding-bottom: 1pt"> </td><td style="text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">June 30, 2026</td><td style="text-align: center; padding-bottom: 1pt"> </td><td style="text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">June 30, 2025</td><td style="text-align: center; padding-bottom: 1pt"> </td></tr> <tr id="xdx_405_ecustom--ResearchAndDevelopmentExpenseIncludingProductionCostAdjustment_pn3n3_hsrt--ProductOrServiceAxis__custom--ClinicalStudiesMember_zvy3PiXFMT1l" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: justify">Clinical studies</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">476</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">734</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">661</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">1,328</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_ecustom--ResearchAndDevelopmentExpenseIncludingProductionCostAdjustment_pn3n3_hsrt--ProductOrServiceAxis__custom--ManufacturingAndEngineeringMember_z2OpDS9ojIda" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Manufacturing &amp; Engineering</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(93</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">144</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(23</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">324</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_ecustom--ResearchAndDevelopmentExpenseIncludingProductionCostAdjustment_pn3n3_hsrt--ProductOrServiceAxis__custom--QualityControlMember_zg5fe3CI6B2j" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Quality control</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">197</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">232</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">395</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">462</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_ecustom--ResearchAndDevelopmentExpenseIncludingProductionCostAdjustment_pn3n3_hsrt--ProductOrServiceAxis__custom--RegulatoryMember_zWHYhuYH2lH6" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">Regulatory</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">9</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">64</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">38</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">140</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_404_ecustom--ResearchAndDevelopmentExpenseIncludingProductionCostAdjustment_pn3n3_z0gWoEEXEiF6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Totals</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">589</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,174</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,071</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,254</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A9_zJWvoNqoPml7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following summarizes the most substantial of our contracts relating to research, consulting, and supply costs for AIM as they related to research and development costs for the three months and six months ended June 30, 2026.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Amarex Clinical Research LLC</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amarex is the principal administrator of several of AIM’s largest clinical studies. AIM has multiple contracts with Amarex Clinical Research LLC (“Amarex”). During the six months ended June 30, 2026 and 2025, the Company incurred $<span id="xdx_90E_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20260101__20260630__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember_zKXmRudSCzRe" title="Research and development expense">118</span> thousand and $<span id="xdx_905_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20250101__20250630__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember_z9SJd7q3BK09" title="Research and development expense">200</span> thousand, respectively, related to these ongoing agreements:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pancreatic Cancer - In April 2022, AIM executed a work order with Amarex pursuant to which Amarex is managing a Phase 2 clinical trial in locally advanced pancreatic cancer patients designated AMP-270. Per the work order, AIM anticipates that Amarex’s management of the study will cost approximately $<span id="xdx_901_eus-gaap--ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_pn5n6_c20220401__20220430__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember_zKZU6hIV0Eqj" title="Research and development expense excluding acquired in process cost">8.4</span> million. This estimate includes pass-through costs of approximately $<span id="xdx_904_eus-gaap--DevelopmentCosts_pn6n6_c20220401__20220430__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember_zYUrXqMD431d" title="Development cost">1</span> million and excludes certain third-party and investigator costs and escalations necessary for study completion. AIM anticipates that the study will take approximately 4.6 years to complete.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Post-COVID Conditions - In September 2022, AIM executed a work order with Amarex, pursuant to which Amarex is managing a Phase 2 trial in patients with Post-COVID Conditions. AIM is sponsoring the study. AIM anticipates that the study will cost approximately $<span id="xdx_90F_eus-gaap--ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_pn5n6_c20220901__20220930__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember_zAJYLsx9Yl1c">6.4</span> million, which includes passthrough costs of approximately $<span id="xdx_907_eus-gaap--DevelopmentCosts_pn3n3_c20220901__20220930__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember_zU1fhs7qdCid" title="Development cost">125</span> thousand, investigator costs estimated at about $<span id="xdx_90E_eus-gaap--CostMaintenance_pn5n6_c20220901__20220930__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember_zwfCN1wB6AM9" title="Invigilators cost">4.4</span> million and excludes certain other third-party costs and escalations. During 2023, the original work order increased to $<span id="xdx_902_eus-gaap--DevelopmentCosts_pn5n6_c20230101__20231231__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember_zqVLdJLbQN8e" title="Development cost">6.6</span> million for the addition of patient reported outcome (PRO) electronic questionnaires (devices/tablets for patients to complete); services associated with the ePRO system and additional safety monitoring services as well as changes to study documentation (such as protocol amendments) which resulted in additional IND submissions to FDA. The final subject completed the clinical trial in 2023. The end of study close-out tasks finished in 2025.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span id="xdx_C07_gL3SORDETTB-GZ_zUQX05jWTCG5"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Costs incurred pursuant to the Amarex agreements were as follows (thousands):</span></span></p> <div id="xdx_C04_gL3SORDETTB-GZ_z7Q7S4J3juQa"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" id="xdx_305_134_zFnnzF3SkFN2" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Schedule of Research and Development Expenses (Details)"> <tr style="display: none; vertical-align: bottom"> <td style="display: none; text-align: center"> </td><td style="display: none; text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_493_20260401__20260630__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember_zzRAwO4OqMPl" style="border-bottom: Black 1pt solid; display: none; text-align: center">June 30, 2026</td><td style="display: none; text-align: center; padding-bottom: 1pt"> </td><td style="display: none; text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49E_20250401__20250630__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember_zaL89H9zHmQ" style="border-bottom: Black 1pt solid; display: none; text-align: center">June 30, 2025</td><td style="display: none; text-align: center; padding-bottom: 1pt"> </td><td style="display: none; text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20260101__20260630__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember_zSpUkqVtQKXf" style="border-bottom: Black 1pt solid; display: none; text-align: center">June 30, 2026</td><td style="display: none; text-align: center; padding-bottom: 1pt"> </td><td style="display: none; text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20250101__20250630__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember_zn1KXc7WuOPk" style="border-bottom: Black 1pt solid; display: none; text-align: center">June 30, 2025</td><td style="display: none; text-align: center; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Three months ended</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Six months ended</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">June 30, 2026</td><td style="text-align: center; padding-bottom: 1pt"> </td><td style="text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">June 30, 2025</td><td style="text-align: center; padding-bottom: 1pt"> </td><td style="text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">June 30, 2026</td><td style="text-align: center; padding-bottom: 1pt"> </td><td style="text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">June 30, 2025</td><td style="text-align: center; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr id="xdx_40D_eus-gaap--OtherResearchAndDevelopmentExpense_pn3n3_hus-gaap--TypeOfArrangementAxis__custom--PancreaticCancerMember__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember_zo5dEomNRhcd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: justify">Pancreatic Cancer</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">105</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">94</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">118</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">192</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--OtherResearchAndDevelopmentExpense_pn3n3_hus-gaap--TypeOfArrangementAxis__custom--PostCOVIDConditionsMember__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember_z7sX6tEnS4Rj" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">Post Covid Conditions</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1199">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1200">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1201">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">8</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--OtherResearchAndDevelopmentExpense_pn3n3_hdei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember_zotHBBSjlMW2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Totals</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">105</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">94</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">118</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">200</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_C05_gL3SORDETTB-GZ_zpsHjUzTmZn4"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Sterling Pharma Solutions</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In 2022, the Company entered into a Master Service Agreement and a Quality Agreement with Sterling Pharma Solutions (“Sterling”) for the manufacture of the Company’s Poly I and Poly C12U polynucleotides and transfer of associated test methods at Sterling’s Dudley, UK location to produce the polymer precursors to manufacture the drug Ampligen.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsequently, on July 31, 2026, the Company entered into a proposal (the “Sterling Proposal Agreement”) with Sterling Pharma Solutions (“Sterling”) that is related to the Master Service Agreement and a Quality Agreement entered into between the Company and Sterling in 2022. Pursuant to the Sterling Proposal Agreement, Sterling agreed to manufacture further batches of the polynucleotide drug substances PolyI and Poly C12U and transfer of associated test methods at Sterling’s Dudley, UK location to produce the polymer precursors to manufacture the drug Ampligen. The estimated cost to the Company under the Sterling Proposal Agreement is approximately $<span id="xdx_909_eus-gaap--ManufacturingCosts_pn5n6_c20260801__20260815__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SterlingProposalAgreementMember_zrhdkMZlrlgi" title="Manufacturing estimated costs">1.5</span> million to be paid over a period of 12 months, as set forth in more detail in the Sterling Proposal Agreement. The Company anticipates using the manufactured product for ongoing and future clinical trials, including potentially a Phase 3 clinical trial for metastatic pancreatic cancer.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span id="xdx_C0B_gL3SORDETTB-GZ_zT8QPAqCoLua"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Costs incurred pursuant to the Sterling Pharma agreements were as follows (thousands):</span></span></p> <div id="xdx_C0B_gL3SORDETTB-GZ_zEh4foW9Z4Ql"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span> </p> <table cellpadding="0" cellspacing="0" id="xdx_308_134_zCJxR97Zmkn5" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Schedule of Research and Development Expenses (Details)"> <tr style="display: none; vertical-align: bottom"> <td style="display: none; padding-bottom: 1pt; text-align: center">-</td><td style="display: none; padding-bottom: 1pt; text-align: center"> </td> <td colspan="2" id="xdx_49B_20260401__20260630_zIV0xOq7pyg" style="border-bottom: Black 1pt solid; display: none; text-align: center">June 30, 2026</td><td style="display: none; padding-bottom: 1pt; text-align: center"> </td><td style="display: none; padding-bottom: 1pt; text-align: center"> </td> <td colspan="2" id="xdx_492_20250401__20250630_zzNO2GU7hnLj" style="border-bottom: Black 1pt solid; display: none; text-align: center">June 30, 2025</td><td style="display: none; padding-bottom: 1pt; text-align: center"> </td><td style="display: none; padding-bottom: 1pt; text-align: center"> </td> <td colspan="2" id="xdx_49D_20260101__20260630_zb865VAlwhq7" style="border-bottom: Black 1pt solid; display: none; text-align: center">June 30, 2026</td><td style="display: none; padding-bottom: 1pt; text-align: center"> </td><td style="display: none; padding-bottom: 1pt; text-align: center"> </td> <td colspan="2" id="xdx_496_20250101__20250630_z5Smucn0w4m7" style="border-bottom: Black 1pt solid; display: none; text-align: center">June 30, 2025</td><td style="display: none; padding-bottom: 1pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"></td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Three months ended</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Six months ended</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; text-align: center"></td><td style="padding-bottom: 1pt; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">June 30, 2026</td><td style="padding-bottom: 1pt; text-align: center"> </td><td style="padding-bottom: 1pt; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">June 30, 2025</td><td style="padding-bottom: 1pt; text-align: center"> </td><td style="padding-bottom: 1pt; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">June 30, 2026</td><td style="padding-bottom: 1pt; text-align: center"> </td><td style="padding-bottom: 1pt; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">June 30, 2025</td><td style="padding-bottom: 1pt; text-align: center"> </td></tr> <tr id="xdx_400_eus-gaap--OtherResearchAndDevelopmentExpense_pn3n3_hdei--LegalEntityAxis__custom--SterlingPharmaSolutionsMember_zShXWbvBcI4d" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1211">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1212">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">23</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1214">—</span></td><td style="width: 1%; text-align: left"> </td></tr> </table> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_C0A_gL3SORDETTB-GZ_zOps2lWaAfcf"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Azenova Sales International</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In October 2023, the Company entered into a consulting agreement with Azenova, LLC where Azenova will provide business development services for AIM’s Ampligen product for solid tumors for a 12-month term that is extendable upon the agreement of the parties. In exchange for its services, Azenova received a monthly retainer of $<span id="xdx_907_ecustom--RetainerAmount_iI_c20231031__dei--LegalEntityAxis__custom--AzenovaSalesInternationalMember_zv8Cr5wXaNyk" title="Retainer amount">30,000</span> in addition to <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_c20231031__dei--LegalEntityAxis__custom--AzenovaSalesInternationalMember_zMLt0XIQ2SD6" title="Stock options, vested">3,600</span> stock options that vest monthly. The monthly retainer was reduced to $<span id="xdx_907_ecustom--RetainerAmount_iI_c20240831__dei--LegalEntityAxis__custom--AzenovaSalesInternationalMember_z2YBDOAHjocg" title="Retainer amount">10,000</span> in August 2024 and subsequently amended to payments based on hourly billing only. The agreement will end on April 30, 2028, but may be extended upon written agreement of the parties.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span id="xdx_C0C_gL3SORDETTB-GZ_zQYWxpgjKw52"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Costs incurred pursuant to the Azenova agreements were as follows (thousands):</span></span></p> <div id="xdx_C0E_gL3SORDETTB-GZ_zqSXb4aLkNyc"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span> </p> <table cellpadding="0" cellspacing="0" id="xdx_306_134_zonC8dKBQ8A4" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Schedule of Research and Development Expenses (Details)"> <tr style="display: none; vertical-align: bottom"> <td style="display: none; text-align: center; padding-bottom: 1pt"> </td><td style="display: none; text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49B_20260401__20260630_zEZeIiLZp671" style="border-bottom: Black 1pt solid; display: none; text-align: center">June 30, 2026</td><td style="display: none; text-align: center; padding-bottom: 1pt"> </td><td style="display: none; text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20250401__20250630_z9vf823NNtl7" style="border-bottom: Black 1pt solid; display: none; text-align: center">June 30, 2025</td><td style="display: none; text-align: center; padding-bottom: 1pt"> </td><td style="display: none; text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20260101__20260630_zGibyqZ1rXKe" style="border-bottom: Black 1pt solid; display: none; text-align: center">June 30, 2026</td><td style="display: none; text-align: center; padding-bottom: 1pt"> </td><td style="display: none; text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20250101__20250630_zEGUROmtnpUe" style="border-bottom: Black 1pt solid; display: none; text-align: center">June 30, 2025</td><td style="display: none; text-align: center; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Three months ended</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Six months ended</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; padding-bottom: 1pt"> </td><td style="text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">June 30, 2026</td><td style="text-align: center; padding-bottom: 1pt"> </td><td style="text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">June 30, 2025</td><td style="text-align: center; padding-bottom: 1pt"> </td><td style="text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">June 30, 2026</td><td style="text-align: center; padding-bottom: 1pt"> </td><td style="text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">June 30, 2025</td><td style="text-align: center; padding-bottom: 1pt"> </td></tr> <tr id="xdx_405_eus-gaap--OtherResearchAndDevelopmentExpense_pn3n3_hdei--LegalEntityAxis__custom--AzenovaSalesInternationalMember_zfyKY8YRJFul" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 11%; text-align: right">2</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1223">—</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 11%; text-align: right">2</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 11%; text-align: right">15</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_C09_gL3SORDETTB-GZ_zPrZnhCtYdn2"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; background-color: white; color: #212121"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Alcami</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; background-color: white; color: #212121"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white; color: #212121"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In September 2023, the Company entered into an agreement with Alcami Corporation to perform an extractables study for a primary packaging component. The agreement called for fixed costs of $<span id="xdx_909_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20230901__20230930__dei--LegalEntityAxis__custom--AlcamiMember_zRNEywkFp5ej" title="Research and development expense">30</span> thousand upon completion of the study and issue of the final report, along with solvent costs, and pass through items to be billed on a per activity basis. The study is now finalized.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white; color: #212121"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_C01_gL3SORDETTB-GZ_zCYcod4krMzl">Costs incurred pursuant to the Alcami agreements were as follows (thousands):  </span></span></p> <div id="xdx_C02_gL3SORDETTB-GZ_zJnb4rwLSmS8"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" id="xdx_309_134_z4B7FnRjub5d" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Schedule of Research and Development Expenses (Details)"> <tr style="display: none; vertical-align: bottom"> <td style="display: none; text-align: center; padding-bottom: 1pt"> </td><td style="display: none; text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49B_20260401__20260630_zEUAMve60pZi" style="border-bottom: Black 1pt solid; display: none; text-align: center">June 30, 2026</td><td style="display: none; text-align: center; padding-bottom: 1pt"> </td><td style="display: none; text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20250401__20250630_znbmvHLDcYe4" style="border-bottom: Black 1pt solid; display: none; text-align: center">June 30, 2025</td><td style="display: none; text-align: center; padding-bottom: 1pt"> </td><td style="display: none; text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20260101__20260630_zQP1nVaRrhs4" style="border-bottom: Black 1pt solid; display: none; text-align: center">June 30, 2026</td><td style="display: none; text-align: center; padding-bottom: 1pt"> </td><td style="display: none; text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20250101__20250630_zEONqLHwr0Hd" style="border-bottom: Black 1pt solid; display: none; text-align: center">June 30, 2025</td><td style="display: none; text-align: center; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Three months ended</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Six months ended</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; padding-bottom: 1pt"> </td><td style="text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">June 30, 2026</td><td style="text-align: center; padding-bottom: 1pt"> </td><td style="text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">June 30, 2025</td><td style="text-align: center; padding-bottom: 1pt"> </td><td style="text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">June 30, 2026</td><td style="text-align: center; padding-bottom: 1pt"> </td><td style="text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">June 30, 2025</td><td style="text-align: center; padding-bottom: 1pt"> </td></tr> <tr id="xdx_402_eus-gaap--OtherResearchAndDevelopmentExpense_pn3n3_hdei--LegalEntityAxis__custom--AlcamiMember_zabsQRdTdCn8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development expenses</span></td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 11%; text-align: right">8</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 11%; text-align: right">3</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 11%; text-align: right">8</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 11%; text-align: right">10</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_C05_gL3SORDETTB-GZ_z3xonL1rnwk3"> </span></b></span></p> <p id="xdx_891_ecustom--ScheduleOfResearchandDevelopmentExpensesTableTextBlock_gL3SORDETTB-GZ_zTfogRZ6Yn3f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s research and development expenses were comprised of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B5_zBflUJ4n3VG5" style="display: none">Schedule of Research and Development Expenses</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; display: none; text-align: left">(in thousands)</td><td style="display: none; text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49F_20260401__20260630_zCyIlHwPCYl5" style="border-bottom: Black 1pt solid; display: none; text-align: center">June 30, 2026</td><td style="display: none; text-align: center; padding-bottom: 1pt"> </td><td style="display: none; text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_498_20250401__20250630_zxHlcjLoome5" style="border-bottom: Black 1pt solid; display: none; text-align: center">June 30, 2025</td><td style="display: none; text-align: center; padding-bottom: 1pt"> </td><td style="display: none; text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49E_20260101__20260630_zv50wlugg0rh" style="border-bottom: Black 1pt solid; display: none; text-align: center">June 30, 2026</td><td style="display: none; text-align: center; padding-bottom: 1pt"> </td><td style="display: none; text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_493_20250101__20250630_zP3lYqFYaGg4" style="border-bottom: Black 1pt solid; display: none; text-align: center">June 30, 2025</td><td style="display: none; text-align: center; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Three months ended</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Six months ended</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; text-align: left">(in thousands)</td><td style="text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">June 30, 2026</td><td style="text-align: center; padding-bottom: 1pt"> </td><td style="text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">June 30, 2025</td><td style="text-align: center; padding-bottom: 1pt"> </td><td style="text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">June 30, 2026</td><td style="text-align: center; padding-bottom: 1pt"> </td><td style="text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">June 30, 2025</td><td style="text-align: center; padding-bottom: 1pt"> </td></tr> <tr id="xdx_405_ecustom--ResearchAndDevelopmentExpenseIncludingProductionCostAdjustment_pn3n3_hsrt--ProductOrServiceAxis__custom--ClinicalStudiesMember_zvy3PiXFMT1l" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: justify">Clinical studies</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">476</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">734</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">661</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">1,328</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_ecustom--ResearchAndDevelopmentExpenseIncludingProductionCostAdjustment_pn3n3_hsrt--ProductOrServiceAxis__custom--ManufacturingAndEngineeringMember_z2OpDS9ojIda" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Manufacturing &amp; Engineering</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(93</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">144</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(23</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">324</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_ecustom--ResearchAndDevelopmentExpenseIncludingProductionCostAdjustment_pn3n3_hsrt--ProductOrServiceAxis__custom--QualityControlMember_zg5fe3CI6B2j" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Quality control</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">197</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">232</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">395</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">462</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_ecustom--ResearchAndDevelopmentExpenseIncludingProductionCostAdjustment_pn3n3_hsrt--ProductOrServiceAxis__custom--RegulatoryMember_zWHYhuYH2lH6" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">Regulatory</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">9</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">64</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">38</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">140</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_404_ecustom--ResearchAndDevelopmentExpenseIncludingProductionCostAdjustment_pn3n3_z0gWoEEXEiF6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Totals</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">589</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,174</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,071</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,254</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Costs incurred pursuant to the Amarex agreements were as follows (thousands):</span><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" id="xdx_305_134_zFnnzF3SkFN2" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Schedule of Research and Development Expenses (Details)"> <tr style="display: none; vertical-align: bottom"> <td style="display: none; text-align: center"> </td><td style="display: none; text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_493_20260401__20260630__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember_zzRAwO4OqMPl" style="border-bottom: Black 1pt solid; display: none; text-align: center">June 30, 2026</td><td style="display: none; text-align: center; padding-bottom: 1pt"> </td><td style="display: none; text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49E_20250401__20250630__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember_zaL89H9zHmQ" style="border-bottom: Black 1pt solid; display: none; text-align: center">June 30, 2025</td><td style="display: none; text-align: center; padding-bottom: 1pt"> </td><td style="display: none; text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20260101__20260630__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember_zSpUkqVtQKXf" style="border-bottom: Black 1pt solid; display: none; text-align: center">June 30, 2026</td><td style="display: none; text-align: center; padding-bottom: 1pt"> </td><td style="display: none; text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20250101__20250630__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember_zn1KXc7WuOPk" style="border-bottom: Black 1pt solid; display: none; text-align: center">June 30, 2025</td><td style="display: none; text-align: center; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Three months ended</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Six months ended</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">June 30, 2026</td><td style="text-align: center; padding-bottom: 1pt"> </td><td style="text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">June 30, 2025</td><td style="text-align: center; padding-bottom: 1pt"> </td><td style="text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">June 30, 2026</td><td style="text-align: center; padding-bottom: 1pt"> </td><td style="text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">June 30, 2025</td><td style="text-align: center; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr id="xdx_40D_eus-gaap--OtherResearchAndDevelopmentExpense_pn3n3_hus-gaap--TypeOfArrangementAxis__custom--PancreaticCancerMember__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember_zo5dEomNRhcd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: justify">Pancreatic Cancer</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">105</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">94</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">118</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">192</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--OtherResearchAndDevelopmentExpense_pn3n3_hus-gaap--TypeOfArrangementAxis__custom--PostCOVIDConditionsMember__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember_z7sX6tEnS4Rj" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">Post Covid Conditions</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1199">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1200">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1201">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">8</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--OtherResearchAndDevelopmentExpense_pn3n3_hdei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember_zotHBBSjlMW2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Totals</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">105</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">94</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">118</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">200</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>  <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Costs incurred pursuant to the Sterling Pharma agreements were as follows (thousands):</span><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span> </p> <table cellpadding="0" cellspacing="0" id="xdx_308_134_zCJxR97Zmkn5" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Schedule of Research and Development Expenses (Details)"> <tr style="display: none; vertical-align: bottom"> <td style="display: none; padding-bottom: 1pt; text-align: center">-</td><td style="display: none; padding-bottom: 1pt; text-align: center"> </td> <td colspan="2" id="xdx_49B_20260401__20260630_zIV0xOq7pyg" style="border-bottom: Black 1pt solid; display: none; text-align: center">June 30, 2026</td><td style="display: none; padding-bottom: 1pt; text-align: center"> </td><td style="display: none; padding-bottom: 1pt; text-align: center"> </td> <td colspan="2" id="xdx_492_20250401__20250630_zzNO2GU7hnLj" style="border-bottom: Black 1pt solid; display: none; text-align: center">June 30, 2025</td><td style="display: none; padding-bottom: 1pt; text-align: center"> </td><td style="display: none; padding-bottom: 1pt; text-align: center"> </td> <td colspan="2" id="xdx_49D_20260101__20260630_zb865VAlwhq7" style="border-bottom: Black 1pt solid; display: none; text-align: center">June 30, 2026</td><td style="display: none; padding-bottom: 1pt; text-align: center"> </td><td style="display: none; padding-bottom: 1pt; text-align: center"> </td> <td colspan="2" id="xdx_496_20250101__20250630_z5Smucn0w4m7" style="border-bottom: Black 1pt solid; display: none; text-align: center">June 30, 2025</td><td style="display: none; padding-bottom: 1pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"></td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Three months ended</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Six months ended</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; text-align: center"></td><td style="padding-bottom: 1pt; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">June 30, 2026</td><td style="padding-bottom: 1pt; text-align: center"> </td><td style="padding-bottom: 1pt; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">June 30, 2025</td><td style="padding-bottom: 1pt; text-align: center"> </td><td style="padding-bottom: 1pt; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">June 30, 2026</td><td style="padding-bottom: 1pt; text-align: center"> </td><td style="padding-bottom: 1pt; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">June 30, 2025</td><td style="padding-bottom: 1pt; text-align: center"> </td></tr> <tr id="xdx_400_eus-gaap--OtherResearchAndDevelopmentExpense_pn3n3_hdei--LegalEntityAxis__custom--SterlingPharmaSolutionsMember_zShXWbvBcI4d" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1211">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1212">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">23</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1214">—</span></td><td style="width: 1%; text-align: left"> </td></tr> </table>  <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Costs incurred pursuant to the Azenova agreements were as follows (thousands):</span><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span> </p> <table cellpadding="0" cellspacing="0" id="xdx_306_134_zonC8dKBQ8A4" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Schedule of Research and Development Expenses (Details)"> <tr style="display: none; vertical-align: bottom"> <td style="display: none; text-align: center; padding-bottom: 1pt"> </td><td style="display: none; text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49B_20260401__20260630_zEZeIiLZp671" style="border-bottom: Black 1pt solid; display: none; text-align: center">June 30, 2026</td><td style="display: none; text-align: center; padding-bottom: 1pt"> </td><td style="display: none; text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20250401__20250630_z9vf823NNtl7" style="border-bottom: Black 1pt solid; display: none; text-align: center">June 30, 2025</td><td style="display: none; text-align: center; padding-bottom: 1pt"> </td><td style="display: none; text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20260101__20260630_zGibyqZ1rXKe" style="border-bottom: Black 1pt solid; display: none; text-align: center">June 30, 2026</td><td style="display: none; text-align: center; padding-bottom: 1pt"> </td><td style="display: none; text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20250101__20250630_zEGUROmtnpUe" style="border-bottom: Black 1pt solid; display: none; text-align: center">June 30, 2025</td><td style="display: none; text-align: center; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Three months ended</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Six months ended</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; padding-bottom: 1pt"> </td><td style="text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">June 30, 2026</td><td style="text-align: center; padding-bottom: 1pt"> </td><td style="text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">June 30, 2025</td><td style="text-align: center; padding-bottom: 1pt"> </td><td style="text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">June 30, 2026</td><td style="text-align: center; padding-bottom: 1pt"> </td><td style="text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">June 30, 2025</td><td style="text-align: center; padding-bottom: 1pt"> </td></tr> <tr id="xdx_405_eus-gaap--OtherResearchAndDevelopmentExpense_pn3n3_hdei--LegalEntityAxis__custom--AzenovaSalesInternationalMember_zfyKY8YRJFul" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 11%; text-align: right">2</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1223">—</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 11%; text-align: right">2</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 11%; text-align: right">15</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>  Costs incurred pursuant to the Alcami agreements were as follows (thousands):  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" id="xdx_309_134_z4B7FnRjub5d" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Schedule of Research and Development Expenses (Details)"> <tr style="display: none; vertical-align: bottom"> <td style="display: none; text-align: center; padding-bottom: 1pt"> </td><td style="display: none; text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49B_20260401__20260630_zEUAMve60pZi" style="border-bottom: Black 1pt solid; display: none; text-align: center">June 30, 2026</td><td style="display: none; text-align: center; padding-bottom: 1pt"> </td><td style="display: none; text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20250401__20250630_znbmvHLDcYe4" style="border-bottom: Black 1pt solid; display: none; text-align: center">June 30, 2025</td><td style="display: none; text-align: center; padding-bottom: 1pt"> </td><td style="display: none; text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20260101__20260630_zQP1nVaRrhs4" style="border-bottom: Black 1pt solid; display: none; text-align: center">June 30, 2026</td><td style="display: none; text-align: center; padding-bottom: 1pt"> </td><td style="display: none; text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20250101__20250630_zEONqLHwr0Hd" style="border-bottom: Black 1pt solid; display: none; text-align: center">June 30, 2025</td><td style="display: none; text-align: center; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Three months ended</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Six months ended</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; padding-bottom: 1pt"> </td><td style="text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">June 30, 2026</td><td style="text-align: center; padding-bottom: 1pt"> </td><td style="text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">June 30, 2025</td><td style="text-align: center; padding-bottom: 1pt"> </td><td style="text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">June 30, 2026</td><td style="text-align: center; padding-bottom: 1pt"> </td><td style="text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">June 30, 2025</td><td style="text-align: center; padding-bottom: 1pt"> </td></tr> <tr id="xdx_402_eus-gaap--OtherResearchAndDevelopmentExpense_pn3n3_hdei--LegalEntityAxis__custom--AlcamiMember_zabsQRdTdCn8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development expenses</span></td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 11%; text-align: right">8</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 11%; text-align: right">3</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 11%; text-align: right">8</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 11%; text-align: right">10</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   476000 734000 661000 1328000 -93000 144000 -23000 324000 197000 232000 395000 462000 9000 64000 38000 140000 589000 1174000 1071000 2254000 118000 200000 8400000 1000000 6400000 125000 4400000 6600000 105000 94000 118000 192000 8000 105000 94000 118000 200000 1500000 23000 30000 3600 10000 2000 2000 15000 30000 8000 3000 8000 10000 <p id="xdx_80E_eus-gaap--CompensationAndEmployeeBenefitPlansTextBlock_zvwkIKgoHfJ1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 11: <span id="xdx_827_zzl4Sr5Kqhib">401(k) Plan</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AIM has a defined contribution plan-the AIM ImmunoTech Employees 401(k) Plan and Trust Agreement (the “401(k) Plan”). AIM’s full-time employees are eligible to participate in the 401(k) Plan following 61 days of employment. Subject to certain limitations imposed by federal tax laws, participants are eligible to contribute up to <span id="xdx_90B_eus-gaap--DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_dp_uPure_c20260101__20260630__us-gaap--RetirementPlanNameAxis__custom--FourZeroOnekPlanMember_zlVILI0YmWn6" title="Percentage of maximum annual contribution per employee, as percentage of their annual salary">15</span>% of their salary (including bonuses and/or commissions) per annum. Participants’ contributions to the 401(k) Plan may be matched by us at a rate determined annually by the Board of Directors.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each participant immediately vests in his or her deferred salary contributions as well as the Company’s safe harbor contributions. A <span id="xdx_90C_eus-gaap--DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage_pid_dp_uPure_c20260101__20260630_zhrriNedW2W" title="Deferred compensation arrangementl, cash awards granted, percentage">6</span>% safe harbor matching contribution by us was reinstated effective January 1, 2021. For the three months ended June 30, 2026 and June 30, 2025 the Company made $<span id="xdx_905_eus-gaap--DefinedContributionPlanEmployerDiscretionaryContributionAmount_pn3n3_c20260401__20260630_ziKDv3T9u5Rl" title="Contribution amount">25</span> thousand and $<span id="xdx_906_eus-gaap--DefinedContributionPlanEmployerDiscretionaryContributionAmount_pn3n3_c20250401__20250630_zEyDtEoVklCf" title="Contribution amount">19</span> thousand in contributions, respectively. For the six months ended June 30, 2026 and June 30, 2025, the Company made $<span id="xdx_900_eus-gaap--DefinedContributionPlanEmployerDiscretionaryContributionAmount_pn3n3_c20260101__20260630_zaJ6cM7oN8H1" title="Contribution amount">47</span> thousand and $<span id="xdx_90A_eus-gaap--DefinedContributionPlanEmployerDiscretionaryContributionAmount_pn3n3_c20250101__20250630_zR1KpCL5dJlj" title="Contribution amount">57</span> thousand in contributions, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; color: red"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> 0.15 0.06 25000 19000 47000 57000 <p id="xdx_807_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zaIE2XsP6tne" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 12: <span id="xdx_82B_z4Y7aiXeacPl">Equity-Based Compensation</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The 2018 Equity Incentive Plan, effective September 12, 2018, as amended and restated on August 19, 2019 (the “2018 Equity Incentive Plan”) authorizes the grant of (i) Incentive Stock Options, (ii) Nonstatutory Stock Options, (iii) Stock Appreciation Rights, (iv) Restricted Stock Awards, (v) Restricted Stock Unit Awards, (vi) Performance Stock Awards, (vii) Performance Cash Awards, and (viii) Other Stock Awards. After the <span id="xdx_908_eus-gaap--StockholdersEquityReverseStockSplit_c20250612__20250612__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_zKtBFg3CIHg5" title="Reverse stock split">100:1</span> reverse stock split which was effective on June 12, 2025, a maximum of <span id="xdx_90B_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20250612__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_ze46LNz5shd2" title="Unissued shares of common stock is reserved for potential issuance">8,980</span> shares of common stock were reserved for potential issuance pursuant to awards under the 2018 Equity Incentive Plan. The number of shares of the Company’s common stock available for grant and issuance under the 2018 Equity Incentive Plan is subject to an annual increase on July 1 of each calendar year, by an amount equal to two percent (2%) of the then outstanding shares of the Company’s common stock (the “2018 Plan Evergreen Provision”). On July 1, 2025, the number of shares of the Company’s common stock available for grant and issuance under the 2018 Equity Incentive Plan increased by an additional <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease_pid_c20250701__20250701__us-gaap--PlanNameAxis__custom--AmendedAndRestatedTwoThousandEighteenEquityIncentivePlanMember_zDdpER2RhcJa" title="Increase in common stock available for grant and issuance">15,283</span> shares. As a result of the 2018 Plan Evergreen Provisions, a maximum of <span id="xdx_907_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20260630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_zxUFkPY84fm6" title="Unissued shares of common stock is reserved for potential issuance">24,263</span> shares of common stock is reserved for potential issuance pursuant to awards under the 2018 Equity Incentive Plan as of June 30, 2026. Subsequently, on July 1, 2026, the number of shares of the Company’s common stock available for grant and issuance under the 2018 Plan increased by <span id="xdx_901_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20260701__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zxpNsrOAL112" title="Unissued shares of common stock is reserved for potential issuance">580,661</span> shares. Unless sooner terminated, the 2018 Equity Incentive Plan will continue in effect for a period of <span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dtY_c20260101__20260630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_z03PToaalkpi" title="Option term">10</span> years from its effective date. During the six months ended June 30, 2026, and 2025, there were no options granted.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As part of the Company’s cash conservation strategy, the Company issued common stock as a substitute for cash salaries to certain executives and directors. For the year ended December 31, 2025, there were <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensationGross_pid_c20250101__20251231_z7foqaXonMjl" title="Shares issued as compensation">4,242</span> shares issued as compensation totaling $<span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensationGross_pn2n3_c20250101__20251231_zb2SNEd9TFf9" title="Shares issued as compensation, value">60</span> thousand. During the six months ended June 30, 2026, there were no shares issued related to the cash conservation program. This compensation is included in the overall equity-based compensation expense.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The fair value of each option and equity warrant award is estimated on the date of grant using a Black-Scholes-Merton option pricing valuation model. Expected volatility is based on the historical volatility of the price of the Company’s stock. The risk-free interest rate is based on U.S. Treasury issues with a term equal to the expected life of the option and equity warrant. The Company uses historical data to estimate expected dividend yield, expected life and forfeiture rates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock options activity during the three months ended June 30, 2026, was as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_897_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_hus-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_gL3SOSBCSOASA-DIJI_zgwakd9cpKG7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock option activity for employees:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BF_z5Fq91zPkFM2" style="display: none">Schedule of Stock Option Activity</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number of<br/> Options</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted<br/> Average <br/>Exercise <br/>Price</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted <br/>Average <br/>Remaining <br/>Contractual <br/>Term <br/>(Years)</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Aggregate <br/>Intrinsic <br/>Value</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Outstanding March 31, 2026</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20260401__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zwJs6Khub2Wg" style="width: 11%; text-align: right" title="Number of options outstanding, beginning of year">21,911</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20260401__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zGr4djSLTTP6" title="Weighted Average Exercise Price Outstanding, Beginning of Period">244.40</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20260401__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zgtXisRhmqGd" title="Weighted Average Remaining Contracted Term (years) Outstanding">9.56</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20260401__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zpzg466NPvIg" style="width: 11%; text-align: right" title="Aggregate Intrinsic Value Outstanding, Beginning of Period"><span style="-sec-ix-hidden: xdx2ixbrl1277">—</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20260401__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zaD5VdjEEwy3" style="text-align: right" title="Number of options, granted"><span style="-sec-ix-hidden: xdx2ixbrl1279">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20260401__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zQLjzgzohtA9" title="Weighted Average Exercise Price, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1281">—</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodTotalIntrinsicValue_pp0p0_c20260401__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zgfB4gW1JD7l" style="text-align: right" title="Aggregate Intrinsic Value, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1283">—</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Forfeited</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20260401__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z3YrmEbjp4i7" style="text-align: right" title="Number of Options, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1285">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20260401__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zz97bUhc70Dg" title="Weighted Average Exercise Price, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1287">—</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodTotalIntrinsicValue_pp0p0_c20260401__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zzjO1kLKbzde" style="text-align: right" title="Aggregate Intrinsic Value, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1289">—</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Expired</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20260401__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zNiBS7jXdfS4" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options, Expired">(10</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20260401__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zrNtmJfWxVnk" title="Weighted Average Exercise Price, Expired">7,128</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodTotalIntrinsicValue_pp0p0_c20260401__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z6kTj6hmhhF6" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate Intrinsic Value, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1295">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Outstanding June 30, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20260401__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z9jmge1zLEq3" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Outstanding, Ending of Period">21,901</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20260401__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zaQ138nogqe9" title="Weighted Average Exercise Price Outstanding, End of Period">241.26</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20260401__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zOW4aDyBFcK2" title="Weighted Average Remaining Contracted Term (years)">9.57</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20260401__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zyamot1hBMgk" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value Outstanding, End of Period"><span style="-sec-ix-hidden: xdx2ixbrl1303">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Vested and expected to vest June 30, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iE_pid_c20260401__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zRoeys8bt0Lg" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options, Vested and Expected to Vest">21,901</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_pid_c20260401__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zXgFvKfqybM8" title="Weighted Average Exercise Price, Vested and Expected to Vest">241.26</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20260401__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z4dqlXbpMbc6" title="Weighted Average Remaining Contracted Term (years), Vested and Expected to Vest">9.57</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iE_pp0p0_c20260401__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zsMAnLERKQKg" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Vested and Expected to Vest"><span style="-sec-ix-hidden: xdx2ixbrl1311">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Exercisable June 30, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20260401__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zDWE6lEJH2He" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Exercisable, End of Period">21,901</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20260401__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z92Mt80pVDE" title="Weighted Average Exercise Price Exercisable, Ending of Period">151.48</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20260401__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z7fZVFpdnNL" title="Weighted Average Remaining Contracted Term (years), Exercisable at End of Period">5.53</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_pp0p0_c20260401__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zjpOXt1Y4CG3" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Exercisable at End of Period"><span style="-sec-ix-hidden: xdx2ixbrl1319">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AA_zxuPfy6XKWTb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_893_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_hus-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_gL3SOSBCSOASA-TDU_zA6VcG0cuqq2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock option activity for non-employees:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B0_zafWMI1AXftg" style="display: none">Schedule of Stock Option Activity</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number of<br/> Options</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted<br/> Average <br/>Exercise <br/>Price</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted <br/>Average <br/>Remaining <br/>Contractual <br/>Term <br/>(Years)</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Aggregate <br/>Intrinsic <br/>Value</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Outstanding March 31, 2026</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20260401__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zHjgYCmx7aKg" style="width: 11%; text-align: right" title="Number of Options Outstanding, Beginning of Period">6,721</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20260401__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z2e2786Tqwxj" style="width: 11%; text-align: right" title="Weighted Average Exercise Price Outstanding, Beginning of Period">185.06</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20260401__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zOnI4WAiLxz8" title="Weighted Average Remaining Contracted Term (years) Outstanding">12.15</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20260401__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zbcHsVDc1Sf9" style="width: 11%; text-align: right" title="Aggregate Intrinsic Value Outstanding, Beginning of Period"><span style="-sec-ix-hidden: xdx2ixbrl1332">—</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20260401__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_ztBrYQLyExTk" style="text-align: right" title="Number of Options, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1334">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20260401__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zSbW5TPwHen7" style="text-align: right" title="Weighted Average Exercise Price, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1336">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodTotalIntrinsicValue_pp0p0_c20260401__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zDhQ5CQ4Fihi" style="text-align: right" title="Aggregate Intrinsic Value Outstanding, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1338">—</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Forfeited</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20260401__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z5c8wVabbmH8" style="text-align: right" title="Number of Options, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1340">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20260401__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z4NvtIOf3Jja" style="text-align: right" title="Weighted Average Exercise Price, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1342">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodTotalIntrinsicValue_pp0p0_c20260401__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zay4IUheXl79" style="text-align: right" title="Aggregate Intrinsic Value, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1344">—</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Expired</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20260401__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zWGnlUMyhEDe" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options, Expired">(4</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20260401__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zz6z8qpjHFR4" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Expired">6,864</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodTotalIntrinsicValue_pp0p0_c20260401__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z6Ew0DR78e1c" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate Intrinsic Value, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1350">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Outstanding June 30, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20260401__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zJEId1xHPF97" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Outstanding, End of Period">6,717</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20260401__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zDEqNEjCz8uc" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Outstanding, End of Period">181.09</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_903_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20260401__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zW8EQOS7ZZg6">12.16</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20260401__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zmdJ52nAylwf" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value Outstanding, End of Period"><span style="-sec-ix-hidden: xdx2ixbrl1357">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Vested and expected to vest June 30, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iE_pid_c20260401__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zZkl6ncbWvXi" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options, Vested and Expected to Vest">6,717</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_pid_c20260401__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zZuInHobODbi" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Vested and Expected to Vest">181.09</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20260401__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zBdSQiAiQ85g" title="Weighted Average Remaining Contracted Term (years), Vested and Expected to Vest">12.16</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iE_pp0p0_c20260401__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z4C1DXzTVZW5" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Vested and Expected to Vest"><span style="-sec-ix-hidden: xdx2ixbrl1365">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Exercisable June 30, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20260401__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z5DauR9BC0if" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Exercisable, End of Period">6,717</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20260401__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zEM846NNNPUk" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Exercisable, End of Period">146.99</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20260401__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z9CW4X2DMnUf" title="Weighted Average Remaining Contracted Term (years), Exercisable at End of Period">12.53</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_pp0p0_c20260401__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zWvhK2trDsj8" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, End of Period"><span style="-sec-ix-hidden: xdx2ixbrl1373">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A5_zlnnZXUkh1V8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock options activity during the six months ended June 30, 2026, was as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_C03_gL3SOSBCSOASA-DIJI_zf2tMPizpbXi">Stock option activity for employees:</span></span></p> <div id="xdx_C04_gL3SOSBCSOASA-DIJI_zEDBLdAHUC39"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" id="xdx_30E_134_z9rMzws77A23" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Schedule of Stock Option Activity (Details)"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number of<br/> Options</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted<br/> Average <br/>Exercise <br/>Price</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted <br/>Average <br/>Remaining <br/>Contractual <br/>Term <br/>(Years)</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Aggregate <br/>Intrinsic <br/>Value</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Outstanding January 1, 2026</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20260101__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zsf2Bkvbo0G" style="width: 11%; text-align: right" title="Number of options outstanding, beginning of year">21,911</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20260101__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zrFOpz0KWbHi" title="Weighted Average Exercise Price Outstanding, Beginning of Period">244.40</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zQM8d9zGLJnh" title="Weighted Average Remaining Contracted Term (years) Outstanding">9.56</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20260101__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zv7lTdnuREy8" style="width: 11%; text-align: right" title="Aggregate Intrinsic Value Outstanding, Beginning of Period"><span style="-sec-ix-hidden: xdx2ixbrl1381">—</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20260101__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z7IeBUqwDX7f" style="text-align: right" title="Number of options, granted"><span style="-sec-ix-hidden: xdx2ixbrl1383">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20260101__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zFjVuQEN6pK7" title="Weighted Average Exercise Price, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1385">—</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodTotalIntrinsicValue_pp0p0_c20260101__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zzH4RKKzuCb" style="text-align: right" title="Aggregate Intrinsic Value, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1387">—</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Forfeited</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20260101__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zRqIFm5PpsR7" style="text-align: right" title="Number of Options, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1389">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20260101__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zzgWfrkfuG1" title="Weighted Average Exercise Price, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1391">—</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodTotalIntrinsicValue_pp0p0_c20260101__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zFz1o1SLsHgh" style="text-align: right" title="Aggregate Intrinsic Value, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1393">—</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Expired</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20260101__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zPW8NoPH7HS7" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options, Expired">(10</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20260101__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zcIPoDyulHM5" title="Weighted Average Exercise Price, Expired">7,128</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodTotalIntrinsicValue_pp0p0_c20260101__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_znvjZihjIm9i" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate Intrinsic Value, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1399">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Outstanding June 30, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20260101__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zarW3yf6Lf85" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Outstanding, Ending of Period">21,901</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20260101__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z6vZZiJNiwpe" title="Weighted Average Exercise Price Outstanding, End of Period">241.26</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_908_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20260101__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zhUVRuXIkk72" title="Weighted Average Remaining Contracted Term (years)">9.57</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20260101__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zVqmeNqOmQpj" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value Outstanding, End of Period"><span style="-sec-ix-hidden: xdx2ixbrl1407">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Vested and expected to vest June 30, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iE_pid_c20260101__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zJJ1VsMNkP94" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options, Vested and Expected to Vest">21,901</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_pid_c20260101__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z0urYSKtvbP6" title="Weighted Average Exercise Price, Vested and Expected to Vest">241.26</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20260101__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zamyoCtBvGCj" title="Weighted Average Remaining Contracted Term (years), Vested and Expected to Vest">9.57</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iE_pp0p0_c20260101__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zCTNWaOwpQFl" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Vested and Expected to Vest"><span style="-sec-ix-hidden: xdx2ixbrl1415">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Exercisable June 30, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20260101__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z97NPGWi3ZX5" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Exercisable, End of Period">21,901</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20260101__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zkSUZ9ybju5k" title="Weighted Average Exercise Price Exercisable, Ending of Period">151.48</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20260101__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zu9dMdpLLP5g" title="Weighted Average Remaining Contracted Term (years), Exercisable at End of Period">5.53</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_pp0p0_c20260101__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zfQRlf0JSFve" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Exercisable at End of Period"><span style="-sec-ix-hidden: xdx2ixbrl1423">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_C05_gL3SOSBCSOASA-DIJI_ze9msTljBDS1"> </span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_C00_gL3SOSBCSOASA-TDU_zYLLfgPcKkO8">Stock option activity for non-employees:</span></span></p> <div id="xdx_C0D_gL3SOSBCSOASA-TDU_zXBFrhvX7Qei"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number of<br/> Options</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted<br/> Average <br/>Exercise <br/>Price</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted <br/>Average <br/>Remaining <br/>Contractual <br/>Term <br/>(Years)</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Aggregate <br/>Intrinsic <br/>Value</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Outstanding January 1, 2026</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20260101__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zqWFnx8Rploa" style="width: 11%; text-align: right" title="Number of Options Outstanding, Beginning of Period">6,721</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20260101__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zmoZJ0Xhui9g" style="width: 11%; text-align: right" title="Weighted Average Exercise Price Outstanding, Beginning of Period">185.06</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zJ2HyXPb5zEc" title="Weighted Average Remaining Contracted Term (years) Outstanding">12.15</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20260101__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z6EIs85VCwS3" style="width: 11%; text-align: right" title="Aggregate Intrinsic Value Outstanding, Beginning of Period"><span style="-sec-ix-hidden: xdx2ixbrl1431">—</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20260101__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zIbrhHMA22D2" style="text-align: right" title="Number of Options, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1433">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20260101__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_ztpRDwaeDS49" style="text-align: right" title="Weighted Average Exercise Price, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1435">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodTotalIntrinsicValue_pp0p0_c20260101__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zED7lx2nYj2g" style="text-align: right" title="Aggregate Intrinsic Value Outstanding, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1437">—</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Forfeited</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20260101__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zxUvDgFdL9Dg" style="text-align: right" title="Number of Options, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1439">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20260101__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zLhlvdlA4lz1" style="text-align: right" title="Weighted Average Exercise Price, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1441">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodTotalIntrinsicValue_pp0p0_c20260101__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z8yaR5rdxVBi" style="text-align: right" title="Aggregate Intrinsic Value, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1443">—</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Expired</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20260101__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zrAbGYXVqDjk" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options, Expired">(4</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20260101__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z8ywdPreFA9b" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Expired">6,864</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodTotalIntrinsicValue_pp0p0_c20260101__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zVXbZW9nStUj" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate Intrinsic Value, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1449">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Outstanding June 30, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20260101__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z5FdFCKm1jjb" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Outstanding, End of Period">6,717</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20260101__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zNhy2IslP7jh" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Outstanding, End of Period">181.09</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20260101__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zhzROHOm4Dhl" title="Weighted Average Remaining Contracted Term (years) Outstanding">12.16</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20260101__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z5oWOx9empJc" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value Outstanding, End of Period"><span style="-sec-ix-hidden: xdx2ixbrl1457">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Vested and expected to vest June 30, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iE_pid_c20260101__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z4KwiGRSeQub" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options, Vested and Expected to Vest">6,717</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_pid_c20260101__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zQho90Y2ZLn5" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Vested and Expected to Vest">181.09</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20260101__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zTo6biR4k4ye" title="Weighted Average Remaining Contracted Term (years), Vested and Expected to Vest">12.16</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iE_pp0p0_c20260101__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zRiNlnEUJGnj" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Vested and Expected to Vest"><span style="-sec-ix-hidden: xdx2ixbrl1465">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Exercisable June 30, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20260101__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zKWZGSZswA2l" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Exercisable, End of Period">6,717</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20260101__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zpkCpyEFOxe9" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Exercisable, End of Period">146.99</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20260101__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zQE05S9urkEl" title="Weighted Average Remaining Contracted Term (years), Exercisable at End of Period">12.53</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_pp0p0_c20260101__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zCnV8kfRU1Kd" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, End of Period"><span style="-sec-ix-hidden: xdx2ixbrl1473">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_C03_gL3SOSBCSOASA-TDU_z1Rv5Ot32fXj"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There was no unvested stock option activity for employees and non-employees.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-based compensation expense was $<span id="xdx_90A_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20260101__20260630_zuvwJxiBreph" title="Share based compensation expense">0</span> and $<span id="xdx_903_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20250101__20250630_zcR9O4SGKL99" title="Share based compensation expense">60</span> thousand for the six months ended June 30, 2026 and 2025, respectively, and is recognized in a decrease in general and administrative expenses.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> 100:1 8980 15283 24263 580661 P10Y 4242 60000 <p id="xdx_897_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_hus-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_gL3SOSBCSOASA-DIJI_zgwakd9cpKG7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock option activity for employees:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BF_z5Fq91zPkFM2" style="display: none">Schedule of Stock Option Activity</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number of<br/> Options</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted<br/> Average <br/>Exercise <br/>Price</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted <br/>Average <br/>Remaining <br/>Contractual <br/>Term <br/>(Years)</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Aggregate <br/>Intrinsic <br/>Value</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Outstanding March 31, 2026</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20260401__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zwJs6Khub2Wg" style="width: 11%; text-align: right" title="Number of options outstanding, beginning of year">21,911</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20260401__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zGr4djSLTTP6" title="Weighted Average Exercise Price Outstanding, Beginning of Period">244.40</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20260401__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zgtXisRhmqGd" title="Weighted Average Remaining Contracted Term (years) Outstanding">9.56</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20260401__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zpzg466NPvIg" style="width: 11%; text-align: right" title="Aggregate Intrinsic Value Outstanding, Beginning of Period"><span style="-sec-ix-hidden: xdx2ixbrl1277">—</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20260401__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zaD5VdjEEwy3" style="text-align: right" title="Number of options, granted"><span style="-sec-ix-hidden: xdx2ixbrl1279">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20260401__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zQLjzgzohtA9" title="Weighted Average Exercise Price, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1281">—</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodTotalIntrinsicValue_pp0p0_c20260401__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zgfB4gW1JD7l" style="text-align: right" title="Aggregate Intrinsic Value, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1283">—</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Forfeited</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20260401__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z3YrmEbjp4i7" style="text-align: right" title="Number of Options, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1285">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20260401__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zz97bUhc70Dg" title="Weighted Average Exercise Price, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1287">—</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodTotalIntrinsicValue_pp0p0_c20260401__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zzjO1kLKbzde" style="text-align: right" title="Aggregate Intrinsic Value, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1289">—</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Expired</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20260401__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zNiBS7jXdfS4" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options, Expired">(10</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20260401__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zrNtmJfWxVnk" title="Weighted Average Exercise Price, Expired">7,128</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodTotalIntrinsicValue_pp0p0_c20260401__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z6kTj6hmhhF6" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate Intrinsic Value, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1295">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Outstanding June 30, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20260401__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z9jmge1zLEq3" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Outstanding, Ending of Period">21,901</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20260401__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zaQ138nogqe9" title="Weighted Average Exercise Price Outstanding, End of Period">241.26</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20260401__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zOW4aDyBFcK2" title="Weighted Average Remaining Contracted Term (years)">9.57</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20260401__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zyamot1hBMgk" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value Outstanding, End of Period"><span style="-sec-ix-hidden: xdx2ixbrl1303">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Vested and expected to vest June 30, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iE_pid_c20260401__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zRoeys8bt0Lg" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options, Vested and Expected to Vest">21,901</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_pid_c20260401__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zXgFvKfqybM8" title="Weighted Average Exercise Price, Vested and Expected to Vest">241.26</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20260401__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z4dqlXbpMbc6" title="Weighted Average Remaining Contracted Term (years), Vested and Expected to Vest">9.57</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iE_pp0p0_c20260401__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zsMAnLERKQKg" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Vested and Expected to Vest"><span style="-sec-ix-hidden: xdx2ixbrl1311">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Exercisable June 30, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20260401__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zDWE6lEJH2He" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Exercisable, End of Period">21,901</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20260401__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z92Mt80pVDE" title="Weighted Average Exercise Price Exercisable, Ending of Period">151.48</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20260401__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z7fZVFpdnNL" title="Weighted Average Remaining Contracted Term (years), Exercisable at End of Period">5.53</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_pp0p0_c20260401__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zjpOXt1Y4CG3" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Exercisable at End of Period"><span style="-sec-ix-hidden: xdx2ixbrl1319">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Stock option activity for employees:<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" id="xdx_30E_134_z9rMzws77A23" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Schedule of Stock Option Activity (Details)"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number of<br/> Options</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted<br/> Average <br/>Exercise <br/>Price</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted <br/>Average <br/>Remaining <br/>Contractual <br/>Term <br/>(Years)</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Aggregate <br/>Intrinsic <br/>Value</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Outstanding January 1, 2026</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20260101__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zsf2Bkvbo0G" style="width: 11%; text-align: right" title="Number of options outstanding, beginning of year">21,911</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20260101__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zrFOpz0KWbHi" title="Weighted Average Exercise Price Outstanding, Beginning of Period">244.40</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zQM8d9zGLJnh" title="Weighted Average Remaining Contracted Term (years) Outstanding">9.56</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20260101__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zv7lTdnuREy8" style="width: 11%; text-align: right" title="Aggregate Intrinsic Value Outstanding, Beginning of Period"><span style="-sec-ix-hidden: xdx2ixbrl1381">—</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20260101__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z7IeBUqwDX7f" style="text-align: right" title="Number of options, granted"><span style="-sec-ix-hidden: xdx2ixbrl1383">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20260101__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zFjVuQEN6pK7" title="Weighted Average Exercise Price, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1385">—</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodTotalIntrinsicValue_pp0p0_c20260101__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zzH4RKKzuCb" style="text-align: right" title="Aggregate Intrinsic Value, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1387">—</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Forfeited</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20260101__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zRqIFm5PpsR7" style="text-align: right" title="Number of Options, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1389">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20260101__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zzgWfrkfuG1" title="Weighted Average Exercise Price, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1391">—</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodTotalIntrinsicValue_pp0p0_c20260101__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zFz1o1SLsHgh" style="text-align: right" title="Aggregate Intrinsic Value, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1393">—</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Expired</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20260101__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zPW8NoPH7HS7" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options, Expired">(10</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20260101__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zcIPoDyulHM5" title="Weighted Average Exercise Price, Expired">7,128</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodTotalIntrinsicValue_pp0p0_c20260101__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_znvjZihjIm9i" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate Intrinsic Value, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1399">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Outstanding June 30, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20260101__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zarW3yf6Lf85" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Outstanding, Ending of Period">21,901</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20260101__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z6vZZiJNiwpe" title="Weighted Average Exercise Price Outstanding, End of Period">241.26</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_908_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20260101__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zhUVRuXIkk72" title="Weighted Average Remaining Contracted Term (years)">9.57</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20260101__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zVqmeNqOmQpj" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value Outstanding, End of Period"><span style="-sec-ix-hidden: xdx2ixbrl1407">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Vested and expected to vest June 30, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iE_pid_c20260101__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zJJ1VsMNkP94" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options, Vested and Expected to Vest">21,901</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_pid_c20260101__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z0urYSKtvbP6" title="Weighted Average Exercise Price, Vested and Expected to Vest">241.26</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20260101__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zamyoCtBvGCj" title="Weighted Average Remaining Contracted Term (years), Vested and Expected to Vest">9.57</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iE_pp0p0_c20260101__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zCTNWaOwpQFl" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Vested and Expected to Vest"><span style="-sec-ix-hidden: xdx2ixbrl1415">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Exercisable June 30, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20260101__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z97NPGWi3ZX5" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Exercisable, End of Period">21,901</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20260101__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zkSUZ9ybju5k" title="Weighted Average Exercise Price Exercisable, Ending of Period">151.48</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20260101__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zu9dMdpLLP5g" title="Weighted Average Remaining Contracted Term (years), Exercisable at End of Period">5.53</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_pp0p0_c20260101__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zfQRlf0JSFve" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Exercisable at End of Period"><span style="-sec-ix-hidden: xdx2ixbrl1423">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   21911 244.40 P9Y6M21D 10 7128 21901 241.26 P9Y6M25D 21901 241.26 P9Y6M25D 21901 151.48 P5Y6M10D <p id="xdx_893_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_hus-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_gL3SOSBCSOASA-TDU_zA6VcG0cuqq2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock option activity for non-employees:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B0_zafWMI1AXftg" style="display: none">Schedule of Stock Option Activity</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number of<br/> Options</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted<br/> Average <br/>Exercise <br/>Price</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted <br/>Average <br/>Remaining <br/>Contractual <br/>Term <br/>(Years)</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Aggregate <br/>Intrinsic <br/>Value</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Outstanding March 31, 2026</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20260401__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zHjgYCmx7aKg" style="width: 11%; text-align: right" title="Number of Options Outstanding, Beginning of Period">6,721</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20260401__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z2e2786Tqwxj" style="width: 11%; text-align: right" title="Weighted Average Exercise Price Outstanding, Beginning of Period">185.06</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20260401__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zOnI4WAiLxz8" title="Weighted Average Remaining Contracted Term (years) Outstanding">12.15</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20260401__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zbcHsVDc1Sf9" style="width: 11%; text-align: right" title="Aggregate Intrinsic Value Outstanding, Beginning of Period"><span style="-sec-ix-hidden: xdx2ixbrl1332">—</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20260401__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_ztBrYQLyExTk" style="text-align: right" title="Number of Options, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1334">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20260401__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zSbW5TPwHen7" style="text-align: right" title="Weighted Average Exercise Price, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1336">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodTotalIntrinsicValue_pp0p0_c20260401__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zDhQ5CQ4Fihi" style="text-align: right" title="Aggregate Intrinsic Value Outstanding, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1338">—</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Forfeited</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20260401__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z5c8wVabbmH8" style="text-align: right" title="Number of Options, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1340">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20260401__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z4NvtIOf3Jja" style="text-align: right" title="Weighted Average Exercise Price, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1342">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodTotalIntrinsicValue_pp0p0_c20260401__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zay4IUheXl79" style="text-align: right" title="Aggregate Intrinsic Value, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1344">—</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Expired</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20260401__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zWGnlUMyhEDe" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options, Expired">(4</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20260401__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zz6z8qpjHFR4" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Expired">6,864</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodTotalIntrinsicValue_pp0p0_c20260401__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z6Ew0DR78e1c" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate Intrinsic Value, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1350">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Outstanding June 30, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20260401__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zJEId1xHPF97" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Outstanding, End of Period">6,717</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20260401__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zDEqNEjCz8uc" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Outstanding, End of Period">181.09</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_903_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20260401__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zW8EQOS7ZZg6">12.16</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20260401__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zmdJ52nAylwf" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value Outstanding, End of Period"><span style="-sec-ix-hidden: xdx2ixbrl1357">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Vested and expected to vest June 30, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iE_pid_c20260401__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zZkl6ncbWvXi" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options, Vested and Expected to Vest">6,717</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_pid_c20260401__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zZuInHobODbi" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Vested and Expected to Vest">181.09</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20260401__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zBdSQiAiQ85g" title="Weighted Average Remaining Contracted Term (years), Vested and Expected to Vest">12.16</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iE_pp0p0_c20260401__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z4C1DXzTVZW5" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Vested and Expected to Vest"><span style="-sec-ix-hidden: xdx2ixbrl1365">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Exercisable June 30, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20260401__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z5DauR9BC0if" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Exercisable, End of Period">6,717</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20260401__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zEM846NNNPUk" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Exercisable, End of Period">146.99</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20260401__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z9CW4X2DMnUf" title="Weighted Average Remaining Contracted Term (years), Exercisable at End of Period">12.53</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_pp0p0_c20260401__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zWvhK2trDsj8" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, End of Period"><span style="-sec-ix-hidden: xdx2ixbrl1373">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Stock option activity for non-employees:<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number of<br/> Options</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted<br/> Average <br/>Exercise <br/>Price</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted <br/>Average <br/>Remaining <br/>Contractual <br/>Term <br/>(Years)</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Aggregate <br/>Intrinsic <br/>Value</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Outstanding January 1, 2026</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20260101__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zqWFnx8Rploa" style="width: 11%; text-align: right" title="Number of Options Outstanding, Beginning of Period">6,721</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20260101__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zmoZJ0Xhui9g" style="width: 11%; text-align: right" title="Weighted Average Exercise Price Outstanding, Beginning of Period">185.06</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zJ2HyXPb5zEc" title="Weighted Average Remaining Contracted Term (years) Outstanding">12.15</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20260101__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z6EIs85VCwS3" style="width: 11%; text-align: right" title="Aggregate Intrinsic Value Outstanding, Beginning of Period"><span style="-sec-ix-hidden: xdx2ixbrl1431">—</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20260101__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zIbrhHMA22D2" style="text-align: right" title="Number of Options, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1433">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20260101__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_ztpRDwaeDS49" style="text-align: right" title="Weighted Average Exercise Price, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1435">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodTotalIntrinsicValue_pp0p0_c20260101__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zED7lx2nYj2g" style="text-align: right" title="Aggregate Intrinsic Value Outstanding, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1437">—</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Forfeited</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20260101__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zxUvDgFdL9Dg" style="text-align: right" title="Number of Options, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1439">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20260101__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zLhlvdlA4lz1" style="text-align: right" title="Weighted Average Exercise Price, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1441">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodTotalIntrinsicValue_pp0p0_c20260101__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z8yaR5rdxVBi" style="text-align: right" title="Aggregate Intrinsic Value, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1443">—</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Expired</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20260101__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zrAbGYXVqDjk" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options, Expired">(4</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20260101__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z8ywdPreFA9b" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Expired">6,864</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodTotalIntrinsicValue_pp0p0_c20260101__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zVXbZW9nStUj" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate Intrinsic Value, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1449">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Outstanding June 30, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20260101__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z5FdFCKm1jjb" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Outstanding, End of Period">6,717</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20260101__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zNhy2IslP7jh" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Outstanding, End of Period">181.09</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20260101__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zhzROHOm4Dhl" title="Weighted Average Remaining Contracted Term (years) Outstanding">12.16</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20260101__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z5oWOx9empJc" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value Outstanding, End of Period"><span style="-sec-ix-hidden: xdx2ixbrl1457">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Vested and expected to vest June 30, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iE_pid_c20260101__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z4KwiGRSeQub" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options, Vested and Expected to Vest">6,717</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_pid_c20260101__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zQho90Y2ZLn5" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Vested and Expected to Vest">181.09</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20260101__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zTo6biR4k4ye" title="Weighted Average Remaining Contracted Term (years), Vested and Expected to Vest">12.16</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iE_pp0p0_c20260101__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zRiNlnEUJGnj" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Vested and Expected to Vest"><span style="-sec-ix-hidden: xdx2ixbrl1465">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Exercisable June 30, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20260101__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zKWZGSZswA2l" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Exercisable, End of Period">6,717</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20260101__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zpkCpyEFOxe9" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Exercisable, End of Period">146.99</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20260101__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zQE05S9urkEl" title="Weighted Average Remaining Contracted Term (years), Exercisable at End of Period">12.53</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_pp0p0_c20260101__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zCnV8kfRU1Kd" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, End of Period"><span style="-sec-ix-hidden: xdx2ixbrl1473">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   6721 185.06 P12Y1M24D 4 6864 6717 181.09 P12Y1M28D 6717 181.09 P12Y1M28D 6717 146.99 P12Y6M10D 21911 244.40 P9Y6M21D 10 7128 21901 241.26 P9Y6M25D 21901 241.26 P9Y6M25D 21901 151.48 P5Y6M10D 6721 185.06 P12Y1M24D 4 6864 6717 181.09 P12Y1M28D 6717 181.09 P12Y1M28D 6717 146.99 P12Y6M10D 0 60000 <p id="xdx_80D_ecustom--StockWarrantsDisclosureTextBlock_zkhApgtV8aa5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 13: <span id="xdx_824_zRlRiuh3jcFd">Stock Warrants</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 31, 2024, the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) to complete an offering (the “Transactions”) with a single accredited investor (the “Purchaser”), pursuant to which, on June 3, 2024, the Company issued to the Purchaser, (i) in a registered direct offering, <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240603__20240603__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_z4Q5CuhaYTIk" title="Number of shares issued upon transaction">56,410</span> shares of the Company’s common stock (the “Shares”) and (ii) in a concurrent private placement, the Company issued to the Purchaser Class A common warrants to purchase an aggregate of up to <span id="xdx_904_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240603__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--ClassAWarrantMember_zKsmC43y1AIl" title="Number of shares issued upon transaction">56,410</span> shares of its common stock (the “A Warrants”) at an exercise price of $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240603__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--ClassAWarrantMember_zNkmip1CwLu5" title="Exercise price">36.30</span> per share and Class B common warrants to purchase an aggregate of up to <span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240603__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--ClassBWarrantMember_zh5nBbUsCtpk" title="Warrants to purchase shares of common stock">56,410</span> shares of its common stock (the “B Warrants” and, along with the A Warrants, the “Common Warrants”) at an exercise price of $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240603__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--ClassBWarrantMember_zZP0DvRMvhVc" title="Warrants exercise price">36.30</span> per share.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On September 30, 2024, the Company entered into a Purchase Agreement with the Purchaser in the May 2024 Securities Purchase Agreement as Purchaser, pursuant to which the Company issued to the Purchaser, (i) in a registered direct offering, <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240930__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zyms6gCYLLe9" title="Number of shares issued">46,530</span> shares of its common stock (“Shares”) and (ii) in the concurrent Private Placement, Class C and Class D Warrants, each to purchase an aggregate of up to <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240930__us-gaap--StatementEquityComponentsAxis__custom--ClassCAndClassDWarrantsMember_za8ZHwSHXlz3" title="Common warrant shares">46,530</span> Shares (the “Common Warrant Shares”) each with an exercise price of $<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240930__us-gaap--StatementEquityComponentsAxis__custom--ClassCAndClassDWarrantsMember_za6phKyhutv8" title="Warrants exercise price">28.00</span>. The Class C and Class D Warrants together, hereinafter the “Common Warrants”. The purchase price for Shares in the registered direct offering was $<span id="xdx_90A_eus-gaap--SharePrice_iI_pid_c20240930__us-gaap--StatementEquityComponentsAxis__custom--ClassCAndClassDWarrantsMember_zgBP3h04tjW6" title="Share price">28.00</span> per Share.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 30, 2025, the Company announced closing a public offering of an aggregate of <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20250730__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zOw314WNi9N2" title="Number of warrant to purchase shares of common stock">2,000,000</span> shares of its common stock (or pre-funded warrants in lieu thereof), Class E warrants to purchase up to <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20250730__us-gaap--StatementEquityComponentsAxis__custom--ClassEWarrantsMember_zqceFe7eTgBd" title="Warrant to purchase shares of common stock">2,000,000</span> shares of common stock, and Class F warrants to purchase up to <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20250730__us-gaap--StatementEquityComponentsAxis__custom--ClassFWarrantsMember_zXxtOELWQWw9" title="Warrant to purchase shares of common stock">2,000,000</span> shares of common stock, at a combined public offering price of $<span id="xdx_90C_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20250730__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zeP1XKx4oV56" title="Offering price per share">4.00</span> per share (or $<span id="xdx_908_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20250730__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember_zyrACfNtwRhc" title="Offering price per share">3.999</span> per pre-funded warrant) and accompanying warrants. The warrants had an exercise price of $<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250730__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z78bHmSS4dll" title="Warrant exercise price">4.00</span> per share and were exercisable immediately upon issuance. The Class E warrants will expire on the fifth anniversary of the original issuance date, and the Class F warrants will expire on the eighteen-month anniversary of the original issuance date. Gross proceeds, before deducting placement agent fees and offering expenses, were $<span id="xdx_908_eus-gaap--ProceedsFromIssuanceOfWarrants_pn6n6_c20250730__20250730__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember_zmKcbhcvzxU6" title="Gross proceeds">8</span> million. Maxim Group LLC acted as sole placement agent in connection with this offering.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on a review of the Class E and F Warrants, it was determined that the warrants met the liability criteria which resulted in Class E &amp; F warrants to be treated as liability under ASC 815 – Derivatives and Hedging. Accordingly, a loss was recognized and the resulting computed value was classified as a liability on the Company’s balance sheet at December 31, 2025.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December 30, 2025, <span id="xdx_909_ecustom--StockDividendsDescription_c20251230__20251230__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zNHJwKs2ZFhj" title="Stock dividends description">the Company declared a stock dividend of one share of common stock for every 1,000 shares of outstanding common stock as well as one share of common stock for every outstanding option or warrant that has a right to receive stock dividends (“Alternate Securities”).</span> <span id="xdx_90D_ecustom--StockDividendsDescription_c20260113__20260113__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zcEfCr5XmxI7" title="Stock dividends description">On January 13, 2026, the Company distributed a dividend of one share of its common stock for every 1,000 shares of common stock issued and outstanding as of January 9, 2026, as well as one share of common stock for every outstanding option or warrant that has a right to receive stock dividends (the “Dividend”).</span> The issuance of the Dividend was a Share Combination Event under Section 3(g) of the Class E &amp; F Common Stock Purchase Warrants. As a result, the number of outstanding warrants of Class E &amp; F Common Stock Purchase Warrants both increased to <span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20260113__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassEAndFCommonStockPurchaseWarrantsMember_zXav1iMQGGke" title="Number of warrents, shares">5,561,125</span> and the exercise price was reduced to $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260113__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassEAndFCommonStockPurchaseWarrantsMember_zVbt8XC31f3c" title="Number of warrents, exercise price">1.439</span> per share of common stock. Due to the Share Combination Event trigger of the Class E &amp; F Common Stock Purchase Warrants, the warrants were reevaluated, resulting in the reclassification of the warrants from liability to equity. The Company recognized a loss on the fair market valuation of the warrants of $<span id="xdx_90B_ecustom--ChangeInFairValueOfWarrantLiability_iN_pn3n3_di_c20260101__20260630_zX7cgI9rWG7j" title="Change in fair value of warrant liability">468</span> thousand in the statements of operations for the six months ended June 30, 2026, and reclassified the Class E &amp; F Common Stock Purchase Warrants from liability to equity in the amount of $<span id="xdx_906_ecustom--WarrantsFromLiabilityToEquity_iI_pn5n6_c20260630_zkhJ4JFRO3fc" title="Warrants from liability to equity">8.7</span> million reflected in the Balance Sheet at June 30, 2026.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 6, 2026, the Company completed a rights offering (the “2026 Rights Offering”) to our stockholders and to holders of certain of our outstanding options and warrants that had the right to participate in the 2026 Rights Offering as of February 10, 2026, the record date. In the Rights Offering the Company issued non-transferable subscription rights to purchase <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20260306__20260306__us-gaap--SubsidiarySaleOfStockAxis__custom--TwoThousandTwentySixRightsOfferingMember_zFcWdHiT7tr3" title="Number of units issued">1,842</span> Units. Each Unit consists of <span id="xdx_90B_eus-gaap--SharesIssued_iI_pid_dc_c20260306__us-gaap--StatementClassOfStockAxis__custom--SeriesGConvertiblePreferredStockMember__us-gaap--SubsidiarySaleOfStockAxis__custom--TwoThousandTwentySixRightsOfferingMember_zFW0yCMvyqYd" title="Shares issued">one</span> share of Series G Convertible Preferred Stock (the “G Preferred”) and <span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20260306__us-gaap--StatementClassOfStockAxis__custom--GWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--TwoThousandTwentySixRightsOfferingMember_zjWkvIEXSIo7" title="Shares issued">2,000</span> warrants to purchase common stock (the “G Warrants”). Each share of G Preferred is convertible, at the option of the holder at any time, into a number of shares of our common stock equal to the quotient of the stated value of the Preferred Stock ($<span id="xdx_903_ecustom--PreferredStockPreferredStockStatedValuePerShare_iI_pn3n3_c20260306__us-gaap--StatementClassOfStockAxis__custom--SeriesGConvertiblePreferredStockMember__us-gaap--SubsidiarySaleOfStockAxis__custom--TwoThousandTwentySixRightsOfferingMember_zOhQaVYittEi" title="Preferred stock, stated value">1</span> thousand) divided by $<span id="xdx_909_eus-gaap--PreferredStockConvertibleConversionPrice_iI_pid_c20260306__us-gaap--StatementClassOfStockAxis__custom--SeriesGConvertiblePreferredStockMember__us-gaap--SubsidiarySaleOfStockAxis__custom--TwoThousandTwentySixRightsOfferingMember_zaAkFfh8UrCg" title="Conversion price">1.00</span>, the conversion price. Each G Warrant is exercisable for one share of our common stock at an exercise price of $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260306__us-gaap--StatementClassOfStockAxis__custom--GWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--TwoThousandTwentySixRightsOfferingMember_zMOj9u28YBZ6" title="Exercise price">1.00</span> per share from March 6, 2026, the date of issuance, through its expiration five years from the date of issuance. The 2026 Rights Offering raised $<span id="xdx_90E_ecustom--ProceedsFromIssuanceOfUnits_pn5n6_c20260306__20260306__us-gaap--SubsidiarySaleOfStockAxis__custom--TwoThousandTwentySixRightsOfferingMember_zDzB7s4BOjqc" title="Proceeds from issuance of units">1.8</span> million in gross proceeds.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 7, 2026, the Company entered into a warrant exercise inducement offer letter agreement with holders of (i) Class A and Class B common stock purchase warrants issued on May 31, 2024 (the “Existing May 2024 Warrants”), exercisable for up to an aggregate of <span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20260507__us-gaap--ClassOfWarrantOrRightAxis__custom--ExistingMayTwoThousandTwentyFourWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--ClassAAndClassBCommonStockMember__us-gaap--TypeOfArrangementAxis__custom--WarrantExerciseInducementOfferLetterAgreementMember_zFdFab7YhQv4" title="Purchase of warrants">112,820</span> shares of the Company’s common stock, par value $<span id="xdx_904_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20260507__us-gaap--ClassOfWarrantOrRightAxis__custom--ExistingMayTwoThousandTwentyFourWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--ClassAAndClassBCommonStockMember__us-gaap--TypeOfArrangementAxis__custom--WarrantExerciseInducementOfferLetterAgreementMember_zl1Y8oR22vJ3" title="Common stock, par value">0.001</span> per share (the “Common Stock”), (ii) Class C and Class D Common Stock purchase warrants issued on September 30, 2024 (the “Existing September 2024 Warrants”) exercisable for up to an aggregate of <span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20260507__us-gaap--ClassOfWarrantOrRightAxis__custom--ExistingSeptemberTwoThousandTwentyFourWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--ClassCAndClassDCommonStockMember__us-gaap--TypeOfArrangementAxis__custom--WarrantExerciseInducementOfferLetterAgreementMember_zVyem1d6q5db" title="Purchase of warrants">93,060</span> shares of Common Stock, and (iii) Class E and Class F Common Stock purchase warrants issued on July 31, 2025 (the “Existing July 2025 Warrants” and together with the Existing May 2024 Warrants and the Existing September 2024 Warrants, the “Existing Warrants”) exercisable for up to an aggregate of <span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20260507__us-gaap--ClassOfWarrantOrRightAxis__custom--ExistingJulyTwoThousandTwentyFiveWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--ClassEAndClassFCommonStockMember__us-gaap--TypeOfArrangementAxis__custom--WarrantExerciseInducementOfferLetterAgreementMember_zdznL0IQ2975" title="Purchase of warrants">8,514,048</span> shares of Common Stock. The Existing May 2024 Warrants had an exercise price of $<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260507__us-gaap--ClassOfWarrantOrRightAxis__custom--ExistingMayTwoThousandTwentyFourWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--ClassAAndClassBCommonStockMember__us-gaap--TypeOfArrangementAxis__custom--WarrantExerciseInducementOfferLetterAgreementMember_zAQPyx0Ks4ue" title="Exercise price">36.30</span> per share, the Existing September 2024 Warrants had an exercise price of $<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260507__us-gaap--ClassOfWarrantOrRightAxis__custom--ExistingSeptemberTwoThousandTwentyFourWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--ClassCAndClassDCommonStockMember__us-gaap--TypeOfArrangementAxis__custom--WarrantExerciseInducementOfferLetterAgreementMember_z1mt1fouYSI" title="Exercise price">28.00</span>, and the Existing July 2025 Warrants had an exercise price of $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260507__us-gaap--ClassOfWarrantOrRightAxis__custom--ExistingJulyTwoThousandTwentyFiveWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--ClassEAndClassFCommonStockMember__us-gaap--TypeOfArrangementAxis__custom--WarrantExerciseInducementOfferLetterAgreementMember_zaF19l4wYet4" title="Exercise price">1.439</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to the Inducement Letter, the Holders agreed to exercise the Existing Warrants for cash at a reduced exercise price of $<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260507__us-gaap--TypeOfArrangementAxis__custom--WarrantExerciseInducementOfferLetterAgreementMember__srt--TitleOfIndividualAxis__custom--InvestorsMember_zlnJs5kLFPjl" title="Exercise price">0.48</span> per share in consideration of the Company’s agreement to issue the Holders new warrants to purchase up to a number of shares of Common Stock equal to <span id="xdx_90E_ecustom--PurchaseOfWarrantsPercentage_iI_pid_dp_c20260507__us-gaap--TypeOfArrangementAxis__custom--WarrantExerciseInducementOfferLetterAgreementMember__srt--TitleOfIndividualAxis__custom--InvestorsMember_z24HKuG0MGI5" title="Purchase of warrants percentage">200</span>% of the number of shares of Common Stock issued pursuant to such Holder’s exercise of Existing Warrants, comprised of new Class H warrants to purchase up to <span id="xdx_904_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20260507__us-gaap--TypeOfArrangementAxis__custom--WarrantExerciseInducementOfferLetterAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassHWarrantsMember__srt--TitleOfIndividualAxis__custom--InvestorsMember_zVQmBVEjVzcf" title="Purchase of warrants">17,439,856</span> shares of Common Stock (the “Inducement Warrants” and the shares of Common Stock underlying the Inducement Warrants, the “Inducement Warrant Shares”) with an exercise term of <span id="xdx_900_ecustom--WarrantExerciseTerm_dtY_c20260507__20260507__us-gaap--TypeOfArrangementAxis__custom--WarrantExerciseInducementOfferLetterAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassHWarrantsMember__srt--TitleOfIndividualAxis__custom--InvestorsMember_zbEJ1ttIQL9f" title="Warrant exercise term">5</span> years from the initial exercise date. The initial exercise date of the Inducement Warrants is the Stockholder Approval Date, and the exercise price thereof is $<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260507__us-gaap--TypeOfArrangementAxis__custom--WarrantExerciseInducementOfferLetterAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassHWarrantsMember__srt--TitleOfIndividualAxis__custom--InvestorsMember_z4XIzMyCGAPa" title="Exercise price">0.60</span> per share.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 8, 2026, the Company completed the Inducement Transaction and received aggregate gross proceeds of approximately $<span id="xdx_90D_eus-gaap--ProceedsFromIssuanceOfWarrants_pn5n6_c20260508__20260508__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--TypeOfArrangementAxis__custom--WarrantExerciseInducementOfferLetterAgreementMember_zee79yOR8BYd" title="Gross proceeds">3.6</span> million and issued the Inducement Warrants.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Ladenburg Thalmann &amp; Co. Inc. acted as placement agent in connection with the Inducement Transaction and received a cash fee of approximately $<span id="xdx_90D_eus-gaap--PaymentsForFees_pn3n3_c20260508__20260508__us-gaap--TypeOfArrangementAxis__custom--WarrantExerciseInducementOfferLetterAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember__dei--LegalEntityAxis__custom--LadenburgThalmannAndCoIncMember_ze2Ibce3RgDc" title="Cash fee">286</span> thousand, equal to <span id="xdx_903_ecustom--CashFeePercentage_iI_pid_dp_c20260508__us-gaap--TypeOfArrangementAxis__custom--WarrantExerciseInducementOfferLetterAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember__dei--LegalEntityAxis__custom--LadenburgThalmannAndCoIncMember_zvH8mKiWHgT6" title="Cash fee percentage">8.0</span>% of the aggregate gross proceeds, $<span id="xdx_90B_eus-gaap--OtherExpenses_pn3n3_c20260508__20260508__us-gaap--TypeOfArrangementAxis__custom--WarrantExerciseInducementOfferLetterAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember__dei--LegalEntityAxis__custom--LadenburgThalmannAndCoIncMember_zORR5pI9AxKi" title="Offering expenses">50</span> thousand for expenses incurred in connection with the offering, and approximately $<span id="xdx_908_eus-gaap--PaymentForManagementFee_pn3n3_c20260508__20260508__us-gaap--TypeOfArrangementAxis__custom--WarrantExerciseInducementOfferLetterAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember__dei--LegalEntityAxis__custom--LadenburgThalmannAndCoIncMember_zNPw6vQoiENa" title="Management fee">27</span> thousand, representing a management fee equal to <span id="xdx_907_ecustom--GrossProceedsOfWarrantsPercentage_iI_pid_dp_c20260508__us-gaap--TypeOfArrangementAxis__custom--WarrantExerciseInducementOfferLetterAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember__dei--LegalEntityAxis__custom--LadenburgThalmannAndCoIncMember_zwA74QzNqZH4" title="Gross proceeds of warrants percentage">0.75</span>% of the aggregate gross proceeds. The Company also issued to the Placement Agent warrants to purchase up to <span id="xdx_90D_ecustom--PurchaseOfWarrantsPercentage_iI_pid_dp_c20260508__us-gaap--TypeOfArrangementAxis__custom--WarrantExerciseInducementOfferLetterAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember__dei--LegalEntityAxis__custom--LadenburgThalmannAndCoIncMember_zabfOLwFD493" title="Purchase of warrants percentage">6.0</span>% of the aggregate number of shares of Common Stock issued upon exercise of the Existing Warrants pursuant to the Inducement Letter. The Placement Agent Warrants have substantially the same terms as the Inducement Warrants, except that the Placement Agent Warrants will be exercisable until the five-year anniversary of the date of issuance, will have an exercise price equal to <span id="xdx_901_ecustom--ExercisePricePercentage_iI_pid_dp_c20260508__us-gaap--TypeOfArrangementAxis__custom--WarrantExerciseInducementOfferLetterAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember__dei--LegalEntityAxis__custom--LadenburgThalmannAndCoIncMember_zywHA9qu3BMc" title="Exercise price percentage">125</span>% of the Reduced Exercise Price, and will include piggyback registration rights that are triggered if there is not an effective registration statement covering all of the Placement Agent Warrant Shares while the Placement Agent Warrants are outstanding.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 21, 2026, the Company issued and sold <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20260521__20260521__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--InvestorsMember_zUAJc6aQ1w5b" title="Shares issued">7,519,351</span> shares of common stock, par value $<span id="xdx_90B_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20260521__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__srt--TitleOfIndividualAxis__custom--InvestorsMember_zSYEZMDdZpIg" title="Common stock, par value">0.001</span> per share, and, in a concurrent private placement, Class I warrants to purchase up to <span id="xdx_904_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20260521__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassIWarrantsMember__srt--TitleOfIndividualAxis__custom--InvestorsMember_z8vSIi1vscxg" title="Purchase of warrants">15,038,702</span> shares of common stock to certain investors for aggregate gross proceeds of approximately $<span id="xdx_90E_eus-gaap--ProceedsFromIssuanceOfWarrants_pn5n6_c20260521__20260521__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassIWarrantsMember__srt--TitleOfIndividualAxis__custom--InvestorsMember_zz6nNUpvvhD1" title="Gross proceeds">2.4</span> million.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 10, 2026, the Company issued and sold <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20260610__20260610__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--InvestorsMember_zaoLd5r6DZpk" title="Shares issued">2,554,119</span> shares of common stock and, in a concurrent private placement, <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20260610__20260610__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__srt--TitleOfIndividualAxis__custom--InvestorsMember_zutglsE1Kdf9" title="Shares issued">771,503</span> shares of common stock, pre-funded warrants to purchase up to <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20260610__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember__srt--TitleOfIndividualAxis__custom--InvestorsMember_zSxvnD7pPuB1" title="Purchase of warrants">1,782,616</span> shares of common stock, and Class J warrants to purchase up to <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20260610__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassJWarrantsMember__srt--TitleOfIndividualAxis__custom--InvestorsMember_zYAfEkxYSL95" title="Purchase of warrants">10,216,476</span> shares of common stock to certain investors for aggregate gross proceeds of approximately $<span id="xdx_905_eus-gaap--ProceedsFromIssuanceOfWarrants_pn5n6_c20260610__20260610__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassJWarrantsMember__srt--TitleOfIndividualAxis__custom--InvestorsMember_zyJVbWmbpOEa" title="Gross proceeds">2.6</span> million.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock warrants are issued as needed by the Board of Directors and have no formal plan.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The fair value of each warrant award is estimated on the date of grant using a Black-Scholes-Merton pricing option valuation model. Expected volatility is based on the historical volatility of the price of the Company’s stock. The risk-free interest rate is based on U.S. Treasury issues with a term equal to the expected life of the warrant. The Company uses historical data to estimate expected dividend yield, life and forfeiture rates. The expected life of the warrants was estimated based on historical option holder’s behavior and represents the period of time that options are expected to be outstanding.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For further information, please refer to Note 14.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> 56410 56410 36.30 56410 36.30 46530 46530 28.00 28.00 2000000 2000000 2000000 4.00 3.999 4.00 8000000 the Company declared a stock dividend of one share of common stock for every 1,000 shares of outstanding common stock as well as one share of common stock for every outstanding option or warrant that has a right to receive stock dividends (“Alternate Securities”). On January 13, 2026, the Company distributed a dividend of one share of its common stock for every 1,000 shares of common stock issued and outstanding as of January 9, 2026, as well as one share of common stock for every outstanding option or warrant that has a right to receive stock dividends (the “Dividend”). 5561125 1.439 -468000 8700000 1842 1 2000 1000 1.00 1.00 1800000 112820 0.001 93060 8514048 36.30 28.00 1.439 0.48 2 17439856 P5Y 0.60 3600000 286000 0.080 50000 27000 0.0075 0.060 1.25 7519351 0.001 15038702 2400000 2554119 771503 1782616 10216476 2600000 <p id="xdx_801_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_znNsFsHY9vue" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 14: <span id="xdx_821_zvEhfq6TMiS4">Stockholders’ Equity</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) Preferred Stock</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is authorized to issue <span id="xdx_90B_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20260630_z1lFs9fGn0Ka" title="Preferred stock, shares authorized">5,000,000</span> shares of $<span id="xdx_90E_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20260630_zTOezSA3XLCf" title="Preferred stock stated value">0.01</span> par value preferred stock with such designations, rights and preferences as may be determined by the Board. Of our authorized preferred stock, <span id="xdx_90A_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20260630__us-gaap--StatementClassOfStockAxis__custom--SeriesAJuniorParticipatingPreferredStockMember_zA44w7HG3tgd" title="Preferred stock, shares authorized">4,000,000</span> shares have been designated as Series A Junior Participating Preferred Stock and <span id="xdx_901_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20260630__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zr1hV80d1rSc" title="Preferred stock, shares authorized">10,000</span> shares have been designated as Series B Convertible Preferred Stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Series A Junior Participating Preferred Stock</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 10, 2023, the Company filed a Certificate of Increase in Delaware, increasing the number of preferred stock designated as Series A Junior Participating Preferred Stock to <span id="xdx_902_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20230510__us-gaap--StatementClassOfStockAxis__custom--SeriesAJuniorParticipatingPreferredStockMember_ztuPNp3d3ug6" title="Preferred stock, shares authorized">4,000,000</span> from <span id="xdx_907_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20230509__us-gaap--StatementClassOfStockAxis__custom--SeriesAJuniorParticipatingPreferredStockMember_zPU23JF1C8p8" title="Preferred stock, shares authorized">250,000</span> shares. At June 30, 2026, there were no Series A Junior Participating Preferred Stock outstanding.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Series B Convertible Preferred Stock</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has designated <span id="xdx_90B_eus-gaap--PreferredStockSharesAuthorized_iI_c20260630__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zElWZFtxkmrl" title="Preferred stock authorized">10,000</span> shares of its preferred stock as Series B Convertible Preferred Stock (the “Preferred Stock”). Each share of Preferred Stock has a par value of $<span id="xdx_909_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20260630__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zAyvZoxL5wR8" title="Preferred stock, par value">0.01</span> per share and a stated value equal to $<span id="xdx_90F_ecustom--PreferredStockStatedValuePerShare_iI_pn3n3_c20260630__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zcKxLeRTc9e9" title="Preferred stock, stated value">1</span> thousand (the “Stated Value”). The shares of Preferred Stock shall initially be issued and maintained in the form of securities held in book-entry form and the Depository Trust Company or its nominee (“DTC”) shall initially be the sole registered holder of the shares of Preferred Stock. At June 30, 2026, there were no Series B Convertible Preferred Stock outstanding.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Series G Convertible Preferred Stock</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 4, 2026, the Company filed a Certificate of Designation of Preference, Rights and Limitations of Series G Convertible Preferred Stock (the “Certificate of Designation”) with the Delaware Secretary of State creating a new series of its authorized preferred stock, par value $<span id="xdx_90B_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20260304__us-gaap--StatementClassOfStockAxis__custom--SeriesGConvertiblePreferredStockMember_za5GXGTBxDV2" title="Preferred stock, par value">0.01</span> per share, designated as the “Series G Convertible Preferred Stock” (the “Series G Preferred Stock”). The number of shares initially constituting the Series G Preferred Stock was set at <span id="xdx_902_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20260304__us-gaap--StatementClassOfStockAxis__custom--SeriesGConvertiblePreferredStockMember_zRL0xkZtYGc" title="Preferred stock, shares authorized">12,000</span> shares.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each share of Series G Preferred Stock will be convertible, at the option of the holder at any time, into the number of shares of the Company’s common stock, par value $<span id="xdx_90B_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20260304__us-gaap--StatementClassOfStockAxis__custom--SeriesGConvertiblePreferredStockMember_zWEKj2aPhbI9" title="Common stock, par value">0.001</span> per share (the “Common Stock”) determined by dividing the $<span id="xdx_90D_ecustom--CommonStockStatedValuePerShare_iI_pn3n3_c20260304__us-gaap--StatementClassOfStockAxis__custom--SeriesGConvertiblePreferredStockMember_zPf2zbi9QZc9" title="Common stock, stated value">1</span> thousand stated value per share of the Series G Preferred Stock by a conversion price initially equal to $<span id="xdx_905_eus-gaap--PreferredStockConvertibleConversionPrice_iI_pid_c20260304__us-gaap--StatementClassOfStockAxis__custom--SeriesGConvertiblePreferredStockMember__us-gaap--SubsidiarySaleOfStockAxis__custom--TwoThousandTwentySixRightsOfferingMember_zkKDh86ir201" title="Conversion price">1.00</span>. In addition, the conversion price per share is subject to adjustment for stock dividends, distributions, subdivisions, combinations or reclassifications. Subject to limited exceptions, a holder of the Series G Preferred Stock will not have the right to convert any portion of the Series G Preferred Stock to the extent that, after giving effect to the conversion, the holder, together with its affiliates, would beneficially own in excess of <span id="xdx_908_ecustom--SharePriceTriggerPercentage_iI_pid_dp_c20260304__us-gaap--StatementClassOfStockAxis__custom--SeriesGConvertiblePreferredStockMember__us-gaap--SubsidiarySaleOfStockAxis__custom--TwoThousandTwentySixRightsOfferingMember_zLAypPm4APU3" title="Standard blocker">4.99</span>% of the number of shares of Common Stock outstanding immediately after giving effect to its conversion. A holder of the Series G Preferred Stock, upon notice to the Company, may increase or decrease the beneficial ownership limitation provisions of such holder’s Series G Preferred Stock, provided that in no event shall the limitation exceed <span id="xdx_90C_ecustom--MaximumThresholdPercentage_iI_pid_dp_c20260304__us-gaap--StatementClassOfStockAxis__custom--SeriesGConvertiblePreferredStockMember__us-gaap--SubsidiarySaleOfStockAxis__custom--TwoThousandTwentySixRightsOfferingMember_zXMTQ9hzUr27" title="Maximum Blocker">9.99</span>% of the number of shares of Common Stock outstanding immediately after giving effect to its conversion.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the event the Company effects certain mergers, consolidations, sales of substantially all of its assets, tender or exchange offers, reclassifications or share exchanges in which the Common Stock is effectively converted into or exchanged for other securities, cash or property, the Company consummates a business combination in which another person acquires 50% of the outstanding shares of Common Stock, then, upon any subsequent conversion of the Series G Preferred Stock, the holders of the Series G Preferred Stock will have the right to receive any shares of the acquiring corporation or other consideration it would have been entitled to receive if it had been a holder of the number of shares of Common Stock then issuable upon conversion in full of the Series G Preferred Stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holders of Series G Preferred Stock shall be entitled to receive dividends (on an as-if-converted-to-common stock basis) in the same form as dividends actually paid on shares of the common stock when, as and if such dividends are paid on shares of Common Stock. Except as otherwise provided in the Certificate of Designation or as otherwise required by law, the Series G Preferred Stock has no voting rights. Upon the Company’s liquidation, dissolution or winding-up, whether voluntary or involuntary, holders of Series G Preferred Stock will be entitled to receive out of the assets, whether capital or surplus, of the Company the same amount that a holder of Common Stock would receive if the Series G Preferred Stock were fully converted (disregarding for such purpose any conversion limitations under the Certificate of Designation) to Common Stock, which amounts shall be paid pari passu with all holders of Common Stock. The Company is not obligated to redeem or repurchase any shares of Series G Preferred Stock. Shares of Series G Preferred Stock are not otherwise entitled to any redemption rights, or mandatory sinking fund or analogous provisions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 6, 2026, the Company completed its previously announced rights offering (the “Rights Offering”) pursuant to its effective registration statement on Form S-1, as amended (Registration No. 333-292085), previously filed with and declared effective by the Securities and Exchange Commission (the “SEC”), a prospectus and a prospectus supplement filed with the SEC. Pursuant to the Rights Offering, the Company sold an aggregate of <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20260306__20260306__us-gaap--SubsidiarySaleOfStockAxis__custom--TwoThousandTwentySixRightsOfferingMember_zpfwrOdAPYcf" title="Number of units issued">1,842</span> units consisting of an aggregate of <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20260306__20260306__us-gaap--SubsidiarySaleOfStockAxis__custom--TwoThousandTwentySixRightsOfferingMember_zNbo0hMdXjTk" title="Number of units issued">1,842</span> shares of Series G Preferred Stock, with each share of Series G Preferred Stock initially convertible into shares of Common Stock at a conversion price of $<span id="xdx_907_eus-gaap--PreferredStockConvertibleConversionPrice_iI_pid_c20260306__us-gaap--SubsidiarySaleOfStockAxis__custom--TwoThousandTwentySixRightsOfferingMember__us-gaap--StatementClassOfStockAxis__custom--SeriesGConvertiblePreferredStockMember_zGxN54nUVfha" title="Conversion price">1.00</span> per share, <span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20260306__us-gaap--SubsidiarySaleOfStockAxis__custom--TwoThousandTwentySixRightsOfferingMember__us-gaap--StatementClassOfStockAxis__custom--SeriesGConvertiblePreferredStockMember_zhboyfvxJsnl" title="Warrants exercisable">3,684,000</span> Class G Warrants, with each warrant exercisable for <span id="xdx_90A_eus-gaap--SharesIssued_iI_dc_c20260306__us-gaap--StatementClassOfStockAxis__custom--GWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--TwoThousandTwentySixRightsOfferingMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zGHUAPE6T0i1" title="Shares issued">one</span> share of Common Stock at an exercise price of $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260306__us-gaap--StatementClassOfStockAxis__custom--GWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--TwoThousandTwentySixRightsOfferingMember_zZVymAKkw9Eb" title="Exercise price">1.00</span> per share and expiring <span id="xdx_90B_ecustom--ClassOfWarrantOrRightTerm_pid_dc_c20260306__20260306__us-gaap--StatementClassOfStockAxis__custom--GWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--TwoThousandTwentySixRightsOfferingMember_zRWpmPeZbbI2" title="Expiration date of issuance">five years</span> from the date of issuance, resulting in gross proceeds to the Company of $<span id="xdx_90E_ecustom--ProceedsFromIssuanceOfUnits_pn5n6_c20260306__20260306__us-gaap--SubsidiarySaleOfStockAxis__custom--TwoThousandTwentySixRightsOfferingMember_zfp85NzzvwD4" title="Proceeds from issuance of units">1.8</span> million.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At June 30, 2026 and December 31, 2025, the Company had <span id="xdx_900_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20260630__us-gaap--StatementClassOfStockAxis__custom--SeriesGConvertiblePreferredStockMember_ztTQNweLOGgc" title="Preferred stock shares outstanding">529</span> and <span id="xdx_902_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesGConvertiblePreferredStockMember_zoFBb3iz2Alf" title="Preferred stock shares outstanding">0</span> shares of Series G Convertible Preferred Stock outstanding, respectively. Subsequently, on July 1, 2026, <span id="xdx_908_eus-gaap--PreferredStockConvertibleSharesIssuable_iI_pid_c20260701__us-gaap--StatementClassOfStockAxis__custom--SeriesGConvertiblePreferredStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zsuMcbXvwrH3" title="Convertible, shares issuable">8</span> shares of the Company’s Series G Preferred stock were converted to <span id="xdx_90E_eus-gaap--ConversionOfStockSharesConverted1_pid_c20260701__20260807__us-gaap--StatementClassOfStockAxis__custom--SeriesGConvertiblePreferredStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zhyDD2Qadiek" title="Conversion of shares">8,000</span> shares of the Company’s common stock. As a result of this conversion, the Company’s outstanding shares of common stock increased by <span id="xdx_90E_eus-gaap--ConversionOfStockSharesConverted1_pid_c20260701__20260807__us-gaap--StatementClassOfStockAxis__custom--SeriesGConvertiblePreferredStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zSE0g8zrWGa" title="Conversion of shares">8,000</span> shares and <span id="xdx_90F_eus-gaap--PreferredStockSharesIssued_iI_pid_c20260807__us-gaap--StatementClassOfStockAxis__custom--SeriesGConvertiblePreferredStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z8EMUjlo7sq1" title="Preferred stock shares issued"><span id="xdx_902_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20260807__us-gaap--StatementClassOfStockAxis__custom--SeriesGConvertiblePreferredStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zPo6br3GbKx7" title="Preferred stock shares outstanding">521</span></span> Series G Preferred stock remains issued and outstanding. The conversions did not result in any cash proceeds to the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) Common Stock and Equity Finances</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has authorized shares of <span id="xdx_908_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20260630_zBDnX7yk5Dul" title="Common stock, shares authorized">350,000,000</span> with specific limitations and restrictions on the usage of <span id="xdx_90E_ecustom--CommonStockSharesWithLimitationsAndRestrictionsOnUsage_iI_pid_c20260630_zOwN0bXGf992" title="Common stock specific limitations and restrictions on usage">8,000,000</span> of the <span id="xdx_904_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20260630_zykVkI2kZrr1" title="Common stock, shares authorized">350,000,000</span> authorized shares. As of June 30, 2026, and December 31, 2025, there were <span id="xdx_906_eus-gaap--CommonStockSharesIssued_iI_pid_c20260630_zTdCA5xM1Oj2" title="Common stock, shares issued"><span id="xdx_900_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20260630_zGmBLokyeCL7" title="Common stock, shares outstanding">28,990,073</span></span> and <span id="xdx_908_eus-gaap--CommonStockSharesIssued_iI_pid_c20251231_zW0I9cZ2rMB4" title="Common stock, shares issued"><span id="xdx_909_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20251231_zWpgYbzGPcC7" title="Common stock, shares outstanding">3,069,875</span></span> shares of common stock issued and outstanding, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Employee Stock Purchase Plan (Not equity compensation)</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 7, 2020, the Board approved a plan pursuant to which all directors, officers, and employees could purchase from the Company up to an aggregate of $<span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_pn3n3_c20200707__20200707__us-gaap--PlanNameAxis__custom--EmployeeStockPurchasePlanMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorsOfficersAndEmployeesMember_zT702AqVC2s4" title="Common stock shares issued, value">500</span> thousand worth of shares at the market price (including subsequent plans, the “Employee Stock Purchase Plan”). Pursuant to NYSE American’s rules, this plan was effective for a sixty-day period commencing upon the date that the NYSE American approved the Company’s Supplemental Listing Application (“SLAP”). The Company created successive new plans following the expiration of the July 7, 2020 plan. Recently, the procedure for purchases under the plan changed. Under the amended rules officers and employees must file a SLAP and the NYSE American must accept the SLAP prior to the purchase of Company stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Equity Distribution Agreement</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 19, 2023, the Company entered into an Equity Distribution Agreement (the “EDA”), with Maxim, pursuant to which it may sell from time to time, shares of its common stock having an aggregate offering price of up to $<span id="xdx_906_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20230419__20230419__dei--LegalEntityAxis__custom--MaximGroupLLCMember__us-gaap--TypeOfArrangementAxis__custom--EquityDistributionAgreementMember_zuLNm7jPQyyh">8.5</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million through Maxim, as agent. The amount was subsequently reduced from $<span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20230419__20230419__dei--LegalEntityAxis__custom--MaximGroupLLCMember__us-gaap--TypeOfArrangementAxis__custom--EquityDistributionAgreementMember__srt--RangeAxis__srt--MaximumMember_z7ipNVipJbAe">8.5</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million to $<span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20230419__20230419__dei--LegalEntityAxis__custom--MaximGroupLLCMember__us-gaap--TypeOfArrangementAxis__custom--EquityDistributionAgreementMember__srt--RangeAxis__srt--MinimumMember_zcU1a3sjixr1">3.1</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million. Sales under the EDA were registered under the S-3 Shelf Registration Statement. Under the terms of the EDA, Maxim is entitled to a transaction fee at a fixed rate of <span id="xdx_908_eus-gaap--SaleOfStockPercentageOfOwnershipAfterTransaction_pid_dp_uPure_c20230419__20230419__dei--LegalEntityAxis__custom--MaximGroupLLCMember__us-gaap--TypeOfArrangementAxis__custom--EquityDistributionAgreementMember_zZGzb0j7mbeg">3.0</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">% of the gross sales price of shares sold under the EDA.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 1, 2025, the Company entered into a new EDA, with Maxim (the “Sales Agreement”) pursuant to which it may issue and sell up to an aggregate of $<span id="xdx_907_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20250401__20250401__dei--LegalEntityAxis__custom--MaximGroupLLCMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_zBmAov0cxDqi">3</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million of the Company’s common stock from time to time through Maxim acting as agent. Under the terms of the Sales Agreement in no event will the Company, inter alia, issue or sell through the sales agreement such number or dollar amount of shares of common stock that would exceed the number or dollar amount of shares of common stock permitted to be sold under Form S-3 (including General Instruction I.B.6 thereof, if applicable). For the year ended December 31, 2025, the Company sold <span id="xdx_90E_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20250101__20251231__dei--LegalEntityAxis__custom--MaximGroupLLCMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_zP9PyW25t4Td">155,874</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares under the new EDA for total gross proceeds of $<span id="xdx_905_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn3n3_c20250101__20251231__dei--LegalEntityAxis__custom--MaximGroupLLCMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_zde5ma0Ku3z7">225</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">thousand, which includes a <span id="xdx_905_eus-gaap--SaleOfStockPercentageOfOwnershipAfterTransaction_pid_dp_uPure_c20250101__20251231__dei--LegalEntityAxis__custom--MaximGroupLLCMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_z5wkpXZVRaR7">3.0</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">% fee to Maxim of $<span id="xdx_90E_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pn3n3_c20250101__20251231__dei--LegalEntityAxis__custom--MaximGroupLLCMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_zS1YQx5v72J8">7</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">thousand.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 10, 2026, the Company entered into Amendment No. 1 to that certain Equity Distribution Agreement dated April 1, 2025 with Maxim Group LLC to act as the Company’s exclusive sales agent with respect to the issuance and sale of up to $<span id="xdx_906_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20260410__20260410__dei--LegalEntityAxis__custom--MaximGroupLLCMember__us-gaap--TypeOfArrangementAxis__custom--EquityDistributionAgreementMember_zwDuEKbBYNpj">3,000,000</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of the Company’s shares of common stock, par value $<span id="xdx_907_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20260410__dei--LegalEntityAxis__custom--MaximGroupLLCMember__us-gaap--TypeOfArrangementAxis__custom--EquityDistributionAgreementMember_zmjUQzRxKwed">0.001</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share, from time to time, in an at-the-market public offering. The Amendment removes the limitation of the amount of Shares to be sold under the Sales Agreement.</span> For the three months ended June 30, 2026, the Company sold <span id="xdx_90C_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20260401__20260630__dei--LegalEntityAxis__custom--MaximGroupLLCMember__us-gaap--TypeOfArrangementAxis__custom--EquityDistributionAgreementMember_zdxfPtiQx3fl">1,019,570</span> shares under the EDA for total gross proceeds of approximately $558 thousand, which includes a 3.0% fee to Maxim of approximately $17 thousand related to this agreement. For the six months ended June 30, 2026, the Company sold <span id="xdx_908_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20260101__20260630__dei--LegalEntityAxis__custom--MaximGroupLLCMember__us-gaap--TypeOfArrangementAxis__custom--EquityDistributionAgreementMember_zmXMpfA3TK0e">3,044,862</span> shares under the EDA for total gross proceeds of approximately $<span id="xdx_907_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20260101__20260630__dei--LegalEntityAxis__custom--MaximGroupLLCMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_zLHwbNh0NFA9" title="Gross proceeds">2.6</span> million, which includes a <span id="xdx_903_eus-gaap--SaleOfStockPercentageOfOwnershipAfterTransaction_pid_dp_uPure_c20260101__20260630__dei--LegalEntityAxis__custom--MaximGroupLLCMember__us-gaap--TypeOfArrangementAxis__custom--EquityDistributionAgreementMember_zkhkZ5rsTUt4">3.0</span>% fee to Maxim of approximately $<span id="xdx_902_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pn3n3_c20260101__20260630__dei--LegalEntityAxis__custom--MaximGroupLLCMember__us-gaap--TypeOfArrangementAxis__custom--EquityDistributionAgreementMember_znZ2pUwpU4wk">78</span> thousand related to this agreement.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsequently, on July 31, 2026, the Company provided notice to the Sales Agent for the mutual termination of the Agreement, effective August 15, 2026. The Company will not incur any termination penalties as a result of the termination of the Agreement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; background-color: white; color: #212529"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following such termination, the Company may not offer or sell any additional shares of its common stock under the Agreement or the related prospectus and prospectus supplement. From April 1, 2025 to July 31, 2026, the Company sold <span id="xdx_90C_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20250401__20260731__dei--LegalEntityAxis__custom--MaximGroupLLCMember__us-gaap--TypeOfArrangementAxis__custom--EquityDistributionAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zAFMN2EbBZza">3,200,736</span> shares of common stock for aggregate gross proceeds of approximately $<span id="xdx_90A_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20250401__20260731__dei--LegalEntityAxis__custom--MaximGroupLLCMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zvLhwH965AH1" title="Gross proceeds">2.8</span> million pursuant to the Agreement. The Company does not intend to issue or sell any additional shares of common stock under the Agreement prior to its termination.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Equity Purchase Agreement</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 28, 2024, the Company entered into a purchase agreement and a registration rights agreement with Atlas Sciences, LLC (“Atlas”), pursuant to which Atlas committed to purchase up to $<span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn6n6_c20240328__20240328__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--AtlasSciencesLlcMember__us-gaap--TypeOfArrangementAxis__custom--EquityPurchaseAgreementMember_z15OPC6GNS6" title="Issuance of common stock">15</span> million of common stock of the Company for a period of 24 months from the date of the purchase agreement. No assurance can be given as to the actual amount that will be raised pursuant to the purchase agreement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under the terms of the purchase agreement, the Company, at its sole discretion, shall have the right to issue Put shares to the Investor at <span id="xdx_907_ecustom--MarketPricePercentage_iI_pid_dp_uPure_c20240328__dei--LegalEntityAxis__custom--AtlasSciencesLlcMember__us-gaap--TypeOfArrangementAxis__custom--EquityPurchaseAgreementMember_zlpeJaYv9Utg" title="Market price, percentage">95</span>% of the Market Price of the shares on the day of trade. Sales under the purchase agreement are limited to a daily maximum of the lessor of: $<span id="xdx_906_ecustom--TradingDailyMaximumLessorAmount_pn3n3_c20240328__20240328__dei--LegalEntityAxis__custom--AtlasSciencesLlcMember__us-gaap--TypeOfArrangementAxis__custom--EquityPurchaseAgreementMember_zzB9DaeMu8T5" title="Trading maximum lessor amount">500</span> thousand, the Median Daily Trading volume, and a beneficial ownership limitation of <span id="xdx_904_ecustom--BeneficialOwnershipPercentage_iI_dp_uPure_c20240328__dei--LegalEntityAxis__custom--AtlasSciencesLlcMember__us-gaap--TypeOfArrangementAxis__custom--EquityPurchaseAgreementMember__srt--RangeAxis__srt--MinimumMember_z7CSm2ruIWZa" title="Beneficial ownership percentage">4.99</span>% and a maximum of <span id="xdx_90D_ecustom--BeneficialOwnershipPercentage_iI_dp_uPure_c20240328__dei--LegalEntityAxis__custom--AtlasSciencesLlcMember__us-gaap--TypeOfArrangementAxis__custom--EquityPurchaseAgreementMember__srt--RangeAxis__srt--MaximumMember_zeshY2pLEgn1" title="Beneficial ownership percentage">19.99</span>% of the outstanding shares at the time of the purchase agreement. In April 2024, the Company filed a registration statement with the SEC on Form S-1 registering a total of <span id="xdx_908_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20240401__20240430__us-gaap--TypeOfArrangementAxis__custom--EquityPurchaseAgreementMember_zhX7b3J0C989" title="Number of stock sold">99,750</span> shares for resale pursuant to the Atlas Agreements, consisting of <span id="xdx_903_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20240401__20240430__dei--LegalEntityAxis__custom--AtlasSciencesLlcMember__us-gaap--TypeOfArrangementAxis__custom--EquityPurchaseAgreementMember_zGDxeDM3T1s4" title="Stock sold by the company">96,364</span> shares that can be sold by the Company to Atlas and <span id="xdx_901_ecustom--StockIssuedDuringPeriodValueCommitmentShares_pid_c20240401__20240430__dei--LegalEntityAxis__custom--AtlasSciencesLlcMember__us-gaap--TypeOfArrangementAxis__custom--EquityPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--CommitmentSharesMember_zO1eHvRJjNpk" title="Commitment shares issued">3,386</span> shares that were issued to Atlas as Commitment Shares. The registration statement was declared effective on May 1, 2024. At December 31, 2024, a total of <span id="xdx_905_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--EquityPurchaseAgreementMember_zkBpw58H5iUi" title="Number of stock sold">7,596</span> shares were issued pursuant to the purchase agreement for a total of $<span id="xdx_906_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pn3n3_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--EquityPurchaseAgreementMember_zgPE3SkboFol" title="Amount of stock sold">128</span> thousand after clearing costs. At December 31, 2025, a total of <span id="xdx_909_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20250101__20251231__us-gaap--TypeOfArrangementAxis__custom--EquityPurchaseAgreementMember_zTBTJQ49Ctu4" title="Number of shares sold">30,829</span> shares were issued pursuant to the purchase agreement for a total of $<span id="xdx_900_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pn3n3_c20250101__20251231__us-gaap--TypeOfArrangementAxis__custom--EquityPurchaseAgreementMember_z5aFRKtcRuib" title="Value of shares sold">398</span> thousand after clearing costs. There were no shares issued subsequent to December 31, 2025. As of February 2026, the purchase agreement is no longer active.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">May 2024 Securities Purchase Agreement</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 31, 2024, the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) to complete an offering (the “Transactions”) with a single accredited investor (the “Purchaser”), pursuant to which, on June 3, 2024, the Company issued to the Purchaser, (i) in a registered direct offering, <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240603__20240603__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zl9pcnqBueti" title="Number of shares issued upon transaction">56,410</span> shares of the Company’s common stock (the “Shares”) and (ii) in a concurrent private placement, the Company issued to the Purchaser Class A common warrants to purchase an aggregate of up to <span id="xdx_904_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240603__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--ClassAWarrantMember_zyQiDOblqw72" title="Number of shares issued upon transaction">56,410</span> shares of its common stock (the “A Warrants”) at an exercise price of $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240603__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--ClassAWarrantMember_z3Ph2sMzWHF6" title="Exercise price">36.30</span> per share and Class B common warrants to purchase an aggregate of up to <span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240603__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--ClassBWarrantMember_zxhppEiRV781" title="Warrants to purchase shares of common stock">56,410</span> shares of its common stock (the “B Warrants” and, along with the A Warrants, the “Common Warrants”) at an exercise price of $<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240603__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--ClassBWarrantMember_zguhZVtbYwxc" title="Warrants exercise price">36.30</span> per share. The A Warrants and B Warrants are not exercisable for six months after the issuance date and expire, respectively, <span id="xdx_908_ecustom--WarrantsAndRightsOutstandingTermDescription_c20240603__20240603__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--ClassBWarrantMember_ztgnOSeAPzlf" title="Warrants term description">five years</span> and six months and twenty-four months after the issuance date. The Common Warrants and the shares of common stock are issuable upon the exercise of such warrants are offered pursuant to an exemption from the registration requirements of the Securities Act provided in Section 4(a)(2) of the Securities Act and Rule 506(b) promulgated thereunder.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Shares were offered by the Company pursuant to a shelf registration statement on Form S-3 (File No. 333-262280), which was declared effective on February 4, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to the terms of the Purchase Agreement, subject to certain exceptions, the Company could not issue any equity securities for 60 days following the issuance date, provided that the Company was able to utilize its at-the-market offering program with Maxim Group LLC (the “Placement Agent”) after 30 days. Additionally, the Company cannot enter into a variable rate transaction (other than the ATM program with the Placement Agent) for 120 days after the issuance date. In addition, the Company’s executive officers and each of the Company’s directors have entered into lock-up agreements with the Company pursuant to which each of them has agreed not to, for a period of 90 days from the closing of the Transactions, offer, sell, transfer or otherwise dispose of the Company’s securities, subject to certain exceptions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The exercise price of the Common Warrants, and the number of Common Warrant Shares, are subject to adjustment in the event of any stock dividend or split, reverse stock split, recapitalization, reorganization or similar transaction, as described in the Common Warrants. If a Fundamental Transaction (as defined in the Common Warrants) occurs, then the successor entity will succeed to, and be substituted for the Company, and may exercise every right and power that the Company may exercise and will assume all of its obligations under the Common Warrants with the same effect as if such successor entity had been named in the warrant itself. Common Warrant Holders will have additional rights defined in the Common Warrants. The Common Warrants are exercisable on a “cashless” basis only if there is not a current registration statement permitting public resale. In this regard, the Company filed a registration statement to register the resale of the Common Warrant Shares providing for the resale of the Shares issued and issuable upon exercise of the Common Warrants. That registration statement was declared effective by the SEC on July 11, 2024. The Company has agreed to use commercially reasonable efforts to cause such registration statement to keep such registration statement effective at all times until no Purchaser owns any Warrants or Warrant Shares issuable upon exercise thereof.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Maxim Group LLC acted as the placement agent on a “commercially reasonable best efforts” basis, in connection with the Transactions pursuant to the Placement Agency Agreement, dated May 31, 2024 (the “Placement Agency Agreement”), by and between the Company and the Placement Agent. Pursuant to the Placement Agency Agreement, the Placement Agent was paid a cash fee of <span id="xdx_900_eus-gaap--SaleOfStockPercentageOfOwnershipAfterTransaction_pid_dp_uPure_c20240501__20240531__us-gaap--SubsidiarySaleOfStockAxis__custom--PlacementAgentMember_zk9SjJ2J4wVd" title="Aggregate gross proceeds, percentage">8</span>% of the aggregate gross proceeds paid to the Company for the securities sold in the Transactions and reimbursement of certain out-of-pocket expenses.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company evaluated the Common Warrants under the guidance of ASC 480 – Distinguishing Liabilities from Equity and determined that they were in scope under the guidance as freestanding financial instruments but did not meet the criteria for liability classification and are classified as equity within the consolidated financial statements. Proceeds allocated to such warrants totaled $<span id="xdx_900_eus-gaap--WarrantsAndRightsOutstanding_iI_pn5n6_c20260630_zqUhIrLLAM87" title="Proceeds from warrants">2.5</span> million. For the three and six months ended June 30, 2026, <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20260401__20260630__us-gaap--StatementEquityComponentsAxis__custom--ClassAWarrantsMember_zfJYL2Z8bxV1" title="Warrant exercised"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__custom--ClassAWarrantsMember_zIIkL7TGG2Ej" title="Warrant exercised">56,410</span></span> Class A Warrants and <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20260401__20260630__us-gaap--StatementEquityComponentsAxis__custom--ClassBWarrantsMember_zjvWvLM6VYfa" title="Warrant exercised"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__custom--ClassBWarrantsMember_z1jPaZYbOtA4" title="Warrant exercised">56,410</span></span> Class B Warrants were exercised at $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260630__us-gaap--StatementEquityComponentsAxis__custom--ClassAWarrantsMember_zlC6uad12Q41" title="Warrants exercise price"><span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260630__us-gaap--StatementEquityComponentsAxis__custom--ClassBWarrantsMember_zPxzKgMjmRP" title="Warrants exercise price">0.48</span></span> per share (See May 2026 Class H Inducement Transaction). There were no Class A or Class B Warrants outstanding at June 30, 2026, related to this agreement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">September 2024 Securities Purchase Agreement</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On September 30, 2024, the Company entered into a Purchase Agreement with the Purchaser in the May 2024 Securities Purchase Agreement as Purchaser, pursuant to which the Company issued to the Purchaser, (i) in a registered direct offering, <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240930__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zMmyxefnY1eg" title="Number of shares issued">46,530</span> shares of its common stock (“Shares”) and (ii) in the concurrent Private Placement, Class C and Class D Warrants, each to purchase an aggregate of up to <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240930__us-gaap--StatementEquityComponentsAxis__custom--ClassCAndClassDWarrantsMember_zBoaEkPbarwl" title="Common warrant shares">46,530</span> Shares (the “Common Warrant Shares”) each with an exercise price of $<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240930__us-gaap--StatementEquityComponentsAxis__custom--ClassCAndClassDWarrantsMember_zqXiBeer26Sk" title="Warrants exercise price">28.00</span>. The Class C and Class D Warrants together, hereinafter the “Common Warrants”. The purchase price for Shares in the registered direct offering was $<span id="xdx_90A_eus-gaap--SharePrice_iI_pid_c20240930__us-gaap--StatementEquityComponentsAxis__custom--ClassCAndClassDWarrantsMember_zCD529H778Re" title="Share price">28.00</span> per Share.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company received aggregate gross proceeds from the Transactions of $<span id="xdx_90B_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20240901__20240930_zvRF7AyusFlj" title="Gross proceeds from transactions">1.3</span> million, before deducting fees to the Placement Agent and other estimated offering expenses payable by it. The Shares were offered by the Company pursuant to a shelf registration statement on Form S-3 (File No. 333-262280), which was declared effective on February 4, 2022. The Common Warrants and the Common Warrant Shares issued in the Private Placement were not registered under the Securities Act. Rather the Common Warrants and the Common Warrant Shares were issued pursuant to the exemption from registration provided in Section 4(a)(2) under the Securities Act and Rule 506(b) promulgated thereunder. The Class C Warrants and the Class D Warrants were not exercisable until December 3, 2024, and will expire, respectively, twenty-four months and five years and six months after that date.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company evaluated the Common Warrants under the guidance of ASC 480 – Distinguishing Liabilities from Equity and determined that they were in scope under the guidance as freestanding financial instruments but did not meet the criteria for liability classification and are classified as equity within the consolidated financial statements. Proceeds allocated to such warrants totaled $<span id="xdx_904_eus-gaap--WarrantsAndRightsOutstanding_iI_pn5n6_c20260630_zPQnqdU7Efk1" title="Proceeds from warrants">2.5</span> million. For the three and six months ended June 30, 2026, <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20260401__20260630__us-gaap--StatementEquityComponentsAxis__custom--ClassCWarrantsMember_zJRNqjLpNkQa" title="Warrant exercised"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__custom--ClassCWarrantsMember_zFXmTr0mCijf" title="Warrant exercised">46,530</span></span> Class C Warrants and <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20260401__20260630__us-gaap--StatementEquityComponentsAxis__custom--ClassDWarrantsMember_zryxpmxE1dog" title="Warrant exercised"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__custom--ClassDWarrantsMember_zOURdVhMfh7a" title="Warrant exercised">46,530</span></span> Class D Warrants were exercised at $<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260630__us-gaap--StatementEquityComponentsAxis__custom--ClassCWarrantsMember_zucJUBllHvGc" title="Warrants exercise price"><span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260630__us-gaap--StatementEquityComponentsAxis__custom--ClassDWarrantsMember_zSYD8SOHbE6i" title="Warrants exercise price">0.48</span></span> per share (See May 2026 Class H Inducement Transaction). There were no Class C or Class D Warrants outstanding at June 30, 2026, related to this agreement. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">July 2025 Public Offering</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 30, 2025, the Company announced closing a public offering of an aggregate of <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20250730__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zeaVQ9vFQSMc" title="Number of warrant to purchase shares of common stock">2,000,000</span> shares of its common stock (or pre-funded warrants in lieu thereof), Class E Warrants to purchase up to <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20250730__us-gaap--StatementEquityComponentsAxis__custom--ClassEWarrantsMember_ziwIGTU886Mi" title="Warrant to purchase shares of common stock">2,000,000</span> shares of common stock, and Class F Warrants to purchase up to <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20250730__us-gaap--StatementEquityComponentsAxis__custom--ClassFWarrantsMember_zyvOtmetza9i" title="Warrant to purchase shares of common stock">2,000,000</span> shares of common stock, at a combined public offering price of $<span id="xdx_90C_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20250730__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zinrnysI4k6i" title="Offering price per share">4.00</span> per share (or $<span id="xdx_901_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20250730__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember_ziKvlF5exWce" title="Offering price per share">3.999</span> per pre-funded warrant) and accompanying warrants. The warrants had an exercise price of $<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250730__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zD5Gm5WO2Boc" title="Warrant exercise price">4.00</span> per share and were exercisable immediately upon issuance. The Class E Warrants will expire on the fifth anniversary of the original issuance date, and the Class F Warrants will expire on the eighteen-month anniversary of the original issuance date. Gross proceeds, before deducting placement agent fees and offering expenses, were $<span id="xdx_907_eus-gaap--ProceedsFromIssuanceOfWarrants_pn6n6_c20250730__20250730__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember_zXHlZzpevsV6" title="Gross proceeds">8 </span>million. Maxim Group LLC acted as sole placement agent in connection with this offering.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on a review of the Class E and F Warrants, it was determined that the warrants met the liability criteria which resulted in Class E &amp; F warrants to be treated as liability under ASC 815 – Derivatives and Hedging. Accordingly, as the warrants might require the Company to issue additional stock under certain circumstances, a loss was recognized and the resulting computed value was classified as a liability on the Company’s balance sheet at December 31, 2025.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December 30, 2025, <span id="xdx_900_ecustom--StockDividendsDescription_c20251230__20251230_zPBsvqGBeULj">the Company declared a stock dividend of one share of common stock for every 1,000 shares of outstanding common stock as well as one share of common stock for every outstanding option or warrant that has a right to receive stock dividends (“Alternate Securities”).</span> <span id="xdx_903_ecustom--StockDividendsDescription_c20260113__20260113_zAFNLBLb9vW" title="Stock dividends description">On January 13, 2026, the Company distributed a dividend of one share of its common stock for every 1,000 shares of common stock issued and outstanding as of January 9, 2026 as well as one share of common stock for every outstanding option or warrant that has a right to receive stock dividends (the “Dividend”).</span> The issuance of the Dividend was a Share Combination Event under Section 3(g) of the Class E &amp; F Common Stock Purchase Warrants. As a result, the number of outstanding warrants of Class E &amp; F Common Stock Purchase Warrants both have increased to <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20260113__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassEAndFCommonStockPurchaseWarrantsMember_zjMXj3faFZP8">5,561,125</span> and the exercise price reduced to $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260113__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassEAndFCommonStockPurchaseWarrantsMember_zXSlhZywfCH6">1.439</span> per share of common stock. Due to the Share Combination Event trigger of the Class E &amp; F Common Stock Purchase Warrants, reevaluation of the classification resulted in the reclassification of the warrants from liability to equity. The Company recognized a loss on change of warrant liabilities of $<span id="xdx_900_ecustom--ChangeInFairValueOfWarrantLiability_iN_pn3n3_di_c20260101__20260630_zTgn06FLZAQ4" title="Change of warrant liabilities">468</span> thousand in the statements of operations for the six months ended June 30, 2026, and reclassified the Class E &amp; F Common Stock Purchase Warrants from liability to equity. This reclassification totaling $<span id="xdx_90B_ecustom--WarrantsFromLiabilityToEquity_iI_pn5n6_c20260630_zY6PfixRbvFf" title="Warrants from liability to equity">8.7</span> million is reflected in the Balance Sheet at June 30, 2026.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For the three months ended June 30, 2026, <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20260401__20260630__us-gaap--StatementEquityComponentsAxis__custom--ClassEWarrantsMember_zO6EyYUewHqj" title="Warrant exercised">3,563,055</span> Class E Warrants and <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20260401__20260630__us-gaap--StatementEquityComponentsAxis__custom--ClassFWarrantsMember_znTgN2eDaNk6" title="Warrant exercised">3,682,985</span> Class F Warrants were exercised at $<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260630__us-gaap--StatementEquityComponentsAxis__custom--ClassEWarrantsMember_zolq3q0K7gT7" title="Warrants exercise price"><span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260630__us-gaap--StatementEquityComponentsAxis__custom--ClassFWarrantsMember_z8LyI4CJLfwe" title="Warrants exercise price">0.48</span></span> per share (See May 2026 Class H Inducement Transaction). For the six months ended June 30, 2026, <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__custom--ClassEWarrantsMember_z1aPPvZMbEH7" title="Warrant exercised">4,045,555</span> Class E Warrants and <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__custom--ClassFWarrantsMember_zThHlTgZjXKc" title="Warrant exercised">4,483,493</span> Class F Warrants exercised. At June 30, 2026 there were <span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20260630__us-gaap--StatementEquityComponentsAxis__custom--ClassEWarrantsMember_zbm6vSaEdu6d" title="Common warrant shares">1,515,564</span> Class E Warrants and <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20260630__us-gaap--StatementEquityComponentsAxis__custom--ClassFWarrantsMember_zeA6OlJBk8ie" title="Common warrant shares">1,077,625</span> Class F Warrants outstanding at an exercise price of $<span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260630__us-gaap--StatementEquityComponentsAxis__custom--ClassEAndClassFWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zyZqsOkngJrd" title="Warrants exercise price">1.439</span> related to this agreement.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">March 2026 Rights Offering</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 6, 2026, the Company completed a rights offering to its stockholders and to holders of certain of its outstanding options and warrants that had the right to participate in the 2026 Rights Offering, as of February 10, 2026, the record date. In the Rights Offering the Company issued non-transferable subscription rights to purchase <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20260306__20260306__us-gaap--SubsidiarySaleOfStockAxis__custom--TwoThousandTwentySixRightsOfferingMember_zYzouUmWsTlj" title="Number of units issued">1,842</span> Units. Each Unit consists of one share of Series G Convertible Preferred Stock (the “G Preferred”) and <span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20260306__us-gaap--StatementClassOfStockAxis__custom--GWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--TwoThousandTwentySixRightsOfferingMember_zhEQ0oX5Bw55" title="Shares issued">2,000</span> warrants to purchase common stock (the “G Warrants”). Each share of G Preferred is convertible, at the option of the holder at any time, into a number of shares of common stock equal to the quotient of the stated value of the Preferred Stock ($<span id="xdx_90E_ecustom--PreferredStockPreferredStockStatedValuePerShare_iI_pn3n3_c20260306__us-gaap--StatementClassOfStockAxis__custom--SeriesGConvertiblePreferredStockMember__us-gaap--SubsidiarySaleOfStockAxis__custom--TwoThousandTwentySixRightsOfferingMember_zvoW6pAptgr2" title="Preferred stock, stated value">1</span> thousand) divided by $<span id="xdx_909_eus-gaap--PreferredStockConvertibleConversionPrice_iI_pid_c20260306__us-gaap--StatementClassOfStockAxis__custom--SeriesGConvertiblePreferredStockMember__us-gaap--SubsidiarySaleOfStockAxis__custom--TwoThousandTwentySixRightsOfferingMember_zvolgRv6vD3a" title="Conversion price">1.00</span>, the conversion price. Each G Warrant is exercisable for <span id="xdx_90D_eus-gaap--SharesIssued_iI_dc_c20260306__us-gaap--StatementClassOfStockAxis__custom--GWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--TwoThousandTwentySixRightsOfferingMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zwUw1SE9l47g" title="Shares issued">one</span> share of common stock at an exercise price of $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260306__us-gaap--StatementClassOfStockAxis__custom--GWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--TwoThousandTwentySixRightsOfferingMember_zjWTvSBwXvz5" title="Exercise price">1.00</span> per share from March 6, 2026, the date of issuance, through its expiration <span id="xdx_90F_ecustom--ClassOfWarrantOrRightTerm_pid_dc_c20260306__20260306__us-gaap--StatementClassOfStockAxis__custom--GWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--TwoThousandTwentySixRightsOfferingMember_zZQWxAOmvcqi" title="Expiration date of issuance">five years</span> from the date of issuance. Maxim Group LLC acted as the Company’s dealer-manager. The 2026 Rights Offering raised $<span id="xdx_90E_ecustom--ProceedsFromIssuanceOfUnits_pn5n6_c20260306__20260306__us-gaap--SubsidiarySaleOfStockAxis__custom--TwoThousandTwentySixRightsOfferingMember_zYHUboNNpES8" title="Proceeds from issuance of units">1.8</span> million in gross proceeds.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">For the three months ended June 30, 2026, <span id="xdx_90C_eus-gaap--ConversionOfStockSharesConverted1_c20260401__20260630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesGPreferredStockMember_zf1Yhlf7zrOf">149</span> shares of the Series G Preferred had been converted for <span id="xdx_90F_eus-gaap--ConversionOfStockSharesConverted1_c20260401__20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zg15XN0ZneQb">149,000</span> shares of common stock and no Class G Warrants were exercised. <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the six months ended June 30, 2026, <span id="xdx_90F_eus-gaap--ConversionOfStockSharesConverted1_c20260101__20260630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesGPreferredStockMember_zZJ63UmiA412">1,313</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of the Series G Preferred had been converted for <span id="xdx_903_eus-gaap--ConversionOfStockSharesConverted1_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ztZaJgAVqQQj">1,313,000</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock, and <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__custom--ClassGWarrantsMember_zMS5cWaRxPt5" title="Warrant exercised">310,000</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Class G Warrants had been exercised. Subsequent to June 30, 2026, <span id="xdx_90B_eus-gaap--ConversionOfStockSharesConverted1_pid_c20260701__20260815__us-gaap--StatementClassOfStockAxis__custom--SeriesGConvertiblePreferredStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zn1OSj8sKLAg">8</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of the G Preferred had been converted to <span id="xdx_908_eus-gaap--ConversionOfStockSharesConverted1_pid_c20260701__20260815__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zBM5VtS4AxHk">8,000</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock. At June 30, 2026, <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20260630__us-gaap--StatementClassOfStockAxis__custom--ClassGWarrantsMember_zciZRGryKOqk" title="Warrant outstanding">3,374,000</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Class G Warrants and <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20260630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesGPreferredStockMember_zeLtaEkneIM5" title="Warrant outstanding">529</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Series G Preferred were outstanding.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">May 2026 Class H Inducement Transaction</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 7-8, 2026, the Company entered into inducement letter agreements with eight existing warrant holders pursuant to which such holders agreed to immediately exercise an aggregate of <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20260508__us-gaap--TypeOfArrangementAxis__custom--InducementLetterAgreementsMember__us-gaap--StatementClassOfStockAxis__custom--ClassAWarrantMember_zzTATu8a7taf" title="Number of shares issued upon transaction">7,451,920</span> previously outstanding Class A through Class F Warrants at an exercise price of $<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260508__us-gaap--TypeOfArrangementAxis__custom--InducementLetterAgreementsMember__us-gaap--StatementClassOfStockAxis__custom--ClassFWarrantMember_zPvVLQvwdnPl" title="Exercise price">0.48</span> per share, generating gross proceeds to the Company of approximately $<span id="xdx_907_eus-gaap--ProceedsFromIssuanceOfWarrants_pn5n6_c20260507__20260508__us-gaap--TypeOfArrangementAxis__custom--InducementLetterAgreementsMember__us-gaap--StatementClassOfStockAxis__custom--ClassAWarrantMember_zNqvRBQkJKH8" title="Gross proceeds">3.6</span> million. In connection with the inducement, the Company reduced the exercise price of the outstanding Class A through Class F Warrants to $<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260508__us-gaap--TypeOfArrangementAxis__custom--InducementLetterAgreementsMember__us-gaap--StatementClassOfStockAxis__custom--ClassFWarrantMember_zamO699uWTN8" title="Exercise price">0.48</span> per share. In consideration for the immediate exercises, the Company issued to such holders an aggregate of <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20260508__us-gaap--TypeOfArrangementAxis__custom--InducementLetterAgreementsMember__us-gaap--StatementClassOfStockAxis__custom--ClassHWarrantMember_zz0wOZrwX6v" title="Number of shares issued upon transaction">14,903,840</span> new Class H Common Stock Purchase Warrants with an exercise price of $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260508__us-gaap--TypeOfArrangementAxis__custom--InducementLetterAgreementsMember__us-gaap--StatementClassOfStockAxis__custom--ClassHWarrantMember_zz3TevLtKNzi" title="Exercise price">0.60</span> per share and a five-year term commencing on the Stockholder Approval Date. In connection with the inducement transaction, the Company also issued <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20260508__us-gaap--TypeOfArrangementAxis__custom--InducementLetterAgreementsMember__dei--LegalEntityAxis__custom--LadenburgThalmannAndCoMember_zBJBdfzIWCSc" title="Number of shares issued upon transaction">447,116</span> Placement Agent Warrants to Ladenburg Thalmann &amp; Co., Inc. with an exercise price of $<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260508__us-gaap--TypeOfArrangementAxis__custom--InducementLetterAgreementsMember__dei--LegalEntityAxis__custom--LadenburgThalmannAndCoMember_zv1xbCiuTIkj" title="Exercise price">0.60</span> per share and a five-year term commencing on the issue date, issued pursuant to the Investment Banking Agreement dated April 9, 2026. The Class H Warrants and Class H Placement Agent Warrants are equity-classified. The Class H Warrants are not exercisable until the Company obtains stockholder approval (<span style="background-color: white">See </span>Note 17: Subsequent Events) and include a beneficial ownership limitation of <span id="xdx_902_ecustom--SharePriceTriggerPercentage_iI_pid_dp_c20260508__us-gaap--TypeOfArrangementAxis__custom--InducementLetterAgreementsMember__dei--LegalEntityAxis__custom--LadenburgThalmannAndCoMember_zR5NDAmvFfK7" title="Standard blocker">4.99</span>%, or <span id="xdx_909_ecustom--BeneficialOwnershipPercentage_iI_dp_uPure_c20260508__dei--LegalEntityAxis__custom--LadenburgThalmannAndCoMember__us-gaap--TypeOfArrangementAxis__custom--InducementLetterAgreementsMember_z8s6G7XJVtvd" title="Beneficial ownership percentage">9.99</span>% upon election, customary anti-dilution adjustments, cashless exercise rights if there is no effective registration statement or available prospectus for resale of the underlying shares, and fundamental transaction provisions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company evaluated the temporary reduction in the exercise price of the Class A through Class F Warrants as a modification of freestanding equity-classified written call options. The incremental fair value effect of the modification was approximately $<span id="xdx_90D_eus-gaap--FairValueAdjustmentOfWarrants_c20260507__20260508__us-gaap--TypeOfArrangementAxis__custom--InducementLetterAgreementsMember_zv61GRdpuGBe" title="Incremental fair value">8,235</span> based on a class-by-class analysis and was attributable to the Class A and Class C Warrants. The aggregate fair value of the new Class H Warrants issued to the exercising holders was approximately $<span id="xdx_90C_eus-gaap--FairValueAdjustmentOfWarrants_pn5n6_c20260507__20260508__us-gaap--TypeOfArrangementAxis__custom--InducementLetterAgreementsMember__us-gaap--StatementClassOfStockAxis__custom--ClassHWarrantMember_zMciuxFixvy1" title="Incremental fair value">6.6</span> million. Accordingly, the aggregate value transferred to the exercising warrant holders was approximately $<span id="xdx_905_eus-gaap--ProceedsFromWarrantExercises_pn5n6_c20260507__20260508__us-gaap--TypeOfArrangementAxis__custom--InducementLetterAgreementsMember__us-gaap--StatementClassOfStockAxis__custom--ClassHWarrantMember_zzDO4LnsbXWl" title="Warrant exercised">6.6</span> million.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company also incurred approximately $<span id="xdx_900_eus-gaap--ProceedsFromIssuanceOfWarrants_pn3n3_c20260507__20260508__us-gaap--TypeOfArrangementAxis__custom--InducementLetterAgreementsMember__us-gaap--StatementClassOfStockAxis__custom--PlacementAgentWarrantMember_zEOwZhctIH1a" title="Warrant transaction cost">561</span> thousand of placement-agent costs in connection with the transaction, consisting of approximately $<span id="xdx_90B_eus-gaap--PaymentsForFees_pn3n3_c20260507__20260508__us-gaap--TypeOfArrangementAxis__custom--InducementLetterAgreementsMember__us-gaap--StatementClassOfStockAxis__custom--PlacementAgentWarrantMember_znuGoc1SrfNj" title="Cash fees">363</span> thousand of cash placement-agent fees and approximately $<span id="xdx_908_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20260507__20260508__us-gaap--TypeOfArrangementAxis__custom--InducementLetterAgreementsMember__us-gaap--StatementClassOfStockAxis__custom--ClassHPlacementAgentWarrantMember_z9ST1qKbckog" title="Fair value adjustment of warrants">198</span> thousand representing the fair value of the Class H Placement Agent Warrants. Total holder-side consideration and placement-agent costs associated with the transaction were therefore approximately $<span id="xdx_900_eus-gaap--ProceedsFromIssuanceOfWarrants_pn5n6_c20260507__20260508__us-gaap--TypeOfArrangementAxis__custom--InducementLetterAgreementsMember__us-gaap--StatementClassOfStockAxis__custom--HolderSideConsiderationAndPlacementAgentWarrantMember_z0yFtNONd1Sg" title="Warrant transaction cost">7.2</span> million.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The transaction generated gross exercise proceeds of approximately $<span id="xdx_90D_eus-gaap--ProceedsFromWarrantExercises_pn5n6_c20260507__20260508__us-gaap--TypeOfArrangementAxis__custom--InducementLetterAgreementsMember_zsmu2bl1NLja" title="Warrant exercised">3.6</span> million. The Company recognized equity issuance costs equal to the gross proceeds of the transaction, consisting of approximately $<span id="xdx_900_eus-gaap--ProceedsFromIssuanceOfWarrants_pn3n3_c20260507__20260508__us-gaap--TypeOfArrangementAxis__custom--InducementLetterAgreementsMember__us-gaap--StatementClassOfStockAxis__custom--PlacementAgentWarrantMember_zBnYbGzJePGc" title="Warrant transaction cost">561</span> thouand of placement-agent costs and approximately $<span id="xdx_90B_eus-gaap--ProceedsFromIssuanceOfWarrants_pn5n6_c20260507__20260508__us-gaap--TypeOfArrangementAxis__custom--InducementLetterAgreementsMember__us-gaap--StatementClassOfStockAxis__custom--HolderSideInducementConsiderationMember_zkq8lVgK6xu4" title="Warrant transaction cost">3.0</span> million of holder-side inducement consideration. The remaining approximately $<span id="xdx_90A_eus-gaap--ProceedsFromWarrantExercises_pn5n6_c20260507__20260508__us-gaap--TypeOfArrangementAxis__custom--InducementLetterAgreementsMember_zBOnFoq3OEL2" title="Warrant exercised">3.6</span> million of value transferred to the exercising warrant holders exceeded the proceeds available to absorb the transaction costs and was recognized as a deemed dividend. Because the Company had an accumulated deficit, the deemed dividend was recorded as a reduction of additional paid-in capital.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The deemed dividend did not affect the Company’s net loss or total stockholders’ equity but was deducted in determining net loss available to common stockholders for purposes of calculating basic earnings per share. The noncash entries associated with the Class H Warrants, the Existing Warrant modification, and the Class H Placement Agent Warrants also had no net effect on total stockholders’ equity. After payment of the cash placement-agent costs, the transaction increased total stockholders’ equity by approximately $<span id="xdx_909_eus-gaap--StockholdersEquityPeriodIncreaseDecrease_pn5n6_c20260507__20260508_zKgiNod4udUl" title="Increase decrease in stockholders equity">3.2</span> million, representing the net cash proceeds received.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At June 30, 2026 <span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20260630__us-gaap--StatementEquityComponentsAxis__custom--PlacementAgentWarrantsMember_z4p4FS2kXcl2" title="Common warrant shares">447,116</span> Placement Agent Warrants and <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20260630__us-gaap--StatementEquityComponentsAxis__custom--ClassHWarrantsMember_zJyIOwsgK3l5" title="Common warrant shares">14,903,840</span> Class H warrants were outstanding.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">May 2026 Class I Offering</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 21, 2026, the Company closed a registered direct offering (the ‘May 2026 Class I Offering’) of</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0; text-align: justify"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20260521__20260521__us-gaap--ClassOfWarrantOrRightAxis__custom--MayClassTwoThousandTwentySixClassIOfferingMember_zSW4lMeXPAPb" title="Registered shares of common stock">7,519,351</span> registered shares of common stock and</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Class I Common Stock Purchase Warrants to purchase up to <span id="xdx_904_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20260521__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassICommonStockPurchaseWarrantsMember_zv6cp5DC0gXi" title="Warrant to purchase shares of common stock">15,038,702</span> shares of common stock at an exercise price of $<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260521__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassICommonStockPurchaseWarrantsMember_zRtBijyJuG73" title="Warrants exercise price">0.325</span> per share, exercisable for a five-year period commencing on the Stockholder Approval Date.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The combined offering price was $<span id="xdx_903_eus-gaap--SharesIssuedPricePerShare_iI_c20260521__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassIWarrantsMember_zd6QuMaFwmv9" title="Offering price">0.325</span> per share of common stock and accompanying Class I Warrants. Although the Class I Securities Purchase Agreement permitted each Purchaser to elect Pre-Funded Warrants in lieu of common stock, no Purchaser elected to receive Pre-Funded Warrants at closing, and consequently no May 2026 Pre-Funded Warrants were issued. Gross proceeds to the Company totaled approximately $<span id="xdx_90A_eus-gaap--ProceedsFromWarrantExercises_pn5n6_c20260521__20260521__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassIWarrantsMember_zGnYRNSxQma6" title="Gross proceeds">2.4</span> million.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ladenburg Thalmann &amp; Co., Inc. acted as the placement agent for the May 2026 Class I Offering and received an <span id="xdx_905_ecustom--CashCommissionPercentage_iI_dp_uPure_c20260521__us-gaap--ClassOfWarrantOrRightAxis__custom--MayClassTwoThousandTwentySixClassIOfferingMember__dei--LegalEntityAxis__custom--LadenburgThalmannAndCoIncMember_zXMywUu9xR62" title="Cash commission percentage">8.0</span>% cash commission of approximately $<span id="xdx_901_ecustom--CommissionFees_pn3n3_c20260521__20260521__us-gaap--ClassOfWarrantOrRightAxis__custom--MayClassTwoThousandTwentySixClassIOfferingMember__dei--LegalEntityAxis__custom--LadenburgThalmannAndCoIncMember_zNspPmVHtMv5" title="Cash commission">196</span> thousand, a <span id="xdx_909_eus-gaap--ManagementAndServiceFeesRate_dp_uPure_c20260521__20260521__us-gaap--ClassOfWarrantOrRightAxis__custom--MayClassTwoThousandTwentySixClassIOfferingMember__dei--LegalEntityAxis__custom--LadenburgThalmannAndCoIncMember_zsfbcAuL2lwb" title="Managemment fee percentage">0.75</span>% management fee of approximately $<span id="xdx_904_eus-gaap--ManagementFeeExpense_pn3n3_c20260521__20260521__us-gaap--ClassOfWarrantOrRightAxis__custom--MayClassTwoThousandTwentySixClassIOfferingMember__dei--LegalEntityAxis__custom--LadenburgThalmannAndCoIncMember_z8mlhyzubEP5" title="Management fee">18</span> thousand, reimbursement of expenses of $<span id="xdx_907_ecustom--ReimbursementExpenses_pn3n3_c20260521__20260521__us-gaap--ClassOfWarrantOrRightAxis__custom--MayClassTwoThousandTwentySixClassIOfferingMember__dei--LegalEntityAxis__custom--LadenburgThalmannAndCoIncMember_zQuCoYys1wbf" title="Reimbursement expenses">100</span> thousand, and <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20260521__us-gaap--ClassOfWarrantOrRightAxis__custom--MayClassTwoThousandTwentySixClassIOfferingMember__dei--LegalEntityAxis__custom--LadenburgThalmannAndCoIncMember__us-gaap--SubsidiarySaleOfStockAxis__custom--PlacementAgentMember_z0W3O2GQOWFh" title="Warrants exercisable shares">451,161</span> Placement Agent Warrants exercisable at approximately $<span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260521__us-gaap--ClassOfWarrantOrRightAxis__custom--MayClassTwoThousandTwentySixClassIOfferingMember__dei--LegalEntityAxis__custom--LadenburgThalmannAndCoIncMember_zGJe0bmL3Lpa" title="Exercisable">0.41</span> per share (<span id="xdx_90E_ecustom--OfferingPricePercentage_iI_pid_dp_uPure_c20260521__us-gaap--ClassOfWarrantOrRightAxis__custom--MayClassTwoThousandTwentySixClassIOfferingMember__dei--LegalEntityAxis__custom--LadenburgThalmannAndCoIncMember_zqN5v2NIP4vc" title="Offering price percentage">125</span>% of the offering price) for a five-year period from the effective date of the Registration Statement. The Class I Warrants and Class I Placement Agent Warrants are all classified within stockholders’ equity. The Company applied the relative fair value method per ASC 470-20-25-2 to allocate the gross proceeds between the common stock and the Class I Warrants, resulting in allocations of approximately $<span id="xdx_90E_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20260521__20260521__us-gaap--ClassOfWarrantOrRightAxis__custom--MayClassTwoThousandTwentySixClassIOfferingMember__dei--LegalEntityAxis__custom--LadenburgThalmannAndCoIncMember__us-gaap--StatementEquityComponentsAxis__custom--ClassIWarrantdMember_zCUk5pftVjV4" title="Reimbursement expenses">939 thousand</span> to common stock and $<span id="xdx_90B_eus-gaap--ProceedsFromIssuanceOfWarrants_pn5n6_c20260521__20260521__us-gaap--ClassOfWarrantOrRightAxis__custom--MayClassTwoThousandTwentySixClassIOfferingMember__dei--LegalEntityAxis__custom--LadenburgThalmannAndCoIncMember__us-gaap--StatementEquityComponentsAxis__custom--ClassIWarrantdMember_z1un6CGJ4s67" title="Reimbursement expenses">1.5</span> million to Class I Warrants. The Class I Warrants will become exercisable only upon receipt of stockholder approval, which the Company is required to seek at a stockholder meeting to be held no later than July 21, 2026. (See Note 17: Subsequent Events)</span> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At June 30, 2026 there were <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20260630__us-gaap--StatementEquityComponentsAxis__custom--PlacementAgentWarrantsMember__dei--LegalEntityAxis__custom--LadenburgThalmannAndCoIncMember_z8ef4M4tS428" title="Common warrant shares">451,161</span> Placement Agent Warrants and <span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20260630__us-gaap--StatementEquityComponentsAxis__custom--ClassIWarrantsMember__dei--LegalEntityAxis__custom--LadenburgThalmannAndCoIncMember_zd2VtiWIVgzh" title="Common warrant shares">15,038,702</span> Class I Warrants outstanding.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">June 2026 Class J Offering</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 10, 2026, the Company closed a registered direct offering and concurrent private placement (the “June 2026 Class J Offering”) of <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20260610__20260610__us-gaap--ClassOfWarrantOrRightAxis__custom--JuneClassTwoThousandTwentySixClassJOfferingMember_zNXoe03UAFC">2,554,119</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">registered shares of common stock, <span id="xdx_90C_ecustom--UnregisteredSharesOfCommonStock_c20260610__20260610__us-gaap--ClassOfWarrantOrRightAxis__custom--JuneClassTwoThousandTwentySixClassJOfferingMember_zdYsRCp8sP52" title="Unregistered shares">771,503</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">unregistered shares of common stock, Pre-Funded Warrants to purchase up to <span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20260610__us-gaap--ClassOfWarrantOrRightAxis__custom--JuneClassTwoThousandTwentySixClassJOfferingMember_z1T8VxdMFP6">1,782,616</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock at a nominal exercise price of $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260610__us-gaap--ClassOfWarrantOrRightAxis__custom--JuneClassTwoThousandTwentySixClassJOfferingMember_zisHqed0r2qg">0.001</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share (fully pre-funded at closing), and Class J Common Stock Purchase Warrants to purchase up to <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20260610__us-gaap--ClassOfWarrantOrRightAxis__custom--JuneClassTwoThousandTwentySixClassJOfferingMember__us-gaap--StatementEquityComponentsAxis__custom--ClassJWarrantsMember_zS8G5kughD54">10,216,476</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock at an exercise price of approximately $<span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260610__us-gaap--ClassOfWarrantOrRightAxis__custom--JuneClassTwoThousandTwentySixClassJOfferingMember__us-gaap--StatementEquityComponentsAxis__custom--ClassJWarrantsMember_zHlRNrOMalEa">0.52</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share, exercisable for a five-year period commencing on the Stockholder Approval Date.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The combined offering price was approximately $<span id="xdx_907_eus-gaap--SharesIssuedPricePerShare_iI_c20260610__us-gaap--ClassOfWarrantOrRightAxis__custom--JuneClassTwoThousandTwentySixClassJOfferingMember_z7kVaczqTnh5" title="Offering price">0.52</span> per share and accompanying warrant. Gross proceeds to the Company totaled approximately $<span id="xdx_90C_eus-gaap--ProceedsFromWarrantExercises_pn5n6_c20260610__20260610__us-gaap--ClassOfWarrantOrRightAxis__custom--JuneClassTwoThousandTwentySixClassJOfferingMember_zJfxst5ShI96" title="Gross proceeds">2.6</span> million.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ladenburg Thalmann &amp; Co., Inc. acted as the placement agent for the June 2026 Class J Offering and received an <span id="xdx_904_ecustom--CashCommissionPercentage_iI_dp_uPure_c20260610__us-gaap--ClassOfWarrantOrRightAxis__custom--JuneClassTwoThousandTwentySixClassJOfferingMember__dei--LegalEntityAxis__custom--LadenburgThalmannAndCoIncMember_zm7wHZ9qIzMa" title="Cash commission percentage">8.0</span>% cash commission of approximately $<span id="xdx_90D_ecustom--CommissionFees_pn3n3_c20260610__20260610__us-gaap--ClassOfWarrantOrRightAxis__custom--JuneClassTwoThousandTwentySixClassJOfferingMember__dei--LegalEntityAxis__custom--LadenburgThalmannAndCoIncMember_zCoIDMuFF4A5" title="Cash commission">212</span> thousand, a <span id="xdx_905_eus-gaap--ManagementAndServiceFeesRate_dp_uPure_c20260610__20260610__us-gaap--ClassOfWarrantOrRightAxis__custom--JuneClassTwoThousandTwentySixClassJOfferingMember__dei--LegalEntityAxis__custom--LadenburgThalmannAndCoIncMember_zSUqooRpTh4i" title="Managemment fee percentage">0.75</span>% management fee of approximately $<span id="xdx_903_eus-gaap--ManagementFeeExpense_pn3n3_c20260610__20260610__us-gaap--ClassOfWarrantOrRightAxis__custom--JuneClassTwoThousandTwentySixClassJOfferingMember__dei--LegalEntityAxis__custom--LadenburgThalmannAndCoIncMember_zQ0R5T0fnje" title="Management fee">20</span> thousand, reimbursement of expenses of $<span id="xdx_90F_ecustom--ReimbursementExpenses_pn3n3_c20260610__20260610__us-gaap--ClassOfWarrantOrRightAxis__custom--JuneClassTwoThousandTwentySixClassJOfferingMember__dei--LegalEntityAxis__custom--LadenburgThalmannAndCoIncMember_z0rL3EKeWnF2" title="Reimbursement expenses">100</span> thousand, and <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20260610__us-gaap--ClassOfWarrantOrRightAxis__custom--JuneClassTwoThousandTwentySixClassJOfferingMember__dei--LegalEntityAxis__custom--LadenburgThalmannAndCoIncMember__us-gaap--SubsidiarySaleOfStockAxis__custom--PlacementAgentMember_zqeZAWt1S2Oa" title="Warrants exercisable shares">306,494</span> Placement Agent Warrants exercisable at approximately $<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260610__us-gaap--ClassOfWarrantOrRightAxis__custom--JuneClassTwoThousandTwentySixClassJOfferingMember__dei--LegalEntityAxis__custom--LadenburgThalmannAndCoIncMember_zsRS0LET7CU2" title="Exercisable">0.65</span> per share with a five-year term. The Class J Warrants, June 2026 Pre-Funded Warrants, and Class J Placement Agent Warrants are all classified within stockholders’ equity. The Company applied the relative fair value method per ASC 470-20-25-2 to allocate the gross proceeds among the common stock, Pre-Funded Warrants, and Class J Warrants. The Class J Warrants will become exercisable only upon receipt of stockholder approval, which the Company is required to seek at a stockholder meeting to be held no later than July 21, 2026 (concurrent with the Class I and Class H Warrants). (See Note 17: Subsequent Events)</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the three months ended June 30, 2026, prefunded warrants were exercised for <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20260401__20260630__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember_zl4Z4HIJ4dq8" title="Warrant exercised">1,300,828</span> shares of common stock. At June 30, 2026, <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20260630__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember__dei--LegalEntityAxis__custom--LadenburgThalmannAndCoIncMember__us-gaap--StatementClassOfStockAxis__custom--June2026ClassJOfferingMember_zyCwRn7dOnql" title="Common warrant shares">481,788</span> Pre-Funded Warrants, <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20260630__us-gaap--StatementEquityComponentsAxis__custom--PlacementAgentWarrantsMember__dei--LegalEntityAxis__custom--LadenburgThalmannAndCoIncMember__us-gaap--StatementClassOfStockAxis__custom--June2026ClassJOfferingMember_zxWAZNXZQNBa" title="Common warrant shares">306,494</span> Placement Agent Warrants and <span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20260630__us-gaap--StatementEquityComponentsAxis__custom--ClassJWarrantsMember__dei--LegalEntityAxis__custom--LadenburgThalmannAndCoIncMember__us-gaap--StatementClassOfStockAxis__custom--June2026ClassJOfferingMember_z0hkFLs1RPoc" title="Common warrant shares">10,216,476</span> Class J Warrants were outstanding.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Subsequently, on August 4, 2026, a holder exercised pre-funded warrants to purchase <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20260804__us-gaap--ClassOfWarrantOrRightAxis__custom--JuneClassTwoThousandTwentySixClassJOfferingMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zgb62ChcBS9a" title="Warrant to purchase shares of common stock">481,788</span> shares of common stock upon exercise of the pre-funded warrants and received nominal cash proceeds from the exercise.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> 5000000 0.01 4000000 10000 4000000 250000 10000 0.01 1000 0.01 12000 0.001 1000 1.00 0.0499 0.0999 1842 1842 1.00 3684000 1 1.00 P5Y 1800000 529 0 8 8000 8000 521 521 350000000 8000000 350000000 28990073 28990073 3069875 3069875 500000 8500000 8500000 3100000 0.030 3000000 155874 225000 0.030 7000 3000000 0.001 1019570 3044862 2600000 0.030 78000 3200736 2800000 15000000 0.95 500000 0.0499 0.1999 99750 96364 3386 7596 128000 30829 398000 56410 56410 36.30 56410 36.30 five years 0.08 2500000 56410 56410 56410 56410 0.48 0.48 46530 46530 28.00 28.00 1300000 2500000 46530 46530 46530 46530 0.48 0.48 2000000 2000000 2000000 4.00 3.999 4.00 8000000 the Company declared a stock dividend of one share of common stock for every 1,000 shares of outstanding common stock as well as one share of common stock for every outstanding option or warrant that has a right to receive stock dividends (“Alternate Securities”). On January 13, 2026, the Company distributed a dividend of one share of its common stock for every 1,000 shares of common stock issued and outstanding as of January 9, 2026 as well as one share of common stock for every outstanding option or warrant that has a right to receive stock dividends (the “Dividend”). 5561125 1.439 -468000 8700000 3563055 3682985 0.48 0.48 4045555 4483493 1515564 1077625 1.439 1842 2000 1000 1.00 1 1.00 P5Y 1800000 149 149000 1313 1313000 310000 8 8000 3374000 529 7451920 0.48 3600000 0.48 14903840 0.60 447116 0.60 0.0499 0.0999 8235 6600000 6600000 561000 363000 198000 7200000 3600000 561000 3000000.0 3600000 3200000 447116 14903840 7519351 15038702 0.325 0.325 2400000 0.080 196000 0.0075 18000 100000 451161 0.41 1.25 939 1500000 451161 15038702 2554119 771503 1782616 0.001 10216476 0.52 0.52 2600000 0.080 212000 0.0075 20000 100000 306494 0.65 1300828 481788 306494 10216476 481788 <p id="xdx_80A_eus-gaap--EarningsPerShareTextBlock_zVFaOGSoXNo4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 15: <span id="xdx_821_zgWPpYG3X5fl">Net Loss Per Share</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic and diluted net loss per share is computed using the weighted average number of shares of common stock outstanding during the period. Equivalent common shares, consisting of <span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20260101__20260630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_z6NyZRVnj3T1" title="Stock options, shares">48,470,384</span> and <span id="xdx_901_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20250101__20251231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zfuWFd4qFkC5" title="Warrants, shares">4,334,512</span> of stock options and warrants, are excluded from the calculation of diluted net loss per share for the periods ended June 30, 2026 and December 31, 2025, respectively, since their effect is antidilutive due to the net loss of the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The deemed dividend did not affect the Company’s net loss or total stockholders’ equity but was deducted in determining net loss available to common stockholders for purposes of calculating basic earnings per share. The noncash entries associated with the Class H Warrants, the Existing Warrant modification, and the Class H Placement Agent Warrants also had no net effect on total stockholders’ equity. After payment of the cash placement-agent costs, the transaction increased total stockholders’ equity by approximately $<span id="xdx_902_eus-gaap--StockholdersEquityPeriodIncreaseDecrease_pn5n6_c20260101__20260630_z0lzoitSqnH1" title="Increase decrease in stockholders equity">3.2</span> million, representing the net cash proceeds received.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> 48470384 4334512 3200000 <p id="xdx_800_eus-gaap--FairValueDisclosuresTextBlock_zo6YiZbtgxVi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 16: <span id="xdx_825_zlRiXMA1JmL8">Fair Value</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fair Value</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company complies with the provisions of FASB ASC 820 “Fair Value Measurements” for its financial and non-financial assets and liabilities. ASC 820 defines fair value, establishes a framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The fair values of cash and cash equivalents, other assets, accounts payable and accrued expenses approximate their carrying values due to the short-term maturities of these items and are considered a Level 1 instrument of the fair value measurements standard. The Company also has certain warrants with a cash settlement feature in the occurrence of a Fundamental Transaction. The fair value of the Class A and Class B warrants (“June 2024 Warrants”) related to the Company’s June 2024 common stock and warrant issuance, are calculated using a Black-Scholes Model. The fair value of the Class C and Class D warrants (“October 2024 Warrants”) related to the Company’s October 2024 common stock and warrant issuance, are calculated using a Black-Scholes Model. The fair value of the Class E and Class F warrants (“July 2025 Warrants”) related to the Company’s July 2025 common stock and warrant issuance, are calculated using a Black-Scholes Model. The fair value of the Class G warrants (“March 2026 Warrants”) related to the Company’s March 2026 common stock and warrant issuance, are calculated using a Black-Scholes Model.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company estimated the fair value of the Class A Warrants, Class B Warrants, Class C Warrants, Class D Warrants, Class E Warrants, Class F Warrants, Class G Warrants, Class H Warrants, Class I Warrants, Class J Warrants using the Black-Scholes Model, which uses multiple inputs including the Company’s stock price, the exercise price of the warrant, volatility of the Company’s stock price, the risk-free interest rate and the expected term of the warrants.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_897_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_z431otgD6bFe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company utilized the following assumptions to estimate the fair value of the Class A Warrants:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8B1_ztCpenWEmIXf" style="display: none">Schedule of Assumptions to Estimate Fair Value of Warrants</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" id="xdx_49D_20240630_zlGRSeof1mO2" style="text-align: center">June 30,</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_405_eus-gaap--SharePrice_iI_pid_hus-gaap--StatementEquityComponentsAxis__custom--ClassAWarrantMember_zVUoDAOimHy3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%">Underlying price per share</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">35.00</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__us-gaap--StatementEquityComponentsAxis__custom--ClassAWarrantMember_zubogpc6s7dh" style="vertical-align: bottom; background-color: White"> <td>Exercise price per share</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">36.30</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__custom--ClassAWarrantMember_zlMOsy9xZTNk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4.42</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Expected holding period</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20240630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--StatementEquityComponentsAxis__custom--ClassAWarrantMember_zdbfh3NlOHs7" title="Expected holding period">5.5</span> years</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementEquityComponentsAxis__custom--ClassAWarrantMember_z9VeRQ6FOdaa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">110</td><td style="text-align: left">%</td></tr> <tr id="xdx_40B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementEquityComponentsAxis__custom--ClassAWarrantMember_zYWhZuij8fd1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1981">—</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementEquityComponentsAxis__custom--ClassAWarrantMember_zVUkbjC8d27h" style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrants measurement input</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1983">—</span></td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company utilized the following assumptions to estimate the fair value of the Class B Warrants:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" id="xdx_497_20240630_zKBtjwbx4GJj" style="text-align: center">June 30,</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_406_ecustom--UnderlyingPricePerShare_iI_pid_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--StatementEquityComponentsAxis__custom--ClassBWarrantMember_zOUfukucOfyk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%">Underlying price per share</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">35.00</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__us-gaap--StatementEquityComponentsAxis__custom--ClassBWarrantMember_zg1BdUQmfRqe" style="vertical-align: bottom; background-color: White"> <td>Exercise price per share</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">36.30</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__custom--ClassBWarrantMember_zn8zfod0e0Pc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4.82</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Expected holding period</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20240630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--StatementEquityComponentsAxis__custom--ClassBWarrantMember_zHGOV31Ln0c8" title="Expected holding period">2</span> years</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pip0_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementEquityComponentsAxis__custom--ClassBWarrantMember_zESF0MS214P" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">89</td><td style="text-align: left">%</td></tr> <tr id="xdx_402_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementEquityComponentsAxis__custom--ClassBWarrantMember_zRsP1ECgYPn" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1995">—</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementEquityComponentsAxis__custom--ClassBWarrantMember_znsK2udplR6k" style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrants measurement input</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1997">—</span></td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company utilized the following assumptions to estimate the fair value of the Class C Warrants:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" id="xdx_498_20251001_zYVbIow80V6j" style="text-align: center">October 1,</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_40C_ecustom--UnderlyingPricePerShare_iI_pid_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--StatementEquityComponentsAxis__custom--ClassCWarrantMember_zAZb8HH7mEnl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%">Underlying price per share</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">26.00</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__us-gaap--StatementEquityComponentsAxis__custom--ClassCWarrantMember_zwcGlZs9o8ga" style="vertical-align: bottom; background-color: White"> <td>Exercise price per share</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">28.00</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__custom--ClassCWarrantMember_zgrlDZGgtj49" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3.6</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Expected holding period</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20251001__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--StatementEquityComponentsAxis__custom--ClassCWarrantMember_zEZBkIwP8dR9" title="Expected holding period">2</span> years</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pip0_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementEquityComponentsAxis__custom--ClassCWarrantMember_z0njmGZ9k8Rc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">82</td><td style="text-align: left">%</td></tr> <tr id="xdx_401_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementEquityComponentsAxis__custom--ClassCWarrantMember_zBxLWuH0w1P6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2009">—</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementEquityComponentsAxis__custom--ClassCWarrantMember_zPqvogTdnF1c" style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrants measurement input</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2011">—</span></td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company utilized the following assumptions to estimate the fair value of the Class D Warrants:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" id="xdx_49E_20251001_zMtKv19kAy5c" style="text-align: center">October 1,</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_406_ecustom--UnderlyingPricePerShare_iI_pid_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--StatementEquityComponentsAxis__custom--ClassDWarrantMember_zx3aGTOYvvb5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%">Underlying price per share</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">26.00</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__us-gaap--StatementEquityComponentsAxis__custom--ClassDWarrantMember_zsO731ljO7k" style="vertical-align: bottom; background-color: White"> <td>Exercise price per share</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">28.00</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__custom--ClassDWarrantMember_zoJeivXKcInl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3.5</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Expected holding period</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20251001__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--StatementEquityComponentsAxis__custom--ClassDWarrantMember_zvMoI3Cky2kl" title="Expected holding period">5.5</span> years</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pip0_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementEquityComponentsAxis__custom--ClassDWarrantMember_zdRHQjxTnk0i" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">91</td><td style="text-align: left">%</td></tr> <tr id="xdx_40D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementEquityComponentsAxis__custom--ClassDWarrantMember_zN8SYWfJwyP8" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2023">—</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementEquityComponentsAxis__custom--ClassDWarrantMember_zXY7eP2KgBE8" style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrant measurement input</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2025">—</span></td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company utilized the following assumptions to estimate the fair value of the Class E Warrants:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" id="xdx_49D_20251231_ziCFThFBXjl6" style="text-align: center">December 31,</td><td> </td><td> </td> <td colspan="2" id="xdx_49E_20260120_z52SmWl9vEx7" style="text-align: center">January 20,</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2026</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_406_ecustom--UnderlyingPricePerShare_iI_pid_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--StatementEquityComponentsAxis__custom--ClassEWarrantMember_zMVFj153k1T" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Underlying price per share</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1.13</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1.18</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__us-gaap--StatementEquityComponentsAxis__custom--ClassEWarrantMember_z8Qq9GtkDC9g" style="vertical-align: bottom; background-color: White"> <td>Exercise price per share</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1.44</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1.439</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__custom--ClassEWarrantMember_zRAKA3XEp9jd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3.7</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3.8</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Expected holding period</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20251231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--StatementEquityComponentsAxis__custom--ClassEWarrantMember_zWiPvUPHqa1" title="Expected holding period">4.58</span> years</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20260120__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--StatementEquityComponentsAxis__custom--ClassEWarrantMember_zTto270n4Coe" title="Expected holding period">4.52</span> years</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pip0_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementEquityComponentsAxis__custom--ClassEWarrantMember_zX9IzrT9v375" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">106</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">107</td><td style="text-align: left">%</td></tr> <tr id="xdx_407_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementEquityComponentsAxis__custom--ClassEWarrantMember_zqRsxnw9vcqi" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2043">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2044">—</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementEquityComponentsAxis__custom--ClassEWarrantMember_zWUO7UiGR5R3" style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrant measurement input</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2046">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2047">—</span></td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company utilized the following assumptions to estimate the fair value of the Class F Warrants:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" id="xdx_490_20251231_z1MjvaNU285c" style="text-align: center">December 31,</td><td> </td><td> </td> <td colspan="2" id="xdx_495_20260120_zMAec6Fh7f06" style="text-align: center">January 20,</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2026</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_401_ecustom--UnderlyingPricePerShare_iI_pid_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--StatementEquityComponentsAxis__custom--ClassFWarrantMember_zQUAPMvDEJhk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Underlying price per share</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1.13</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1.18</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__us-gaap--StatementEquityComponentsAxis__custom--ClassFWarrantMember_zGjVYXdPlEL8" style="vertical-align: bottom; background-color: White"> <td>Exercise price per share</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1.44</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1.439</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__custom--ClassFWarrantMember_zBqW4HjqDAV7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3.5</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3.5</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Expected holding period</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20251231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--StatementEquityComponentsAxis__custom--ClassFWarrantMember_zKhFqcDUGs61" title="Expected holding period">1.09</span> years</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20260120__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--StatementEquityComponentsAxis__custom--ClassFWarrantMember_zCrNMHtX8ZZ1" title="Expected holding period">1.03</span> years</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pip0_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementEquityComponentsAxis__custom--ClassFWarrantMember_zKKcBbDFfrMl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">168</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">172</td><td style="text-align: left">%</td></tr> <tr id="xdx_401_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementEquityComponentsAxis__custom--ClassFWarrantMember_zVNwejqtkyS4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2065">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2066">—</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementEquityComponentsAxis__custom--ClassFWarrantMember_zWKm5KRmWCD4" style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrant measurement input</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2068">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2069">—</span></td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company utilized the following assumptions to estimate the fair value of the Class G Warrants:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" id="xdx_492_20260306_zQVxZcz06Qml" style="text-align: center">March 6,</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2026</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_405_ecustom--UnderlyingPricePerShare_iI_pid_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--StatementEquityComponentsAxis__custom--ClassGWarrantMember_zB23IUXfLt9g" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%">Underlying price per share</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">0.694</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__us-gaap--StatementEquityComponentsAxis__custom--ClassGWarrantMember_zfl15KMF4Qt9" style="vertical-align: bottom; background-color: White"> <td>Exercise price per share</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1.00</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__custom--ClassGWarrantMember_zzmssqjVDaxg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3.5</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Expected holding period</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20260306__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--StatementEquityComponentsAxis__custom--ClassGWarrantMember_zRC2gNUZfL8" title="Expected holding period">5</span> years</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pip0_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementEquityComponentsAxis__custom--ClassGWarrantMember_zADKRyDRNVVi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">104</td><td style="text-align: left">%</td></tr> <tr id="xdx_404_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementEquityComponentsAxis__custom--ClassGWarrantMember_zN2kQUrQm0J1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2081">—</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementEquityComponentsAxis__custom--ClassGWarrantMember_zkugqFlY2T4b" style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrant measurement input</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2083">—</span></td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company utilized the following assumptions to estimate the fair value of the Class H Warrants:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" id="xdx_491_20260507_zmLYvUcYvPoh" style="text-align: center">May 7,</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2026</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_405_ecustom--UnderlyingPricePerShare_iI_pid_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--StatementEquityComponentsAxis__custom--ClassHWarrantMember_z48gYDEow233" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%">Underlying price per share</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">0.56</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__us-gaap--StatementEquityComponentsAxis__custom--ClassHWarrantMember_zNfR6ow7Exb8" style="vertical-align: bottom; background-color: White"> <td>Exercise price per share</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.60</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__custom--ClassHWarrantMember_zJrFf60oSRv4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4.04</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Expected holding period</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20260507__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--StatementEquityComponentsAxis__custom--ClassHWarrantMember_zapN36tGRVcl" title="Expected holding period">5</span> years</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pip0_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementEquityComponentsAxis__custom--ClassHWarrantMember_zdZwpXNtNjL" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">109</td><td style="text-align: left">%</td></tr> <tr id="xdx_404_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementEquityComponentsAxis__custom--ClassHWarrantMember_zgqhmWy7ZFh8" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2095">—</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementEquityComponentsAxis__custom--ClassHWarrantMember_zKG7ql8V7nlg" style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2097">—</span></td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company utilized the following assumptions to estimate the fair value of the Class I Warrants:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" id="xdx_49A_20260520_z2BC8QRpE602" style="text-align: center">May 20,</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2026</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_40E_ecustom--UnderlyingPricePerShare_iI_pid_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--StatementEquityComponentsAxis__custom--ClassIWarrantMember_zjJUimwCl2wc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%">Underlying price per share</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">0.2531</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__us-gaap--StatementEquityComponentsAxis__custom--ClassIWarrantMember_zWtZqW27BkL6" style="vertical-align: bottom; background-color: White"> <td>Exercise price per share</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.4063</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__custom--ClassIWarrantMember_zb0XjJVhLrS9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4.22</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Expected holding period</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20260520__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--StatementEquityComponentsAxis__custom--ClassHWarrantMember_zg3qfTan2kP9" title="Expected holding period">5</span> years</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pip0_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementEquityComponentsAxis__custom--ClassIWarrantMember_zs4MZmzbNHlj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">115</td><td style="text-align: left">%</td></tr> <tr id="xdx_406_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementEquityComponentsAxis__custom--ClassIWarrantMember_zHz405McSYn4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2109">—</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementEquityComponentsAxis__custom--ClassIWarrantMember_zpPVEVHKyZ98" style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrant measurement input</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2111">—</span></td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company utilized the following assumptions to estimate the fair value of the Class J Warrants:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" id="xdx_49E_20260610_zJTqFvsg8qUf" style="text-align: center">June 10,</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2026</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_409_ecustom--UnderlyingPricePerShare_iI_pid_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--StatementEquityComponentsAxis__custom--ClassJWarrantsMember_z1upeEDVbGFj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%">Underlying price per share</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">0.4376</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__us-gaap--StatementEquityComponentsAxis__custom--ClassJWarrantsMember_zG95EUOksYc2" style="vertical-align: bottom; background-color: White"> <td>Exercise price per share</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.6486</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__custom--ClassJWarrantsMember_zFUuuUt11BE6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4.27</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Expected holding period</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20260610__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--StatementEquityComponentsAxis__custom--ClassJWarrantsMember_zOIBb6qxFN8b" title="Expected holding period">5</span> years</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pip0_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementEquityComponentsAxis__custom--ClassJWarrantsMember_zxUFILP3qKjl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">125</td><td style="text-align: left">%</td></tr> <tr id="xdx_40A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementEquityComponentsAxis__custom--ClassJWarrantsMember_zJEkQSyRT7Q4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2123">—</span></td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8A1_zv40fWVwNIBd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The significant assumptions using the Black-Scholes Model approach for valuation of the Warrants are:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Risk-Free Interest Rate</i>. The risk-free interest rates for the Warrants are based on U.S. Treasury constant maturities for periods commensurate with the remaining expected holding periods of the warrants.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Expected Holding Period</i>. The expected holding period represents the period of time that the Warrants are expected to be outstanding until they are exercised. The Company utilizes the remaining contractual term of the Warrants at each valuation date as the expected holding period.</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Expected Volatility</i>. Expected stock volatility is based on daily observations of the Company’s historical stock values for a period commensurate with the remaining expected holding period on the last day of the period for which the computation is made.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Expected Dividend Yield</i>. The expected dividend yield is based on the Company’s anticipated dividend payments over the remaining expected holding period. As the Company has never issued dividends, the expected dividend yield is <span id="xdx_90B_ecustom--FairValueMeasurementInputPercentage_iI_pid_dp_uPure_c20260630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zMZ1HAjvBcLk" title="Fair value measurement, input percentage">0</span>% and this assumption will be continued in future calculations unless the Company changes its dividend policy.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Expected Probability of a Fundamental Transaction.</i> Put rights arise if a Fundamental Transaction 1) is an all cash transaction; (2) results in the Company going private; or (3) is a transaction involving a person or entity not traded on a national securities exchange. The Company believes such an occurrence is unlikely because:</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 58.5pt; text-align: justify; text-indent: -22.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company only has one product that is FDA approved but is currently not available for commercial sales.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company will have to perform additional clinical trials for FDA approval of its flagship product.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Industry and market conditions continue to include uncertainty, adding risk to any transaction.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The nature of a life sciences company is heavily dependent on future funding and high fixed costs, including Research &amp; Development.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has minimal revenues streams which are insufficient to meet the funding needs for the cost of operations or construction at their manufacturing facility; and</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s Rights Agreement and Executive Agreements make it less attractive to a potential buyer.</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">With the above factors utilized in analysis of the likelihood of the Put’s potential Liability, the Company estimated the range of probabilities related to a Put right being triggered as:</span></p> <p id="xdx_898_ecustom--ScheduleOfRangeOfProbabilitiesTableTextBlock_zzNS2bGa27Oe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8B9_zp66NiQ963V6" style="display: none">Schedule of Range of Probabilities</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%; margin-left: 0.5in"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; text-align: center">Range of Probability</td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Probability</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: center">Low</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 20%; text-align: right"><span id="xdx_90A_ecustom--PercentageOfProbability_pid_dp_uPure_c20260101__20260630__srt--RangeAxis__srt--MinimumMember_zJ9HbhM9Nifb" title="Percentage of probability">0.5</span></td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center">Medium</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_ecustom--PercentageOfProbability_pid_dp_uPure_c20260101__20260630__srt--RangeAxis__srt--WeightedAverageMember_z3XKDIAvdgHd" title="Percentage of probability">1.0</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center">High</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90D_ecustom--PercentageOfProbability_pid_dp_uPure_c20260101__20260630__srt--RangeAxis__srt--MaximumMember_zCU0h0BlZzRe" title="Percentage of probability">5.0</span></td><td style="text-align: left">%</td></tr> </table> <p id="xdx_8A2_z3RKDksIFBNg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Black-Scholes Model has incorporated a <span id="xdx_900_ecustom--PercentageOfProbability_pid_dp_c20260101__20260630_zrPOcvMOQZI5" title="Percentage of probability">5.0</span>% probability of a Fundamental Transaction to date for the life of the securities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vi)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Expected Timing of Announcement of a Fundamental Transaction.</i> As the Company has no specific expectation of a Fundamental Transaction, for reasons elucidated above, the Company utilized a discrete uniform probability distribution over the Expected Holding Period to model in the potential announcement of a Fundamental Transaction occurring during the Expected Holding Period.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vii)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Expected 100 Day Volatility at Announcement of a Fundamental Transaction</i>. An estimate of future volatility is necessary as there is no mechanism for directly measuring future stock price movements. Daily observations of the Company’s historical stock values for the 100 days immediately prior to the Warrants’ grant dates, with a floor of 100%, were utilized as a proxy for future volatility estimates.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(viii)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Expected Risk-Free Interest Rate at Announcement of a Fundamental Transaction</i>. The Company utilized a risk-free interest rate corresponding to the forward U.S. Treasury rate for the period equal to the time between the date forecast for the public announcement of a Fundamental Transaction and the Warrant expiration date for each simulation.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(ix)</i></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Expected Time Between Announcement and Consummation of a Fundamental Transaction.</i> The expected time between the announcement and the consummation of a Fundamental Transaction is based on the Company’s experience with the due diligence process performed by acquirers and is estimated to be six months. The Black-Scholes Model approach incorporates this additional period to reflect the delay Warrant Holders would experience in receiving the proceeds of the Put.</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 63pt; text-align: justify; text-indent: -27pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While the assumptions remain consistent from period to period (e.g., utilizing historical stock prices), the actual historical prices input for the relevant period input change.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for certain assets and liabilities at fair value. The hierarchy below lists three levels of fair value based on the extent to which inputs used in measuring fair value are observable in the market. AIM categorizes each of its fair value measurements in one of these three levels based on the lowest level input that is significant to the fair value measurement in its entirety. These levels are:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1 – Quoted prices are available in active markets for identical assets or liabilities at the reporting date. Generally, this includes debt and equity securities that are traded in an active market.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2 – Observable inputs other than Level 1 prices such as quote prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Generally, this includes debt and equity securities that are not traded in an active market.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Level 3 assets and liabilities include financial instruments whose value is determined using pricing models, discounted cash flow methodologies, or other valuation techniques, as well as instruments for which the determination of fair value requires significant management judgment or estimation. As of December 31, 2025, the Company has classified the warrants with cash settlement features as Level 3. Management evaluates a variety of inputs and then estimates fair value based on those inputs. As discussed above, the Company utilized the Black-Scholes Model in valuing the warrants.</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s marketable securities consist solely of mutual funds. The Company determine realized gains and losses for marketable securities using the specific identification method and measure the fair value of our marketable securities using a market approach where identical or comparable prices are available. If quoted market prices are not available, fair values of investments are determined using prices from a pricing service, pricing models, quoted prices of investments with similar characteristics or discounted cash flow models.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89D_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zb0JS9xd4WU3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The table below presents the balances of assets and liabilities measured at fair value on a recurring basis by level within the hierarchy as (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8B8_z2UX9OI4HlP8" style="display: none">Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; text-align: center">As of June 30, 2026</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Total</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Level 1</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Level 2</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Level 3</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 40%; text-align: left; padding-bottom: 1pt">Cash equivalents</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20260630__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zNHVNDlo45g7" style="border-bottom: Black 1pt solid; width: 11%; text-align: right">8,989</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20260630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z6ECeglgdZP9" style="border-bottom: Black 1pt solid; width: 11%; text-align: right">8,989</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20260630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z0epea90BWQi" style="border-bottom: Black 1pt solid; width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2140">—</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20260630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zcAZvcxUd6C3" style="border-bottom: Black 1pt solid; width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2141">—</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Marketable securities</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_988_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20260630__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zd43lHxqlwU4" style="border-bottom: Black 1pt solid; text-align: right" title="Marketable securities">64</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_989_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20260630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zngrbUUotsk4" style="border-bottom: Black 1pt solid; text-align: right" title="Marketable securities">64</td><td style="padding-bottom: 1pt; text-align: left"></td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_982_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20260630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zTQ4zmVTiR51" style="border-bottom: Black 1pt solid; text-align: right" title="Marketable securities"><span style="-sec-ix-hidden: xdx2ixbrl2147">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_985_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20260630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zlGMhsigCUu4" style="border-bottom: Black 1pt solid; text-align: right" title="Marketable securities"><span style="-sec-ix-hidden: xdx2ixbrl2149">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; text-align: center">As of December 31, 2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Total</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Level 1</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Level 2</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Level 3</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 40%; text-align: left; padding-bottom: 1pt">Cash equivalents</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20251231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_za242RxIuWLk" style="border-bottom: Black 1pt solid; width: 11%; text-align: right">931</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zIrKBBg2BQA9" style="border-bottom: Black 1pt solid; width: 11%; text-align: right">931</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z8su67nawgP3" style="border-bottom: Black 1pt solid; width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2152">—</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zoauiGJ5Vmcd" style="border-bottom: Black 1pt solid; width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2153">—</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Marketable securities</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_980_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20251231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zFkVYzL7kR0k" style="border-bottom: Black 1pt solid; text-align: right" title="Marketable securities">62</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_987_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zv9ZpemRgWK8" style="border-bottom: Black 1pt solid; text-align: right" title="Marketable securities">62</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_984_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zF0iDU8YMLS" style="border-bottom: Black 1pt solid; text-align: right" title="Marketable securities"><span style="-sec-ix-hidden: xdx2ixbrl2159">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98E_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zZkf6x6ZWPX5" style="border-bottom: Black 1pt solid; text-align: right" title="Marketable securities"><span style="-sec-ix-hidden: xdx2ixbrl2161">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Warrant liability</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_988_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_pn3n3_c20251231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z81DnOS20F84" style="border-bottom: Black 1pt solid; text-align: right" title="Warrant liability">8,244</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98A_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_pn3n3_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zHHPR8rTeaxc" style="border-bottom: Black 1pt solid; text-align: right" title="Warrant liability"><span style="-sec-ix-hidden: xdx2ixbrl2165">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_988_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_pn3n3_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z6vWGsTMhnEk" style="border-bottom: Black 1pt solid; text-align: right" title="Warrant liability"><span style="-sec-ix-hidden: xdx2ixbrl2167">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_984_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_pn3n3_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zRWGR4Hmg6K4" style="border-bottom: Black 1pt solid; text-align: right" title="Warrant liability">8,244</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table> <p id="xdx_8A5_zKchcVtrK5Jb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_897_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_z431otgD6bFe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company utilized the following assumptions to estimate the fair value of the Class A Warrants:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8B1_ztCpenWEmIXf" style="display: none">Schedule of Assumptions to Estimate Fair Value of Warrants</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" id="xdx_49D_20240630_zlGRSeof1mO2" style="text-align: center">June 30,</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_405_eus-gaap--SharePrice_iI_pid_hus-gaap--StatementEquityComponentsAxis__custom--ClassAWarrantMember_zVUoDAOimHy3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%">Underlying price per share</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">35.00</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__us-gaap--StatementEquityComponentsAxis__custom--ClassAWarrantMember_zubogpc6s7dh" style="vertical-align: bottom; background-color: White"> <td>Exercise price per share</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">36.30</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__custom--ClassAWarrantMember_zlMOsy9xZTNk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4.42</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Expected holding period</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20240630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--StatementEquityComponentsAxis__custom--ClassAWarrantMember_zdbfh3NlOHs7" title="Expected holding period">5.5</span> years</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementEquityComponentsAxis__custom--ClassAWarrantMember_z9VeRQ6FOdaa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">110</td><td style="text-align: left">%</td></tr> <tr id="xdx_40B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementEquityComponentsAxis__custom--ClassAWarrantMember_zYWhZuij8fd1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1981">—</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementEquityComponentsAxis__custom--ClassAWarrantMember_zVUkbjC8d27h" style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrants measurement input</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1983">—</span></td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company utilized the following assumptions to estimate the fair value of the Class B Warrants:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" id="xdx_497_20240630_zKBtjwbx4GJj" style="text-align: center">June 30,</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_406_ecustom--UnderlyingPricePerShare_iI_pid_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--StatementEquityComponentsAxis__custom--ClassBWarrantMember_zOUfukucOfyk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%">Underlying price per share</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">35.00</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__us-gaap--StatementEquityComponentsAxis__custom--ClassBWarrantMember_zg1BdUQmfRqe" style="vertical-align: bottom; background-color: White"> <td>Exercise price per share</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">36.30</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__custom--ClassBWarrantMember_zn8zfod0e0Pc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4.82</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Expected holding period</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20240630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--StatementEquityComponentsAxis__custom--ClassBWarrantMember_zHGOV31Ln0c8" title="Expected holding period">2</span> years</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pip0_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementEquityComponentsAxis__custom--ClassBWarrantMember_zESF0MS214P" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">89</td><td style="text-align: left">%</td></tr> <tr id="xdx_402_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementEquityComponentsAxis__custom--ClassBWarrantMember_zRsP1ECgYPn" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1995">—</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementEquityComponentsAxis__custom--ClassBWarrantMember_znsK2udplR6k" style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrants measurement input</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1997">—</span></td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company utilized the following assumptions to estimate the fair value of the Class C Warrants:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" id="xdx_498_20251001_zYVbIow80V6j" style="text-align: center">October 1,</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_40C_ecustom--UnderlyingPricePerShare_iI_pid_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--StatementEquityComponentsAxis__custom--ClassCWarrantMember_zAZb8HH7mEnl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%">Underlying price per share</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">26.00</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__us-gaap--StatementEquityComponentsAxis__custom--ClassCWarrantMember_zwcGlZs9o8ga" style="vertical-align: bottom; background-color: White"> <td>Exercise price per share</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">28.00</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__custom--ClassCWarrantMember_zgrlDZGgtj49" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3.6</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Expected holding period</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20251001__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--StatementEquityComponentsAxis__custom--ClassCWarrantMember_zEZBkIwP8dR9" title="Expected holding period">2</span> years</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pip0_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementEquityComponentsAxis__custom--ClassCWarrantMember_z0njmGZ9k8Rc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">82</td><td style="text-align: left">%</td></tr> <tr id="xdx_401_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementEquityComponentsAxis__custom--ClassCWarrantMember_zBxLWuH0w1P6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2009">—</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementEquityComponentsAxis__custom--ClassCWarrantMember_zPqvogTdnF1c" style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrants measurement input</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2011">—</span></td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company utilized the following assumptions to estimate the fair value of the Class D Warrants:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" id="xdx_49E_20251001_zMtKv19kAy5c" style="text-align: center">October 1,</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_406_ecustom--UnderlyingPricePerShare_iI_pid_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--StatementEquityComponentsAxis__custom--ClassDWarrantMember_zx3aGTOYvvb5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%">Underlying price per share</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">26.00</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__us-gaap--StatementEquityComponentsAxis__custom--ClassDWarrantMember_zsO731ljO7k" style="vertical-align: bottom; background-color: White"> <td>Exercise price per share</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">28.00</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__custom--ClassDWarrantMember_zoJeivXKcInl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3.5</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Expected holding period</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20251001__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--StatementEquityComponentsAxis__custom--ClassDWarrantMember_zvMoI3Cky2kl" title="Expected holding period">5.5</span> years</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pip0_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementEquityComponentsAxis__custom--ClassDWarrantMember_zdRHQjxTnk0i" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">91</td><td style="text-align: left">%</td></tr> <tr id="xdx_40D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementEquityComponentsAxis__custom--ClassDWarrantMember_zN8SYWfJwyP8" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2023">—</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementEquityComponentsAxis__custom--ClassDWarrantMember_zXY7eP2KgBE8" style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrant measurement input</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2025">—</span></td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company utilized the following assumptions to estimate the fair value of the Class E Warrants:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" id="xdx_49D_20251231_ziCFThFBXjl6" style="text-align: center">December 31,</td><td> </td><td> </td> <td colspan="2" id="xdx_49E_20260120_z52SmWl9vEx7" style="text-align: center">January 20,</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2026</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_406_ecustom--UnderlyingPricePerShare_iI_pid_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--StatementEquityComponentsAxis__custom--ClassEWarrantMember_zMVFj153k1T" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Underlying price per share</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1.13</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1.18</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__us-gaap--StatementEquityComponentsAxis__custom--ClassEWarrantMember_z8Qq9GtkDC9g" style="vertical-align: bottom; background-color: White"> <td>Exercise price per share</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1.44</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1.439</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__custom--ClassEWarrantMember_zRAKA3XEp9jd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3.7</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3.8</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Expected holding period</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20251231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--StatementEquityComponentsAxis__custom--ClassEWarrantMember_zWiPvUPHqa1" title="Expected holding period">4.58</span> years</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20260120__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--StatementEquityComponentsAxis__custom--ClassEWarrantMember_zTto270n4Coe" title="Expected holding period">4.52</span> years</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pip0_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementEquityComponentsAxis__custom--ClassEWarrantMember_zX9IzrT9v375" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">106</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">107</td><td style="text-align: left">%</td></tr> <tr id="xdx_407_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementEquityComponentsAxis__custom--ClassEWarrantMember_zqRsxnw9vcqi" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2043">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2044">—</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementEquityComponentsAxis__custom--ClassEWarrantMember_zWUO7UiGR5R3" style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrant measurement input</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2046">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2047">—</span></td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company utilized the following assumptions to estimate the fair value of the Class F Warrants:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" id="xdx_490_20251231_z1MjvaNU285c" style="text-align: center">December 31,</td><td> </td><td> </td> <td colspan="2" id="xdx_495_20260120_zMAec6Fh7f06" style="text-align: center">January 20,</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2026</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_401_ecustom--UnderlyingPricePerShare_iI_pid_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--StatementEquityComponentsAxis__custom--ClassFWarrantMember_zQUAPMvDEJhk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Underlying price per share</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1.13</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1.18</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__us-gaap--StatementEquityComponentsAxis__custom--ClassFWarrantMember_zGjVYXdPlEL8" style="vertical-align: bottom; background-color: White"> <td>Exercise price per share</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1.44</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1.439</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__custom--ClassFWarrantMember_zBqW4HjqDAV7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3.5</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3.5</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Expected holding period</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20251231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--StatementEquityComponentsAxis__custom--ClassFWarrantMember_zKhFqcDUGs61" title="Expected holding period">1.09</span> years</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20260120__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--StatementEquityComponentsAxis__custom--ClassFWarrantMember_zCrNMHtX8ZZ1" title="Expected holding period">1.03</span> years</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pip0_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementEquityComponentsAxis__custom--ClassFWarrantMember_zKKcBbDFfrMl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">168</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">172</td><td style="text-align: left">%</td></tr> <tr id="xdx_401_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementEquityComponentsAxis__custom--ClassFWarrantMember_zVNwejqtkyS4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2065">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2066">—</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementEquityComponentsAxis__custom--ClassFWarrantMember_zWKm5KRmWCD4" style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrant measurement input</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2068">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2069">—</span></td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company utilized the following assumptions to estimate the fair value of the Class G Warrants:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" id="xdx_492_20260306_zQVxZcz06Qml" style="text-align: center">March 6,</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2026</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_405_ecustom--UnderlyingPricePerShare_iI_pid_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--StatementEquityComponentsAxis__custom--ClassGWarrantMember_zB23IUXfLt9g" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%">Underlying price per share</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">0.694</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__us-gaap--StatementEquityComponentsAxis__custom--ClassGWarrantMember_zfl15KMF4Qt9" style="vertical-align: bottom; background-color: White"> <td>Exercise price per share</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1.00</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__custom--ClassGWarrantMember_zzmssqjVDaxg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3.5</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Expected holding period</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20260306__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--StatementEquityComponentsAxis__custom--ClassGWarrantMember_zRC2gNUZfL8" title="Expected holding period">5</span> years</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pip0_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementEquityComponentsAxis__custom--ClassGWarrantMember_zADKRyDRNVVi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">104</td><td style="text-align: left">%</td></tr> <tr id="xdx_404_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementEquityComponentsAxis__custom--ClassGWarrantMember_zN2kQUrQm0J1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2081">—</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementEquityComponentsAxis__custom--ClassGWarrantMember_zkugqFlY2T4b" style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrant measurement input</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2083">—</span></td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company utilized the following assumptions to estimate the fair value of the Class H Warrants:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" id="xdx_491_20260507_zmLYvUcYvPoh" style="text-align: center">May 7,</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2026</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_405_ecustom--UnderlyingPricePerShare_iI_pid_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--StatementEquityComponentsAxis__custom--ClassHWarrantMember_z48gYDEow233" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%">Underlying price per share</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">0.56</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__us-gaap--StatementEquityComponentsAxis__custom--ClassHWarrantMember_zNfR6ow7Exb8" style="vertical-align: bottom; background-color: White"> <td>Exercise price per share</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.60</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__custom--ClassHWarrantMember_zJrFf60oSRv4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4.04</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Expected holding period</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20260507__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--StatementEquityComponentsAxis__custom--ClassHWarrantMember_zapN36tGRVcl" title="Expected holding period">5</span> years</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pip0_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementEquityComponentsAxis__custom--ClassHWarrantMember_zdZwpXNtNjL" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">109</td><td style="text-align: left">%</td></tr> <tr id="xdx_404_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementEquityComponentsAxis__custom--ClassHWarrantMember_zgqhmWy7ZFh8" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2095">—</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementEquityComponentsAxis__custom--ClassHWarrantMember_zKG7ql8V7nlg" style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2097">—</span></td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company utilized the following assumptions to estimate the fair value of the Class I Warrants:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" id="xdx_49A_20260520_z2BC8QRpE602" style="text-align: center">May 20,</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2026</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_40E_ecustom--UnderlyingPricePerShare_iI_pid_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--StatementEquityComponentsAxis__custom--ClassIWarrantMember_zjJUimwCl2wc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%">Underlying price per share</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">0.2531</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__us-gaap--StatementEquityComponentsAxis__custom--ClassIWarrantMember_zWtZqW27BkL6" style="vertical-align: bottom; background-color: White"> <td>Exercise price per share</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.4063</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__custom--ClassIWarrantMember_zb0XjJVhLrS9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4.22</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Expected holding period</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20260520__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--StatementEquityComponentsAxis__custom--ClassHWarrantMember_zg3qfTan2kP9" title="Expected holding period">5</span> years</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pip0_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementEquityComponentsAxis__custom--ClassIWarrantMember_zs4MZmzbNHlj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">115</td><td style="text-align: left">%</td></tr> <tr id="xdx_406_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementEquityComponentsAxis__custom--ClassIWarrantMember_zHz405McSYn4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2109">—</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementEquityComponentsAxis__custom--ClassIWarrantMember_zpPVEVHKyZ98" style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrant measurement input</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2111">—</span></td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company utilized the following assumptions to estimate the fair value of the Class J Warrants:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" id="xdx_49E_20260610_zJTqFvsg8qUf" style="text-align: center">June 10,</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2026</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_409_ecustom--UnderlyingPricePerShare_iI_pid_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--StatementEquityComponentsAxis__custom--ClassJWarrantsMember_z1upeEDVbGFj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%">Underlying price per share</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">0.4376</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__us-gaap--StatementEquityComponentsAxis__custom--ClassJWarrantsMember_zG95EUOksYc2" style="vertical-align: bottom; background-color: White"> <td>Exercise price per share</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.6486</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__custom--ClassJWarrantsMember_zFUuuUt11BE6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4.27</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Expected holding period</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20260610__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--StatementEquityComponentsAxis__custom--ClassJWarrantsMember_zOIBb6qxFN8b" title="Expected holding period">5</span> years</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pip0_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementEquityComponentsAxis__custom--ClassJWarrantsMember_zxUFILP3qKjl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">125</td><td style="text-align: left">%</td></tr> <tr id="xdx_40A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementEquityComponentsAxis__custom--ClassJWarrantsMember_zJEkQSyRT7Q4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2123">—</span></td><td style="text-align: left"> </td></tr> </table> 35.00 36.30 4.42 P5Y6M 110 35.00 36.30 4.82 P2Y 89 26.00 28.00 3.6 P2Y 82 26.00 28.00 3.5 P5Y6M 91 1.13 1.18 1.44 1.439 3.7 3.8 P4Y6M29D P4Y6M7D 106 107 1.13 1.18 1.44 1.439 3.5 3.5 P1Y1M2D P1Y10D 168 172 0.694 1.00 3.5 P5Y 104 0.56 0.60 4.04 P5Y 109 0.2531 0.4063 4.22 P5Y 115 0.4376 0.6486 4.27 P5Y 125 0 <p id="xdx_898_ecustom--ScheduleOfRangeOfProbabilitiesTableTextBlock_zzNS2bGa27Oe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8B9_zp66NiQ963V6" style="display: none">Schedule of Range of Probabilities</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%; margin-left: 0.5in"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; text-align: center">Range of Probability</td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Probability</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: center">Low</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 20%; text-align: right"><span id="xdx_90A_ecustom--PercentageOfProbability_pid_dp_uPure_c20260101__20260630__srt--RangeAxis__srt--MinimumMember_zJ9HbhM9Nifb" title="Percentage of probability">0.5</span></td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center">Medium</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_ecustom--PercentageOfProbability_pid_dp_uPure_c20260101__20260630__srt--RangeAxis__srt--WeightedAverageMember_z3XKDIAvdgHd" title="Percentage of probability">1.0</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center">High</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90D_ecustom--PercentageOfProbability_pid_dp_uPure_c20260101__20260630__srt--RangeAxis__srt--MaximumMember_zCU0h0BlZzRe" title="Percentage of probability">5.0</span></td><td style="text-align: left">%</td></tr> </table> 0.005 0.010 0.050 0.050 <p id="xdx_89D_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zb0JS9xd4WU3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The table below presents the balances of assets and liabilities measured at fair value on a recurring basis by level within the hierarchy as (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8B8_z2UX9OI4HlP8" style="display: none">Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; text-align: center">As of June 30, 2026</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Total</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Level 1</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Level 2</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Level 3</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 40%; text-align: left; padding-bottom: 1pt">Cash equivalents</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20260630__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zNHVNDlo45g7" style="border-bottom: Black 1pt solid; width: 11%; text-align: right">8,989</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20260630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z6ECeglgdZP9" style="border-bottom: Black 1pt solid; width: 11%; text-align: right">8,989</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20260630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z0epea90BWQi" style="border-bottom: Black 1pt solid; width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2140">—</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20260630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zcAZvcxUd6C3" style="border-bottom: Black 1pt solid; width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2141">—</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Marketable securities</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_988_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20260630__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zd43lHxqlwU4" style="border-bottom: Black 1pt solid; text-align: right" title="Marketable securities">64</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_989_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20260630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zngrbUUotsk4" style="border-bottom: Black 1pt solid; text-align: right" title="Marketable securities">64</td><td style="padding-bottom: 1pt; text-align: left"></td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_982_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20260630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zTQ4zmVTiR51" style="border-bottom: Black 1pt solid; text-align: right" title="Marketable securities"><span style="-sec-ix-hidden: xdx2ixbrl2147">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_985_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20260630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zlGMhsigCUu4" style="border-bottom: Black 1pt solid; text-align: right" title="Marketable securities"><span style="-sec-ix-hidden: xdx2ixbrl2149">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; text-align: center">As of December 31, 2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Total</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Level 1</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Level 2</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Level 3</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 40%; text-align: left; padding-bottom: 1pt">Cash equivalents</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20251231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_za242RxIuWLk" style="border-bottom: Black 1pt solid; width: 11%; text-align: right">931</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zIrKBBg2BQA9" style="border-bottom: Black 1pt solid; width: 11%; text-align: right">931</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z8su67nawgP3" style="border-bottom: Black 1pt solid; width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2152">—</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zoauiGJ5Vmcd" style="border-bottom: Black 1pt solid; width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2153">—</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Marketable securities</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_980_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20251231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zFkVYzL7kR0k" style="border-bottom: Black 1pt solid; text-align: right" title="Marketable securities">62</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_987_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zv9ZpemRgWK8" style="border-bottom: Black 1pt solid; text-align: right" title="Marketable securities">62</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_984_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zF0iDU8YMLS" style="border-bottom: Black 1pt solid; text-align: right" title="Marketable securities"><span style="-sec-ix-hidden: xdx2ixbrl2159">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98E_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zZkf6x6ZWPX5" style="border-bottom: Black 1pt solid; text-align: right" title="Marketable securities"><span style="-sec-ix-hidden: xdx2ixbrl2161">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Warrant liability</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_988_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_pn3n3_c20251231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z81DnOS20F84" style="border-bottom: Black 1pt solid; text-align: right" title="Warrant liability">8,244</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98A_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_pn3n3_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zHHPR8rTeaxc" style="border-bottom: Black 1pt solid; text-align: right" title="Warrant liability"><span style="-sec-ix-hidden: xdx2ixbrl2165">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_988_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_pn3n3_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z6vWGsTMhnEk" style="border-bottom: Black 1pt solid; text-align: right" title="Warrant liability"><span style="-sec-ix-hidden: xdx2ixbrl2167">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_984_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_pn3n3_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zRWGR4Hmg6K4" style="border-bottom: Black 1pt solid; text-align: right" title="Warrant liability">8,244</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table> 8989000 8989000 64000 64000 931000 931000 62000 62000 8244000 8244000 <p id="xdx_805_eus-gaap--SubsequentEventsTextBlock_zRIEu2r2rW98" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 17: <span id="xdx_826_zhRk9XZSpyA">Subsequent Events</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Company’s Amended and Restated 2018 Equity Incentive Plan</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 1, 2026, <span id="xdx_908_eus-gaap--PreferredStockConvertibleSharesIssuable_iI_pid_c20260701__us-gaap--StatementClassOfStockAxis__custom--SeriesGConvertiblePreferredStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zMIti68OJ2Ul">8</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of the Company’s Preferred Series G stock were converted to <span id="xdx_908_eus-gaap--ConversionOfStockSharesConverted1_pid_c20260701__20260701__us-gaap--StatementClassOfStockAxis__custom--SeriesGConvertiblePreferredStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zgrwJNHXKQxj">8,000</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of the Company’s common stock. As a result of this conversion, the Company’s outstanding shares of common stock increased by <span id="xdx_901_eus-gaap--ConversionOfStockSharesConverted1_pid_c20260701__20260701__us-gaap--StatementClassOfStockAxis__custom--SeriesGConvertiblePreferredStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z1bniSphNyhf">8,000</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares and <span id="xdx_909_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20260701__us-gaap--StatementClassOfStockAxis__custom--SeriesGConvertiblePreferredStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z5aFFGvUVxt8">521</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preferred Series G remains issued and outstanding. The conversions did not result in any cash proceeds to the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 9, 2026, the Company filed a Registration Statement registering additional shares of common stock under the Company’s Amended and Restated 2018 Equity Incentive Plan. The number of shares of the Company’s common stock available for grant and issuance under the Plan is subject to an annual increase on July 1 of each calendar year, by an amount equal to two percent (<span id="xdx_90E_ecustom--OutstandingSharesPercentage_iI_pid_dp_c20260709__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z7aYtFJQcWL8" title="Outstanding shares percentage">2</span>%) of the then outstanding shares of the Company’s common stock. On July 1, 2026, the number of shares of the Company’s common stock available for grant and issuance under the 2018 Plan increased by <span id="xdx_90F_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20260701__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z1n5vuBI1Pu3" title="Number of shares of the common stock available for grant and issuance">580,661</span> shares pursuant to the 2018 Plan Evergreen Provision.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Special Meeting of Stockholders</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 15, 2026, <span id="xdx_909_eus-gaap--CommonStockVotingRights_c20260715__20260715__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zzXb03FHIEya" title="Special meeting description">the Company held a Special Meeting of Stockholders. As of the record date for the Special Meeting, there were <span id="xdx_90E_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20260715__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zcFwu6LQAmL6" title="Common stock, shares outstanding">27,724,245</span> outstanding shares of the Company’s common stock outstanding and entitled to vote at the Special Meeting. Of the record date outstanding shares, <span id="xdx_907_ecustom--NumberOfOutstandingSharesRequirementForRepresentingAtMeeting_pid_c20260715__20260715__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z7xfdn2Pz8Af" title="Number of outstanding shares requirement for representing at the meeting">10,671,690</span> shares, or approximately 38.5%, were represented at the Special Meeting either in person or by proxy, meaning the requisite quorum for the meeting of 33 and 1/3% was present.</span><br/> Based on the final voting results reported by the Inspector of Election, all Proposals were approved.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Equity Distribution Agreement</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 31, 2026, the Company and Maxim mutually agreed to terminate the Equity Distribution Agreement, effective August 15, 2026.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Sterling Proposal Agreement</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 31, 2026, the Company entered into a proposal (the “Sterling Proposal Agreement”) with Sterling Pharma Solutions (“Sterling”) that is related to the Master Service Agreement and a Quality Agreement entered into between the Company and Sterling in 2022. Pursuant to the Sterling Proposal Agreement, Sterling agreed to manufacture further batches of the polynucleotide drug substances PolyI and Poly C12U and transfer of associated test methods at Sterling’s Dudley, UK location to produce the polymer precursors to manufacture the drug Ampligen. The estimated cost to the Company under the Sterling Proposal Agreement is approximately $<span id="xdx_909_eus-gaap--ManufacturingCosts_pn5n6_c20260801__20260815__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SterlingProposalAgreementMember_zwrK7rXojcJk" title="Manufacturing estimated costs">1.5</span> million to be paid over a period of 12 months, as set forth in more detail in the Sterling Proposal Agreement. The Company anticipates using the manufactured product for ongoing and future clinical trials, including potentially a Phase 3 clinical trial for metastatic pancreatic cancer.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The foregoing summary of the Sterling Proposal Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Sterling Proposal Agreement, which was filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on August 6, 2026 and incorporated herein by reference.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Unsecured Promissory Note</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 6, 2026, the Company redeemed <span id="xdx_90B_eus-gaap--StockRedeemedOrCalledDuringPeriodShares_pid_c20260806__20260806__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--UnsecuredPromissoryNoteMember_zHUQGdteBzZ6" title="Number of common shares redeemed">384,911</span> shares of its common stock issued pursuant to the terms of the promissory note for an aggregate redemption price of $<span id="xdx_909_eus-gaap--StockRedeemedOrCalledDuringPeriodValue_c20260806__20260806__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--UnsecuredPromissoryNoteMember_zghteBmAT3Gj" title="Common shares redemption price">100,000</span> and redeemed <span id="xdx_903_eus-gaap--StockRedeemedOrCalledDuringPeriodShares_pid_c20260806__20260806__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--UnsecuredPromissoryNoteOneMember_zNDxXPaEPh3b" title="Number of common shares redeemed">577,367</span> shares of its common stock issued pursuant to the terms of the promissory note for an aggregate redemption price of $<span id="xdx_90D_eus-gaap--StockRedeemedOrCalledDuringPeriodValue_c20260806__20260806__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--UnsecuredPromissoryNoteOneMember_za89wizgL9w1" title="Common shares redemption price">150,000</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">June 2026 Class J Offering</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On August 4, 2026, a holder exercised pre-funded warrants to purchase <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20260804__us-gaap--ClassOfWarrantOrRightAxis__custom--JuneClassTwoThousandTwentySixClassJOfferingMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zj8EWeE4cera" title="Warrant to purchase shares of common stock">481,788</span> shares of common stock upon exercise of the pre-funded warrants and received nominal cash proceeds from the exercise.</span></p> 8 8000 8000 521 0.02 580661 the Company held a Special Meeting of Stockholders. As of the record date for the Special Meeting, there were 27,724,245 outstanding shares of the Company’s common stock outstanding and entitled to vote at the Special Meeting. Of the record date outstanding shares, 10,671,690 shares, or approximately 38.5%, were represented at the Special Meeting either in person or by proxy, meaning the requisite quorum for the meeting of 33 and 1/3% was present. 27724245 10671690 1500000 384911 100000 577367 150000 481788 false false false false